Carboxamido-pyrimidine derivatives as SHP2 antagonists

Abstract

The present invention relates to carboxamido-pyrimidine derivatives of general formula I, or pharmaceutically acceptable salts thereof, and to the use of the compounds of the invention for the treatment of hyperproliferative diseases and disorders in mammals, particularly humans, and to pharmaceutical compositions containing such compounds. JPEG2022524759000237.jpg46170

Description

[Technical Field]

[0001] The present invention relates to compounds of general formula I:

[0002] [ka]

[0003] and the use of the compounds of the invention for the treatment and / or prevention of hyperproliferative diseases and disorders in mammals, particularly humans, and pharmaceutical compositions containing such compounds. [Background technology]

[0004] Background of the Invention Src homology domain 2 (SH2)-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene that contributes to multiple cellular functions, including proliferation, differentiation, cell cycle maintenance, and migration. SHP2 is involved in signaling via the Ras-mitogen-activated protein kinase pathway, the JAK-STAT pathway, or the phosphoinositol 3-kinase-AKT pathway. SHP2 contains two N-terminal Src homology 2 domains (N-SH2 and C-SH2), a catalytic domain (PTP), and a C-terminal tail. The two SH2 domains control the subcellular localization and functional regulation of SHP2. The molecule exists in an inactive, autoinhibited conformation stabilized by a network of bonds involving residues from both the N-SH2 and PTP domains. Stimulation by, for example, cytokines or growth factors, leads to exposure of the catalytic site, resulting in enzymatic activation of SHP2.

[0005] SHP2 is ubiquitously expressed in various tissues and cell types. It plays an important role in diverse signaling pathways for regulating cellular biological processes and is involved in various growth factor and cytokine signaling pathways. Within a single signaling pathway, SHP2 can play both positive (signal enhancement) and negative (signal attenuation) roles in intracellular signaling processes. SHP2 is thought to function by dephosphorylating its associated signaling molecules, thereby attenuating local signal flow. However, the primary effect of SHP2 action in most signaling pathways (e.g., growth factor, cytokine, and extracellular matrix receptors) is signal enhancement. For example, SHP2 is a positive regulator of the ERK / MAPK signaling pathway, which plays an important role in regulating cell proliferation and survival (K.S. Grossman et al., Adv. Cancer Res., 2010, 106, 53-89 and references cited therein).

[0006] Mutations in the PTPN11 gene affecting N-SH2 or PTP domain residues involved in the basal inhibition of SHP2 result in a more readily activatable form of the SHP2 protein, which can lead to unregulated or increased SHP2 activity. Such activated mutants of SHP2 are involved in developmental disorders such as Noonan syndrome, in which nearly all mutant forms of SHP2 exhibit increased PTP activity. Activating SHP2 mutations have also been detected in juvenile myelomonocytic leukemia (e.g., Q506P), chronic myelomonocytic leukemia (e.g., Y63C), neuroblastoma (e.g., T507K), melanoma (e.g., R138Q), acute myeloid leukemia (e.g., G503V), breast cancer, lung cancer (e.g., E76V), and colorectal cancer (e.g., E76G) (M. Bentires-Alj et al., Cancer Res. 2004, 64, 8816-8820; and references cited therein). Additional PTPN1 mutations associated with cancer are disclosed in WO2015 / 107495 and the references cited therein.

[0007] Mutations in the PTPN11 gene and subsequent mutations in SHP2 have been identified in several human diseases, such as Noonan syndrome (NS), Leopard syndrome, diabetes, neutropenia (Kostmann syndrome), systemic lupus erythematosus, neuroblastoma, melanoma, juvenile myelomonocytic leukemia, acute myeloid leukemia, juvenile leukemia, chronic myelomonocytic leukemia, and other cancers associated with dysregulation of SHP2, such as lung, colon, and breast cancers, including HER2-positive breast cancer, triple-negative breast cancer, ductal carcinoma, invasive ductal carcinoma, non-small cell lung cancer (including lung adenocarcinoma), esophageal cancer, gastric cancer, squamous cell carcinoma of the head and neck (SCCHN), and colon cancer (N. Aceto et al., Nature Medicine, 2012, 28, 529-538; C.M. Furcht et al., Oncogene, 2013, 32, 2346-2355; VE Schneeberger et al., Oncotarget, 2015, 6, 6191-6202; P. Cai et al., Biomedicine & Pharmacotherapy 2014, 6, 285-290; and references cited therein).

[0008] Therefore, SHP2 represents a highly attractive target for the development of novel therapies for the treatment of various diseases. The compounds of the present disclosure fulfill the need for small molecules to inhibit the activity of SHP2.

[0009] SHP2 phosphatase inhibitors are disclosed, for example, in WO2015 / 107493, WO2015 / 107494, WO2015 / 107495, WO2016 / 203404, WO2016 / 203405, WO2016 / 203406, WO2017 / 216706, WO2018 / 013597, WO2018 / 136264, WO2018 / 136265, WO2018 / 057884, WO2018 / 081091, and J. G. Fortanet et al., J. Med. Chem. 2016, doi: 10.1021 / acs.jmedchem.6b00600 and references cited therein. The effects of SHP2 phosphatase inhibition are described, for example, in Y.-N.P. Chen et al., Nature, 2016, doi. 10.1038 / nature / 18621; J. Wang et al., J. Clin. Invest., 2016, 126, 2077-2092, and references cited therein. Examples of SHP2 phosphatase inhibitors include 8-hydroxy-7-[(6-sulfo-2-naphthyl)azo]-5-quinolinesulfonic acid (NSC87077) and SHP099.

[0010] However, known compounds such as SHP099 (or the compound of WO2015 / 107493) and / or RMC-4550 (the compound of WO2018 / 013597) do not exhibit a high degree of selectivity for hErg, which is of great importance with regard to the safety of compounds intended to be used for the prevention or treatment of diseases.

[0011] Furthermore, the compounds of the present invention exhibit superior pharmacokinetic properties (e.g., lower clearance and / or higher exposure) compared to known compounds such as SHP099 (or the compound in WO2015 / 107493) or RMC-4550 (the compound in WO2018 / 013597).

[0012] Thus, there remains a need for highly effective SHP2 inhibitors that do not exhibit the described drawbacks. It was a specific object of the invention to provide improved methods for preventing or treating hyperproliferative diseases and disorders in a host, and in particular to provide effective SHP2 antagonists for the treatment and prevention of such diseases. Summary of the Invention

[0013] Summary of the Invention It has surprisingly been found that the carboxamido-pyrimidine derivatives of the present invention are highly effective inhibitors of SHP2 and therefore can be used for the treatment of hyperproliferative diseases and disorders such as cancer.

[0014] In addition, the compounds of the present invention are highly effective inhibitors of ERK1 / 2, a downstream SHP2 form of target in the signaling pathway (as mentioned above, SHP2 is a positive regulator of the ERK / MAPK signaling pathway, and ERK phosphorylation is dependent on SHP2 activation), which plays an important role in regulating cell proliferation and survival. This also confirms that the compounds of the present invention can be used to treat hyperproliferative diseases and disorders, such as cancer.

[0015] At the same time, the compounds of the present invention surprisingly possess a much higher selectivity for hErg (ion channel Kv11.1) than the known SHP2 antagonists SHP099, RMC-4550, and similar pyrimidine derivatives. The high hErg inhibitory activity of SHP099, RMC-4550, and similar pyrimidine derivatives clearly implies a risk of potential cardiotoxicity, which is avoided by the compounds of the present invention. This improved safety profile of the compounds of the present invention is coupled with more desirable pharmacokinetic properties and enhanced target engagement (lower IC50). The surprising properties of the compounds of the present invention represent an important and needed advance in the field of SHP2 inhibitors. [Brief explanation of the drawings]

[0016] [Figure 1] FIG. 1 shows that MSC2714002 suppressed MCP-1 production in U937 cells. DETAILED DESCRIPTION OF THE INVENTION

[0017] The present invention relates to compounds of general formula I*:

[0018] [ka]

[0019] (In the formula, R1 is a monocyclic or bicyclic alkyl, heterocyclyl, heteroaryl, or bicyclic alkylaryl containing 3 to 14 carbon atoms and 0 to 4 heteroatoms independently selected from N, O, and S, which is unsubstituted or (CH2) n NH2, (CH2) n OH, (CH2) n mono-, di- or tri-substituted by CH3 or Hal, X is a single bond, -NH or -N(CH3)-, (CH2) n or O, R2 is unsubstituted or (CH2) n NH2, (CH2) n aryl or heteroaryl, S-aryl or S-heteroaryl, mono-, di- or tri-substituted by OH, COOH, CONH2, alkyl, =S, =O, =NH, CN or Hal; R3 is H, NH2, OH, Hal or alkyl; Y is N or O; R4, R5 are both H, or one of R4 and R5 is OH, COOH, NH2, CONH2, or methyl or ethyl unsubstituted or substituted by =S, =O, OH, COOH, =NH, NH2, CONH2; Hal is F, Cl, Br, or I; n is 0, 1, 2 or 3 and physiologically acceptable salts, derivatives, solvates, prodrugs, stereoisomers and atropisomers thereof, including mixtures thereof in all ratios.

[0020] The present invention preferably comprises a compound of general formula I:

[0021] [ka]

[0022] or a pharmaceutically acceptable salt thereof, wherein R1 is monocycloalkyl, bicycloalkyl, monoheterocyclyl, or biheterocyclyl, any of which is optionally spiro bonded to the monocycloalkyl, bicycloalkyl, monoheterocyclyl, or biheterocyclyl, each of which mono- or bicycloalkyl and heterocyclyl is each optionally and independently substituted with 1 to 3 groups selected from C1-C6 alkyl, -F, -Cl, -CF3, -NH2, C1-C3 aminoalkyl, -OH, C1-C3 alkoxy, C1-C3 hydroxyalkyl, and phenyl; X is a bond, —NH—, or —N(Me)—; R2 is aryl or heteroaryl substituted with 1 to 3 groups selected from -F, -Cl, -CF3, C1-C3 alkoxy, and C1-C3 alkyl; R3 is -H, -NH2, -OH, -Cl, -F, -Br, or -CH3; Y is -N; and R4 and R5 are independently -H, -NH2, -OH, C1-C3 alkyl, or C1-C3 hydroxyalkyl).

[0023] The present invention preferably comprises compounds of the general formula Ia:

[0024] [ka]

[0025] or a pharmaceutically acceptable salt thereof, wherein each of R6, R7, and R8 is independently selected from -H, -F, -Cl, -CF3, C1-C3 alkoxy, and C1-C3 alkyl, and the remaining variables are as described for compounds of formula I.

[0026] The present invention preferably comprises a compound of general formula Ib:

[0027] [ka]

[0028] or a pharmaceutically acceptable salt thereof, wherein R1:

[0029] [ka]

[0030] and when A is the point of attachment to the pyrimidine ring of formula Ib: Each of R6, R7, and R8 is independently selected from -H, -F, -Cl, -CF3, C1-C3 alkoxy, and C1-C3 alkyl; n is 0, 1, 2, or 3; and Each of R9, R10, R11, R12, R13, R14, R15 and R16, if present, is independently selected from -H, C1-C3 alkyl, -NH2, -OH, -Cl, -F, -Br, C1-C3 aminoalkyl, C1-C3 hydroxyalkyl, C1-C3 alkoxy, and phenyl; or two of R9, R11, R13 and R16 together form a bridged bicyclic heterocyclic ring system optionally substituted with 1 to 3 substituents selected from C1-C3 alkyl, -NH2, -OH, -Cl, -F, -Br, C1-C3 aminoalkyl, C1-C3 hydroxyalkyl, C1-C3 alkoxy, and phenyl; or two of R9, R10, R11, R12, R13, R14, R15, and R16 bonded to the same carbon atom together form a monocyclic or bicyclic spirocyclyl optionally substituted with 1 to 3 substituents selected from C1-C3 alkyl, -NH2, -OH, -Cl, -F, -Br, C1-C3 aminoalkyl, C1-C3 hydroxyalkyl, C1-C3 alkoxy, and phenyl; or two of R9, R10, R11, R12, R13, R14, R15, and R16 bonded to adjacent anthrax atoms together form a fused carbocyclyl or heterocyclyl optionally substituted with 1 to 3 substituents selected from C1-C3 alkyl, -NH2, -OH, -Cl, -F, -Br, C1-C3 aminoalkyl, C1-C3 hydroxyalkyl, C1-C3 alkoxy, and phenyl; and the remaining variables have the meanings set forth for Formula I above.

[0031] The present invention preferably comprises compounds of the general formula Ic:

[0032] [ka]

[0033] wherein the remaining variables have the meanings described for Formula I above.

[0034] The present invention preferably comprises compounds of the general formula Id:

[0035] [ka]

[0036] wherein the remaining variables have the meanings described for Formula I above.

[0037] The present invention preferably comprises compounds of the general formula Ie:

[0038] [ka]

[0039] wherein the remaining variables have the meanings described for Formula I above.

[0040] The present invention preferably comprises a compound of the general formula If:

[0041] [ka]

[0042] wherein the remaining variables have the meanings described for Formula I above.

[0043] The present invention preferably relates to a compound in which R1 is one of the following structures:

[0044] [ka]

[0045] [ka]

[0046] which is unsubstituted or mono-, di- or trisubstituted by C1-C6 alkyl, -F, -Cl, -CF3, -NH2, C1-C3 aminoalkyl, -OH, C1-C3 alkoxy, or C1-C3 hydroxyalkyl, and X, R2, R3, Y, R4 and R5 have the meanings set out above.

[0047] The present invention is more preferably directed to compounds wherein X-R1 is one of the following structures:

[0048] [ka]

[0049] [ka]

[0050] wherein A represents the point of attachment to the pyrimidine ring, and the remaining variables have the meanings described for the formulae above, relative to compounds of formula I or formula Ia.

[0051] In one embodiment of the invention, with respect to Formula I or Formula Ia, X-R1 is:

[0052] [ka]

[0053] wherein A represents the point of attachment to the pyrimidine ring.

[0054] In one embodiment of the invention, with respect to Formula I or Formula Ia, X-R1 is:

[0055] [ka]

[0056] wherein A represents the point of attachment to the pyrimidine ring.

[0057] In one embodiment of the invention, with respect to Formula I or Formula Ia, X-R1 is:

[0058] [ka]

[0059] wherein A represents the point of attachment to the pyrimidine ring.

[0060] The present invention preferably relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein R2 is phenyl which is unsubstituted or mono-, di- or trisubstituted by -F, -Cl and / or -Br, and X, R1, R3, Y, R4 and R5 have the meanings set out above.

[0061] The present invention preferably provides a compound of formula (I) wherein R2 is one of the following structures:

[0062] [ka]

[0063] and X, R1, R3, Y, R4 and R5 have the meanings set out above, or a pharmaceutically acceptable salt thereof.

[0064] The present invention preferably relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein R3 is -NH2, and X, R1, R2, Y, R4 and R5 have the meanings set out above.

[0065] The present invention preferably relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein R3 is -CH3, and X, R1, R2, Y, R4 and R5 have the meanings set out above.

[0066] The present invention preferably relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein R3 is -H and X, R1, R2, Y, R4 and R5 have the meanings set out above.

[0067] The present invention preferably relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein R3 is -Cl and X, R1, R2, Y, R4 and R5 have the meanings set out above.

[0068] The present invention preferably relates to compounds of formula I, or a pharmaceutically acceptable salt thereof, wherein X is a single bond, -NH- or -N(CH3)-, and Y, R1, R2, R3, R4 and R5 have the meanings set out above.

[0069] In one aspect, the present invention provides a compound of formula Ib, or a pharmaceutically acceptable salt thereof, wherein R1 is:

[0070] [ka]

[0071] and when A is the point of attachment to the pyrimidine ring of formula Ib: Each of R6, R7, and R8 is independently selected from -H, -F, -Cl, -CF3, C1-C3 alkoxy, and C1-C3 alkyl; n is 0, 1, 2, or 3; and Each of R9, R10, R11, R12, R13, R14, R15 and R16, if present, is independently selected from -H, C1-C3 alkyl, -NH2, -OH, -Cl, -F, -Br, C1-C3 aminoalkyl, C1-C3 hydroxyalkyl, C1-C3 alkoxy, and phenyl; or two of R9, R11, R13 and R16 together form a bridged bicyclic heterocyclic ring system optionally substituted with 1 to 3 substituents selected from C1-C3 alkyl, -NH2, -OH, -Cl, -F, -Br, C1-C3 aminoalkyl, C1-C3 hydroxyalkyl, C1-C3 alkoxy, and phenyl; or two of R9, R10, R11, R12, R13, R14, R15, and R16 bonded to the same carbon atom together form a monocyclic or bicyclic spirocyclyl optionally substituted with 1 to 3 substituents selected from C1-C3 alkyl, -NH2, -OH, -Cl, -F, -Br, C1-C3 aminoalkyl, C1-C3 hydroxyalkyl, C1-C3 alkoxy, and phenyl; or Two of R9, R10, R11, R12, R13, R14, R15, and R16 bonded to adjacent anthrax atoms together form a fused carbocyclyl or heterocyclyl optionally substituted with 1 to 3 substituents selected from C1-C3 alkyl, -NH2, -OH, -Cl, -F, -Br, C1-C3 aminoalkyl, C1-C3 hydroxyalkyl, C1-C3 alkoxy, and phenyl.

[0072] The present invention particularly preferably relates to compounds selected from the group consisting of the following, and their pharmaceutically acceptable salts and atropisomers, including mixtures thereof in all ratios:

[0073] [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5]

Table 1-6

Table 1-7

Table 1-8

Table 1-9

Table 1-10

Table 1-11

Table 1-12

Table 1-13

Table 1-14

Table 1-15

Table 1-16

Table 1-17

Table 1-18

Table 1-19

Table 1-20

Table 1-21

Table 1-22

[0074] Where a variable of any one of the compounds of formula I, Ia, Ib, Ic, Id, Ie, and If is present, all of the above-mentioned embodiments of the above definition of that variable, it is to be understood that any of these specific embodiments can be combined with another in any possible embodiment in combination to produce a compound of the invention.

[0075] Alkyl is a saturated unbranched or branched hydrocarbon chain having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. Examples of "alkyl" groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl.

[0076] An aminoalkyl is an alkyl as defined above substituted with an -NH2 group.

[0077] Hydroxyalkyl is an alkyl as defined above substituted with an --OH group.

[0078] Alkoxy is a group of the formula -O(CH2) n It is a saturated unbranched or branched hydrocarbon chain having 1 to 10 C atoms of the formula CH3, where n is 0 to 9. Examples of alkoxy include methoxy, ethoxy, isopropoxy, etc.

[0079] Cyclic alkyl or cycloalkyl is a saturated cyclic hydrocarbon chain having 3 to 15 carbon atoms and can be in the form of a bridged, monocyclic, bicyclic and / or spiro-linked ring system. Monocyclic cycloalkyl groups preferably have 3 to 7 carbon atoms and preferably refer to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. Cycloalkyl may also refer to partially unsaturated cyclic alkyl, such as cyclohexenyl or cyclohexynyl. If a cycloalkyl group is part of a bicyclic ring system, at least one of the rings is a 3- to 7-membered cycloalkyl group, which may be fused to a 5- or 6-membered heteroaryl, a phenyl group, a 5- to 7-membered heterocyclyl, or a 5- to 7-membered cycloalkyl group. Examples of bicyclic ring systems embodied in the definition of cycloalkyl include, for example, 2,3-dihydro-1H-indenyl, 4H,5H,6H-cyclopenta[d][1,3]thiazolyl, 1,2,3,4-tetrahydronaphthalenyl, 5,6,7,8-tetrahydroquinolinyl, 5,6,7,8-tetrahydroisoquinolinyl, 5H,6H,7H-cyclopenta(b)pyridinyl, 5H,6H,7H-cyclopenta(c)pyridinyl, and the like.

[0080] Aryl, Ar or aromatic ring means a hydrocarbon chain of a mono- or polycyclic aromatic or fully unsaturated ring system, such as unsubstituted phenyl, naphthyl or biphenyl, more preferably phenyl, naphthyl or biphenyl, each of which is mono-, di- or trisubstituted by, for example, fluorine, chlorine, bromine, iodine, hydroxyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, nitro, cyano, formyl, acetyl, propionyl, trifluoromethyl, amino, methylamino, ethylamino, dimethylamino, diethylamino, benzyloxy, sulfonamido, methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, dimethylsulfonamido, phenylsulfonamido, carboxyl, methoxycarbonyl, ethoxycarbonyl, and / or amidyl.

[0081] Heterocycle and heterocyclyl refer to saturated or unsaturated non-aromatic monocyclic rings or partially or completely non-aromatic ring systems which may be bridged, bicyclic ("fused") and / or spiro-linked. Heterocyclyl contains at least one heteroatom selected from O, S, and N, and may further contain oxidized forms of sulfur, i.e., SO and SO. Monocyclic heterocyclyl groups are preferably 3 to 7 atoms and include azetidine, tetrahydrofuran (THF), dihydrofuran, 1,4-dioxane, morpholine, 1,4-dithiane, piperazine, piperidine, 1,3-dioxolane, imidazolidine, imidazoline, pyrroline, pyrrolidine, tetrahydropyran, dihydropyran, oxathiolane, dithiolane, 1,3-dioxane, 1,3-dithiane, oxathiane, thiomorpholine, oxolane, oxane, azepane, and the like. When a heterocyclyl group is part of a bicyclic ring system, at least one of the rings is a 3- to 7-membered heterocyclic ring, which may be fused to a 5- or 6-membered heteroaryl, a phenyl group, a 5- to 7-membered heterocyclyl, or a 5- to 7-membered cycloalkyl group. Examples of bicyclic ring systems embodied by the definition of heterocyclyl include, for example, 2H,3H-furo[2,3-b]pyridine, 2H,3H-furo[2,3-c]pyridine, 2H,3H-furo[2,3-d]pyridine, 2,3-dihydrobenzofuran, octahydro-1H-isoindole, octahydrocyclopenta[c]pyrrole, octahydropyrrolo[3,4-c]pyrrole, 3-azabicyclo[3.1.0]hexane, 3,9-diazabicyclo[4.2.1]non-3-yl, and the like.

[0082] Heteroaryl means an aromatic or partially aromatic heterocycle containing at least one ring heteroatom selected from O, S, and N. Thus, heteroaryl includes heteroaryls fused to other types of rings, such as aryls, cycloalkyls, and heterocycles that are not aromatic. Examples of heteroaryl groups include pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzofuranyl, indolinyl, pyridazinyl, indazolyl, isoxazolyl, isoindolyl, dihydrobenzothienyl, indolizinyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, carbazolyl, benzodioxinyl, benzodioxolyl, quinoxalinyl, purinyl, furazanyl, thiophenyl, isobenzylfuranyl, benzimidazolyl, benzofuranyl, benzothienyl, quinolyl, indolyl, isoquinolyl, dibenzofuranyl, and the like. With respect to heterocyclyl and heteroaryl groups, rings and ring systems containing from 3 to 15 atoms are included, forming from 1 to 3 rings.

[0083] A spiro-linked cyclic moiety refers to two rings or ring systems joined through a single common carbon atom. Spiro compounds can be fully carbocyclic (all carbon) or heterocyclic (having one or more non-carbon atoms). Spiro-linked cyclic moieties containing two rings are considered bicyclic; spiro-linked cyclic moieties in which a single ring is attached to a bicyclic moiety are considered tricyclic. Examples of spiro-linked bicyclic moieties include 8-azaspiro[4.5]decane, 2-oxa-8-azaspiro[4.5]decane, 2-azaspiro[3.4]octane, 6-azaspiro[3.4]octane, 2-oxa-6-azaspiro[3.4]octane, 2-azaspiro[4.4]nonane, 1-oxa-9-azaspiro[5.5]undecane, 5-azaspiro[2.4]heptane, 1,3-dicyclic cyclohexane, 1,3-di ... Examples include hydrospiro-[indene-2,4'-piperidine], 5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidine], 3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine], 3H-spiro[1-benzofuran-2,4'-piperidine], and 4,6-dihydrospiro[cyclopenta[d][1,3]thiazole-5,4'-piperidine].

[0084] The compounds of the present invention may form atropisomers, which are conformational isomers related to the pyrimidine moiety present in Formula I, Ia, Ib, Ic, Id, Ie and If. Atropisomers are stereoisomers resulting from restricted rotation of a single bond, where the energy difference due to steric strain or other contributing factors creates a barrier to rotation that is high enough to allow separation of individual conformers. There are two different atropisomers observed in the compounds of the present invention, which are shown below, for example, when R2 is phenyl substituted with R6, R7 and R8:

[0085] [ka]

[0086] These configurations are indicated in the naming of the compounds as being of M or P type, depending on the orientation of the aryl or heteroaryl group and the substituent R3 on the pyrimidine ring. Examples of M and P types are provided in the examples. Particularly preferred compounds are those with the following orientation:

[0087] [ka]

[0088] The present invention also relates to pharmaceutical preparations containing the compounds of the invention and / or their physiologically acceptable salts.

[0089] The invention also relates to pharmaceutical preparations of this type according to the invention which further contain excipients and / or adjuvants.

[0090] Additionally, the present invention relates to the above pharmaceutical preparations of the invention which further contain one or more additional therapeutic agents.

[0091] The compounds of the present invention can be used in their free base form. On the other hand, the present invention also encompasses the use of the compounds of the present invention in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic bases by procedures known in the art. The term pharmaceutical salt is used to refer to an ionizable drug combined with a counterion to form a neutral complex. Conversion of a drug to a salt via this process can increase its chemical stability, making the complex easier to administer and enabling manipulation of the drug's pharmacokinetic profile. Salt selection is now a standard operation performed with small ionizable molecules during drug discovery, and in many cases, these drug salts exhibit preferential properties compared to the parent molecule. For the most part, pharmaceutically acceptable salt forms of the compounds of the present invention are prepared by conventional methods.

[0092] In one embodiment, a pharmaceutically acceptable salt of a compound of the invention may be selected from hydrochloride, sodium, sulfate, acetate, phosphate or diphosphate, chloride, potassium, maleate, calcium, citrate, mesylate, nitrate, tartrate, aluminum, gluconate, benzoate, besylate, and edisylate. In one aspect of this embodiment, the pharmaceutically acceptable salt is benzoate, besylate, or edisylate.

[0093] Pharmaceutically acceptable salts of the compounds of the present invention include solvates of said salts. The term solvate is intended to mean an addition of inert solvent molecules to the compounds of the present invention, which occurs due to their mutual attractive force. Solvates are, for example, hydrates, such as monohydrates or dihydrates, or alcoholates, i.e., addition compounds with alcohols, for example, methanol or ethanol.

[0094] The compounds of general formula I may contain one or more chiral centers, and consequently all stereoisomers, enantiomers, diastereomers, etc. of the compounds of general formula I are also claimed by the present invention. The present invention therefore also relates to the optically active forms (stereoisomers), enantiomers, racemates, diastereomers, and hydrates and solvates of these compounds.

[0095] Furthermore, the compounds of Formula I are intended to include their isotopically enriched forms. Isotopically enriched forms of the compounds of Formula I are identical to the compounds except for the fact that one or more atoms of the compound have been replaced by a single atom or atoms having an atomic mass or atomic number different from the atomic mass or atomic number of the atom normally occurring in nature. Examples of isotopes that are readily commercially available and can be incorporated into compounds of Formula I by well-known methods include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, for example, 2 H, 3 H, 13 C. 14 C. 15 N, 18 O. 17 O. 31 P, 32 P,35 S, 18 F and 36 Compounds of Formula I, or pharmaceutically acceptable salts thereof, that contain one or more of the aforementioned isotopes and / or other isotopes of other atoms are intended to be part of the present invention. Isotopically labeled compounds of Formula I can be used in a number of beneficial ways. For example: 3 H or 14 Isotopically labeled compounds of formula I incorporating radioactive isotopes such as C are suitable for drug and / or substrate tissue distribution assays. These radioactive isotopes, i.e., tritium ( 3 H) and carbon-14 ( 14 C) are particularly preferred due to their simple preparation and excellent detectability. Heavier isotopes, such as deuterium ( 2 The incorporation of H) into compounds of formula I has therapeutic advantages due to the higher metabolic stability of the isotopically labeled compounds. Higher metabolic stability translates directly into an extended in vivo half-life or lower doses, which under most circumstances would represent preferred embodiments of the present invention. Isotopically labeled compounds of formula I can generally be prepared by replacing non-isotopically labeled reactants with readily available isotopically labeled reactants and following the procedures set forth in the synthetic schemes and related descriptions in the Examples and Preparations sections of this text.

[0096] Deuterium ( 2 H) can also be incorporated into compounds of formula I. The primary kinetic isotope effect is the change in the rate of a chemical reaction resulting from the exchange of an isotope nucleus, which in turn is caused by a change in the ground state energy required for covalent bond formation after this isotope exchange. Exchange with a heavier isotope usually results in a lowering of the ground state energy for the chemical bond, thus causing a decrease in the rate of rate-limiting bond breaking. If this bond breaking occurs within or near a saddle-point region along the coordinate of a multi-product reaction, the product distribution ratio can be substantially altered. By way of illustration: when deuterium is bonded to a carbon atom at a non-exchanged position, k M / kD A rate difference of 2-7 is representative. When this rate difference is successfully applied to a compound of formula I that is susceptible to oxidation, the in vivo profile of the compound is thereby dramatically altered and results in improved pharmacokinetic properties.

[0097] Substitution of hydrogen with deuterium in compounds of Formula I can also be used to achieve favorable alteration of the metabolic spectrum of the starting compound to reduce or eliminate undesired toxic metabolites. For example, if a toxic metabolite arises from oxidative carbon-hydrogen (C-H) bond cleavage, it can be theorized that a deuterated analog will greatly reduce or eliminate the production of the undesired metabolite, even if this particular oxidation is not the rate-limiting step. Further information on the state of the art regarding deuterium-hydrogen exchange is provided, for example, in Hanzlik et al., J. Org. Chem. 55, 3992-3997, 1990; Reider et al., J. Org. Chem. 52, 3326-3334, 1987; Foster, Adv. Drug Res. 14, 1-40, 1985; Gillette et al., Biochemistry 33(10), 2927-2937, 1994; and Jarman et al., Carsinogenesis 16(4), 683-688, 1993.

[0098] The present invention also relates to mixtures of compounds of formula I of the present invention, for example, mixtures of two atropisomers and / or two or more diastereomers, for example, 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100, or 1:1000. These mixtures of two stereoisomeric compounds are particularly preferred. In one embodiment of the present invention, the mixture of atropisomers and / or diastereomers contains at least 80% of the desired conformation. In one aspect of this embodiment, the mixture of atropisomers and / or diastereomers contains at least 85% of the desired conformation. In another aspect of this embodiment, the mixture of atropisomers and / or diastereomers contains at least 90% of the desired conformation. In one aspect of this embodiment, the mixture of atropisomers and / or diastereomers contains at least 95% of the desired conformation. In one aspect of this embodiment, the mixture of atropisomers and / or diastereomers contains at least 98% of the desired conformation.

[0099] If desired, the starting materials can also be formed in situ by not isolating them from the reaction mixture, but instead immediately further converting them to compounds of formula I.

[0100] The compounds of formula I are preferably obtained by liberating them from their functional derivatives by solvolysis, in particular by hydrolysis, or by hydrogenolysis.Preferred starting materials for solvolysis or hydrogenolysis contain correspondingly protected amino, carboxyl, and / or hydroxyl groups instead of one or more free amino, carboxyl, and / or hydroxyl groups, preferably carrying an amino-protecting group instead of the H atom bonded to the N atom.Furthermore, preference is given to starting materials carrying a hydroxyl-protecting group instead of the H atom of a hydroxyl group.Preference is also given to starting materials carrying a protected carboxyl group instead of a free carboxyl group.It is also possible for multiple identical or different protected amino, carboxyl, and / or hydroxyl groups to be present in the starting material molecule.When the protecting groups present are different from each other, they can often be selectively cleaved.

[0101] The term "amino-protecting group" is generally known and refers to a group suitable for protecting (blocking) an amino group against chemical reaction, but which can be easily removed after the desired chemical reaction has been carried out elsewhere in the molecule. Representatives of such groups are, in particular, unsubstituted or substituted acyl groups, as well as unsubstituted or substituted aryl groups (e.g., 2,4-dinitrophenyl) or aralkyl groups (e.g., benzyl, 4-nitrobenzyl, triphenylmethyl). Since these amino-protecting groups are removed after the desired reaction or reaction sequence, their type and size are not critical, although preference is given to those having 1 to 20, and in particular 1 to 8, carbon atoms. The term "acyl group" is understood in the broadest sense in connection with the present process. It encompasses acyl groups derived from aliphatic, arylaliphatic, aromatic, or heterocyclic carboxylic or sulfonic acids, in particular alkoxycarbonyl, aryloxycarbonyl, and especially aralkoxycarbonyl groups. Examples of such acyl groups include alkanoyl such as acetyl, propionyl, buturyl, aralkanoyl such as phenylacetyl, aroyl such as benzoyl or toluyl, aryoxyalkanoyl such as phenoxyacetyl, alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC, 2-iodoethoxycarbonyl, and aralkoxycarbonyl such as CBZ, 4-methoxybenzyloxycarbonyl, or FMOC. Preferred acyl groups are CBZ, FMOC, benzyl, and acetyl.

[0102] The terms "acid-protecting group" or "carboxyl-protecting group" are likewise commonly known and refer to groups suitable for protecting the -COOH group against chemical reaction, but which can be easily removed after the desired chemical reaction has been carried out elsewhere in the molecule. For example, the use of esters instead of free acids, such as substituted and unsubstituted alkyl esters (such as methyl, ethyl, tert-butyl and their substituted derivatives), substituted and unsubstituted benzyl esters or silyl esters, is typical. The type and size of these acid-protecting groups are not critical, with preference given to those having 1 to 20, in particular 1 to 10, C atoms.

[0103] The term "hydroxyl protecting group" is likewise commonly known and refers to a group that is suitable for protecting a hydroxyl group against chemical reaction, but that can be easily removed after the desired chemical reaction has been carried out elsewhere in the molecule. Representatives of such groups are the aforementioned unsubstituted or substituted aryl, aralkyl or acyl groups, as well as alkyl groups. The type and size of these hydroxyl protecting groups are not critical, but preference is given to those having 1 to 20, in particular 1 to 10, carbon atoms. Examples of hydroxyl protecting groups are, inter alia, benzyl, p-nitrobenzoyl, p-toluenesulfonyl and acetyl, where benzyl and acetyl are preferred.

[0104] Further representative examples of amino-, acid- and hydroxyl-protecting groups can be found, for example, in "Greene's Protective Groups in Organic Synthesis", 4th Edition, Wiley-Interscience, 2007.

[0105] The compounds obtained according to the present invention can be separated from the corresponding solution in which they are prepared (for example, by centrifugation and washing) and can be stored in a separate composition after separation, or can be kept directly in the solution in which they are prepared. The compounds obtained according to the present invention can also be incorporated into a desired solvent for a particular use.

[0106] Usual work-up steps, such as adding water to the reaction mixture and extracting, make it possible to obtain these compounds after removing the solvent. For further purification of the product, it may be advantageous to follow this with distillation or crystallization, or to carry out chromatographic purification.

[0107] Surprisingly, compounds of formula I have been found to have advantageous potency, selectivity, pharmacokinetic properties, dosing schedules, lower toxicity, and / or physical properties compared to prior art compounds.

[0108] The present invention further relates to the use of the compounds of the invention for the preparation of a medicament for the treatment of a disease caused, promoted and / or propagated by SHP2 or an agonist thereof.

[0109] The present invention therefore also relates to a pharmaceutical product containing at least one compound of the invention and / or one of its pharmaceutically acceptable salts, in particular for use in the treatment of physiological and / or pathophysiological conditions. Particular preference is given to physiological and / or pathophysiological conditions linked to SHP2. Physiological and / or pathophysiological conditions are understood to mean medically relevant physiological and / or pathophysiological conditions, such as, for example, diseases or illnesses and medical disorders, complaints or complications, in particular diseases.

[0110] The present invention further relates to a pharmaceutical composition containing at least one compound of the present invention and / or one pharmaceutically acceptable salt thereof for use in the treatment of a physiological and / or pathophysiological condition selected from the group consisting of hyperproliferative diseases and disorders. In one embodiment, the hyperproliferative disease or disorder is cancer.

[0111] The present invention therefore particularly relates to a medicinal product containing at least one compound of the invention and / or one of its pharmaceutically acceptable salts, wherein cancer is selected from the group consisting of acute and chronic lymphocytic leukemia, acute granulocytic leukemia, adrenocortical carcinoma, bladder cancer, brain tumors, breast cancer, cervical cancer, cervical hyperplasia, choriocarcinoma, colon cancer, endometrial cancer, esophageal cancer, essential thrombocytosis, genitourinary cancer, glioma, glioblastoma, hairy cell leukemia, head and neck cancer, Hodgkin's disease, Kaposi's sarcoma, lung cancer, lymphoma, malignant carcinoid tumors, malignant leukemia, leukemia, urinary tract cancer ... The cancer is selected from the group consisting of acute hypercalcemia, malignant melanoma, malignant pancreatic insulinoma, medullary thyroid carcinoma, melanoma, multiple myeloma, mycosis fungoides, myeloid and lymphocytic leukemia, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, polycythemia vera, primary brain tumor, primary macroglobulinemia, prostate cancer, renal cell carcinoma, rhabdomyosarcoma, skin cancer, small cell lung cancer, soft tissue sarcoma, squamous cell carcinoma, gastric cancer, testicular cancer, thyroid cancer, and Wilms' tumor. In one embodiment of the present invention, the cancer is selected from non-small cell lung cancer, small cell lung cancer, head and neck cancer, breast cancer, esophageal cancer, gastric cancer, colorectal cancer, glioblastoma, pancreatic cancer, osteosarcoma, melanoma, and kidney cancer. In one aspect of this embodiment, the cancer is head and neck cancer. In another aspect of this embodiment, the cancer is lung cancer. In one aspect of this embodiment, the lung cancer is non-small cell lung cancer. In another aspect of this embodiment, the lung cancer is small cell lung cancer. In another aspect of this embodiment, the cancer is colorectal cancer. In a further aspect of this embodiment, the cancer is esophageal cancer. In another aspect of this embodiment, the cancer is gastric cancer.

[0112] The present invention further relates to a pharmaceutical product containing at least one compound of the invention and / or one of its pharmaceutically acceptable salts for use in the treatment of a physiological and / or pathophysiological condition selected from the group consisting of hyperproliferative and infectious diseases and disorders, wherein the hyperproliferative disease or disorder is selected from the group consisting of age-related macular degeneration, Crohn's disease, cirrhosis of the liver, chronic inflammation-related disorders, proliferative diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, granulomatous diseases, immune cell hyperproliferation associated with organ or tissue transplantation, and inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus (SLE), vascular hyperproliferation and vasculitis secondary to retinal hypoxia.

[0113] The above-identified medicaments are intended to include the corresponding use of the compounds of the invention for the preparation of medicaments for the treatment of said physiological and / or pathophysiological conditions.

[0114] The above-identified medicaments are additionally intended to include corresponding methods for the treatment of said physiological and / or pathophysiological conditions, in which at least one compound of the invention is administered to a patient in need of such treatment.

[0115] The compounds of the present invention preferably exhibit advantageous biological activity that can be readily demonstrated in enzyme assays and animal studies, such as those described in the Examples. In such enzyme-based assays, the compounds of the present invention preferably exhibit and cause inhibitory effects, which usually have IC values ​​in the suitable range, preferably in the micromolar range and more preferably in the nanomolar range. 50 Documented by value.

[0116] The compounds of the present invention can be administered to humans or animals, particularly mammals such as monkeys, dogs, cats, rats or mice, and can be used in the therapeutic treatment of the human or animal body and in combating the aforementioned diseases. They can also be used as diagnostic agents or reagents.

[0117] Furthermore, the compounds of the present invention can be used to isolate and study the activity or expression of SHP2. In addition, they are particularly suitable for use in diagnostic methods for diseases associated with disrupted SHP2 activity. Thus, the present invention further relates to the use of the compounds of the present invention for the isolation and study of the activity or expression of SHP2, or as binders and inhibitors of SHP2.

[0118] For diagnostic purposes, the compounds of the present invention can be, for example, radiolabeled. Examples of radiolabels are: 3 H, 14 C. 231 I and 125 I. A preferred labeling method is the iodogen method (Fraker et al., 1978). In addition, the compounds of the present invention can be labeled with enzymes, fluorophores, and chromophores. Examples of enzymes are alkaline phosphatase, β-galactosidase, and glucose oxidase; examples of fluorophores are fluorescein; examples of chromophores are luminol; and automated detection systems, e.g., for fluorescence detection, are described in, e.g., US 4,125,828 and US 4,207,554.

[0119] The present invention therefore further relates to pharmaceutical preparations containing at least one compound of formula I and / or a pharmaceutically acceptable salt thereof. In particular, the present invention also relates to pharmaceutical preparations which comprise further excipients and / or adjuvants, as well as pharmaceutical preparations which also comprise at least one further pharmaceutically active compound.

[0120] In particular, the present invention also relates to a process for the preparation of a pharmaceutical preparation, characterized in that a compound of formula I and / or one of its pharmaceutically acceptable salts is brought into a suitable dosage form together with a solid, liquid or semi-liquid excipient or adjuvant and optionally one or more additional therapeutic agents.

[0121] The pharmaceutical preparations of the present invention can be used as medicines in human or veterinary medicine. The patient or host can belong to any mammalian species, such as primate species, particularly humans; rodents, including mice, rats, and hamsters; rabbits; horses, cattle, dogs, cats, etc. Animal models are of interest for experimental research, where they provide models for the treatment of human diseases.

[0122] Suitable carrier materials are organic or inorganic substances suitable for enteral (e.g., oral), parenteral, or topical administration and which do not react with the novel compounds, such as water, vegetable oils (sunflower oil or cod liver oil), benzyl alcohol, polyethylene glycol, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc, lanolin, or petrolatum. Those skilled in the art will be familiar with their expertise in determining which adjuvants are suitable for the desired pharmaceutical formulation. In addition to solvents such as water, saline, or alcohols such as ethanol, propanol, or glycerol, sugar solutions such as glucose or mannitol solutions, or mixtures of such solvents, gel-forming agents, tableting aids, and other active ingredient carriers, it is also possible to use, for example, lubricants, stabilizers and / or wetting agents, emulsifiers, salts for influencing osmotic pressure, antioxidants, dispersants, antifoaming agents, buffers, flavors and / or fragrances or flavor correctors, preservatives, solubilizers, or dyes. If desired, the preparation or medicament according to the invention may contain one or more further active compounds, for example one or more vitamins.

[0123] If desired, the preparations or medicaments of the invention may contain one or more further active compounds and / or one or more action-enhancing agents (adjuvants).

[0124] The terms "pharmaceutical formulation" and "pharmaceutical preparation" are used synonymously for the purposes of the present invention.

[0125] As used herein, "pharmaceutically acceptable" refers to pharmaceutical agents, precipitating reagents, excipients, adjuvants, stabilizers, solvents, and other substances that facilitate the administration of pharmaceutical preparations obtained therefrom to mammals without undesirable physiological side effects, such as, for example, nausea, dizziness, dyspepsia, etc.

[0126] For pharmaceutical preparations for parenteral administration, there are requirements for isotonicity, euhydration and tolerability, as well as safety of the formulation (low toxicity), of the adjuvants used and of the primary packaging. Surprisingly, the compounds of the present invention preferably have the advantage that they can be used directly, and therefore no further purification steps for removing toxicologically unacceptable substances, such as high concentrations of organic solvents or other toxicologically unacceptable adjuvants, are required before using the compounds of the present invention in pharmaceutical preparations.

[0127] The present invention particularly preferably also relates to pharmaceutical preparations containing at least one compound of the invention in precipitated amorphous, precipitated crystalline or dissolved or suspended form, and optionally excipients and / or adjuvants and / or further pharmaceutically active compounds.

[0128] The compounds of the present invention advantageously allow the preparation of highly concentrated formulations without the occurrence of undesirable and undesirable aggregation of the compounds of the present invention. Thus, ready-to-use solutions with high active ingredient contents can be prepared with the compounds of the present invention in aqueous solvents or media.

[0129] The compounds and / or their physiologically acceptable salts and solvates may also be lyophilized and the lyophilizates obtained used, for example, for the preparation of injectable preparations.

[0130] The pharmaceutical preparations of the invention may also contain mixtures of more than one compound of the invention.

[0131] The preparations of the present invention are physiologically well tolerated, easily prepared, accurately dispensed, and preferably stable with respect to assay, degradation products, and aggregation, through storage and transport and multiple freeze-thaw processes. They can preferably be stored in a stable manner at refrigerator temperature (2-8°C) and room temperature (23-27°C) and a relative atmospheric humidity (RH) of 60% for a period of at least 3 months to 2 years.

[0132] For example, the compounds of the present invention can be stored in a stable manner by drying and, if necessary, converted into a ready-to-use pharmaceutical preparation by dissolving or suspending them. Possible drying methods include, but are not limited to, nitrogen-gas drying, vacuum oven drying, freeze drying, washing with organic solvents followed by air drying, liquid bed drying, fluidized bed drying, spray drying, roller drying, layer drying, air drying at room temperature, and further methods.

[0133] The term "effective amount" means an amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, that elicits the biological or medical response required or desired, for example, by a researcher or physician, in a tissue, system, animal or human.

[0134] Additionally, the term "therapeutically effective amount" refers to an amount that has the following result compared to a corresponding subject not receiving this amount: amelioration of one or more symptoms, amelioration or elimination of a disease, syndrome, condition, complaint, or disorder, or prevention of a side effect. A "therapeutically effective amount" also encompasses alleviation of the progression of a disease, complaint, or disorder. In the context of cancer treatment, a "therapeutically effective amount" may lead to a reduction in the subject's tumor tissue burden, a delay in the progression of the disease ("progression-free survival"), an increase in the subject's life expectancy (improved overall survival), a slowing or prevention of metastasis of the primary tumor to other tissues, and / or an improvement in the quality of life of the subject being treated. The term "therapeutically effective amount" also encompasses an amount that is effective with respect to enhancing normal physiological function.

[0135] One embodiment of the present invention is the use of a preparation or medicament comprising a compound of the present invention and / or a pharmaceutically acceptable salt thereof, with the preparation having a dosage of 0.1 to 500 mg, particularly 1 to 300 mg, per unit used. This daily dose is preferably 0.001 to 250 mg / kg, particularly 0.01 to 100 mg / kg of body weight. The preparation can be administered one or more times per day, for example, two, three, or four times per day. However, the individual dosage for a patient will depend on numerous individual factors, including, for example, the efficacy of the specific compound used, age, body weight, general health, sex, nutrition, time and method of administration, excretion rate, combination with other medicinal products, and the severity and duration of the particular disease.

[0136] The measurement of the uptake of a pharmaceutically active compound in an organism is its bioavailability.When a pharmaceutically active compound is delivered to an organism intravenously in the form of an injectable solution, its absolute bioavailability, that is, the proportion of the drug that reaches the systemic blood, i.e., the main circulation, in an unaltered form, is 100%.When a therapeutically active compound is orally administered, this active compound is generally in the form of a solid in a formulation, and therefore must first be dissolved in order to be able to cross the barrier of entry, such as the gastrointestinal tract, oral mucosa, nasal mucosa, or skin, especially the stratum corneum, or be absorbed by the body.Pharmacokinetics, i.e., bioavailability data, can be obtained similarly by the method of J. Shaffer et al., J. Pharm. Sciences, 88 (1999), 313-318.

[0137] Furthermore, such pharmaceutical preparations can be prepared by one of the processes generally known in the pharmaceutical art.

[0138] The medicaments may be adapted for administration via any desired suitable route, for example, oral (including buccal or sublingual), rectal, pulmonary, nasal, topical (including buccal, sublingual or transdermal), vaginal, or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, and especially intra-arterial) routes. Medicaments of this kind may be prepared by any process known in the art of formulation, for example, by combining the active compound with the excipient(s) or adjuvant(s).

[0139] Suitable for enteral administration (oral or rectal) are, in particular, tablets, dragees, capsules, syrups, juices, drops or suppositories, and suitable for topical use are ointments, creams, pastes, lotions, gels, sprays, foams, aerosols, solutions (e.g., solutions in alcohols such as ethanol or isopropanol, acetonitrile, DMF, dimethylacetamide, 1,2-propanediol or mixtures thereof with others and / or with water) or powders. Also particularly suitable for topical use are liposomal preparations.

[0140] It will be appreciated that in addition to the ingredients particularly mentioned above, the pharmaceutical preparations of the present invention may also include other substances common in the art for the particular type of pharmaceutical preparation.

[0141] The present invention also provides a) an effective amount of a compound of formula I and / or its physiologically acceptable salts, derivatives, solvates, prodrugs, stereoisomers and atropisomers, including mixtures thereof in all ratios; and b) an effective amount of a further pharmaceutically active compound, in separate packs.

[0142] The set includes suitable containers, such as a box or carton, individual bottles, bags, or ampoules, and includes, for example, individual ampoules, each containing an effective amount of a compound of Formula I and / or a pharmaceutically acceptable salt thereof, in dissolved or lyophilized form, and an effective amount of one or more additional therapeutic agents.

[0143] Additionally, the pharmaceutical agents of the present invention can be used to provide additive or synergistic effects with certain known therapies and / or can be used to restore the effectiveness of certain existing therapies.

[0144] In addition to the compounds of the invention, the pharmaceutical preparations of the invention may also contain one or more additional therapeutic agents, such as other anti-tumor drugs for use in the treatment of cancer. For the treatment of the other diseases mentioned, the pharmaceutical preparations of the invention may also contain, in addition to the compounds of the invention, further pharmaceutically active compounds known to those skilled in the art for their treatment.

[0145] In one embodiment, a compound of the invention or a pharmaceutically acceptable salt thereof is administered in combination with one or more additional therapeutic agents. In one aspect of the invention, the one or more additional therapeutic agents are an EGFR inhibitor, a MET inhibitor, a PD-L1 inhibitor, a MEK1 / 2 inhibitor, a TGF-βR pathway inhibitor, or a combination thereof. In another aspect of this embodiment, the one or more additional therapeutic agents are erbitux, tepotinib, avelumab, Muc1-TGFβR2Nb, EGFR-Muc1-ADC, pimasertib, pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, or a combination thereof. In one aspect of this embodiment, the one or more additional therapeutic agents are erbitux, tepotinib, avelumab, pimasertib, or a combination thereof.

[0146] In one major embodiment, a method for enhancing an immune response in a host in need thereof is provided. The immune response can be enhanced by reducing T cell tolerance, including by increasing IFN-γ release, reducing the generation or activation of regulatory T cells, or increasing the generation of antigen-specific memory T cells in the host. In one embodiment, the method comprises administering a compound of the present invention to a host, in combination or alternation with an antibody. In one aspect of this embodiment, the antibody is a therapeutic antibody. In one particular embodiment, a method for enhancing the effectiveness of passive antibody therapy is provided, comprising administering a compound of the present invention in combination or alternation with one or more passive antibodies. This method can enhance the effectiveness of antibody therapy for the treatment of abnormal cell proliferative disorders such as cancer, or can enhance the effectiveness of therapy in the treatment or prevention of infectious diseases. The compound of the present invention can be administered in combination or alternation with an antibody, such as, for example, rituximab, Herceptin, or Erbitux.

[0147] In another main embodiment, there is provided a method of treating or preventing abnormal cell growth comprising administering to a host in need thereof a compound of this invention in the substantial absence of another anti-cancer agent.

[0148] In another major embodiment, a method is provided for treating or preventing abnormal cell growth in a host in need thereof, comprising administering to the host a first compound of the present invention substantially in combination with a first anti-cancer agent, followed by administration of a second SHP2 antagonist. In one aspect of this embodiment, the second antagonist is administered in the substantial absence of another anti-cancer agent. In another major embodiment, a method is provided for treating or preventing abnormal cell growth in a host in need thereof, comprising administering to the host a compound of the present invention substantially in combination with a first anti-cancer agent, followed by administration of a second anti-cancer agent in the substantial absence of the antagonist.

[0149] Thus, the cancer treatments disclosed herein can be carried out as therapy with the compounds of the present invention or in combination with surgery, radiation, or chemotherapy. Such chemotherapy can include the use of one or more additional therapeutic agents selected from the group consisting of: (i) Antiproliferative / antineoplastic / DNA-damaging active compounds and combinations thereof, as used in medical oncology, such as alkylating agents (e.g., cisplatin, parvoplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulfan and nitrosoureas); antimetabolites (e.g., antifolates, e.g., fluoropyrimidines such as 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea and gemcitabine); antitumor antibiotics (e.g., anthracyclines, e.g., adriamycin, bleomycin, thiazolinone); isin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin, and mithramycin); antimitotic agents (e.g., vinca alkaloids, such as vincristine, vinblastine, vindesine, and vinorelbine, and taxoids, such as taxol and taxotere); topoisomerase inhibitors (e.g., epipodophyllotoxins, such as etoposide and teniposide, amsacrine, topotecan, irinotecan, and camptothecin), and cell differentiation inducers (e.g., all-trans-retinoic acid, 13-cis-retinoic acid, and fenretinide); (ii) Cytostatic agents, such as antiestrogens (e.g., tamoxifen, toremifene, raloxifene, droloxifene, and iodoxifene), estrogen receptor modulators (e.g., fulvestrant), antiandrogens (e.g., bicalutamide, flutamide, nilutamide, and cyproterone acetate), LHRH antagonists or agonists (e.g., goserelin, leuprorelin, and buserelin), progesterones (e.g., megestrol acetate), aromatase inhibitors (e.g., anastrazole, letrozole, vorazole, and exemestane), and 5α-reductase inhibitors, such as finasteride; (iii) active compounds that inhibit cancer invasion, such as metalloproteinase inhibitors, as well as inhibitors of urokinase plasminogen activator receptor function, such as marimastat; (iv) inhibitors of growth factor function, such as, for example, growth factor antibodies, growth factor receptor antibodies, for example, the anti-erbb2 antibody trastuzumab [Herceptin™] and the anti-erbb1 antibody cetuximab [C225]), farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine / threonine kinase inhibitors, for example, inhibitors of the epidermal growth factor family (for example, EGFR family tyrosine kinase inhibitors, for example, N(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033), for example, inhibitors of the platelet-derived growth factor family, for example, inhibitors of the hepatocyte growth factor family; (v) antiangiogenic agents, such as bevacizumab, angiostatin, endostatin, linomide, batimastat, captopril, cartilage-derived inhibitors, genistein, interleukin-12, lavendustin, merodoxyprogesterone acetate, recombinant human platelet factor 4, tecogalan, thrombospondin, TNP-470, anti-VEGF monoclonal antibodies, soluble VEGF-receptor chimeric proteins, anti-VEGF receptor antibodies, anti-PDGF receptors, inhibitors of integrins, tyrosine kinase inhibitors, serine / threonine kinase inhibitors, antisense oligonucleotides, antisense oligodeoxynucleotides, siRNA, anti-VEGF aptamers, pigment epithelium-derived factors, and compounds disclosed in International Patent Applications WO 97 / 22596, WO 97 / 30035, WO 97 / 32856 and WO 98 / 13354); (vi) vascular disrupting agents, such as combretastatin A4 and compounds disclosed in international patent applications WO99 / 02166, WO00 / 40529, WO00 / 41669, WO01 / 92224, WO02 / 04434 and WO02 / 08213; (vii) antisense therapy, e.g., directed against the aforementioned targets, e.g., ISIS 2503, anti-Ras antisense; (viii) gene therapy approaches, including approaches for the replacement of abnormally modified genes, such as, for example, abnormal p53 or abnormal BRCA1 or BRCA2, GDEPT approaches (gene-directed enzyme prodrug therapy), for example, those using cytosine deaminase, thymidine kinase, or bacterial nitroreductase enzymes, and approaches to increasing a patient's tolerance to chemotherapy or radiation therapy, such as multidrug resistance therapy; and (ix) immunotherapeutic approaches, including, for example, ex vivo and in vivo approaches to increase the immunogenicity of a patient's tumor cells, e.g., transfection with cytokines such as interleukin-2, interleukin-4, or granulocyte-macrophage colony-stimulating factor, approaches to reduce T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumor cells, and approaches using anti-idiotypic antibodies; (x) For example, abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amifostine, anastrazole, arsenic trioxide, asparaginase, live BCG, bevacizumab, bexarotene, bleomycin, bortezomib, busulfan, calucelone, camptothecin, capecitabine, carboplatin, carmustine, celecoxib, cetuximab, chlorambucil, cinacalcet, and cisplatin Chemotherapeutic agents, including cladribine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, darbepoetin alfa, daunorubicin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone, epirubicin, epoetin alfa, estramustine, etoposide, exemestane, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, and gemcitabine.

[0150] The additional therapeutic agents of Table 1 may be preferably, but not exclusively, combined with compounds of Formula I.

[0151] [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Example]

[0152] It is contemplated that those skilled in the art will be able to use the preceding description to its fullest extent, even without further embodiments, and the preferred embodiments are therefore merely considered to be descriptive disclosures that are definitive but not limiting in any way.

[0153] The following examples are therefore intended to illustrate the invention without limiting it. Unless otherwise indicated, percentage data mean percentages by weight. All temperatures are given in degrees Celsius. "Normal work-up": water is added if necessary, the pH is adjusted if necessary to a value between 2 and 10, the mixture is extracted with ethyl acetate or dichloromethane depending on the composition of the final product, the phases are separated, the organic phase is dried over sodium sulfate, filtered and evaporated, and the product is purified by chromatography on silica gel and / or crystallization.

[0154] List of abbreviations AUC Area under the plasma drug concentration-time curve C max Maximum plasma concentration CL Clearance CV coefficient of variation CYP cytochrome P450 DMSO dimethyl sulfoxide %F Bioavailability f a Absorption rate iv intravenous LC-MS / MS Liquid Chromatography Tandem Mass Spectrometry LLOQ Lower limit of quantitation NC No calculation NT not tested PEG polyethylene glycol Pgp permeability glycoprotein PK Pharmacokinetics(s) po: by mouth (oral) t 1 / 2 Half-life t max Time to reach maximum plasma concentration of the drug UPLC Ultra High Performance Liquid Chromatography Vss Volume of distribution (at steady state) v / v volume to volume

[0155] Example 1: Examples of compounds of the invention The present invention relates to the compounds of Table 2 and their physiologically acceptable salts, derivatives, solvates, prodrugs, stereoisomers and atropisomers, including mixtures thereof in all proportions.

[0156] [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7] [Table 3-8] [Table 3-9] [Table 3-10] [Table 3-11] [Table 3-12] [Table 3-13]

Table 3-14

Table 3-15

Table 3-16

Table 3-17

Table 3-18

Table 3-19

Table 3-20

Table 3-21

Table 3-22

Table 3-23

Table 3-24

Table 3-25

Table 3-26

Table 3-27

Table 3-28

Table 3-29

Table 3-30

[0157] Example 2: Preparation and analytical methods of compounds of the invention The following abbreviations have the following meanings: Boc ter-butoxycarbonyl CBZ benzyloxycarbonyl DNP 2,4-dinitrophenyl FMOC 9-Fluorenylmethoxycarbonyl imi-DNP 2,4-dinitrophenyl at the 1-position of the imidazole ring OMe methyl ester POA Phenoxyacetyl DCCI Dicyclohexylcarbodiimide HOBt 1-hydroxybenzotriazole

[0158] In general, compounds of Formula (I) and related formulae of the present invention can be prepared from readily available starting materials. Where such starting materials are not commercially available, they may be prepared by standard synthetic techniques. In general, the synthetic routes for individual compounds of Formula (I) and related formulae will depend on the specific substituents of each molecule, and such factors will be understood by those of skill in the art. The following general methods and procedures, illustrated below in the Examples, may be utilized to prepare compounds of Formula (I) and related formulae. These methods are illustrative and are not intended to limit the possible methods that one of skill in the art may use to prepare the compounds disclosed herein. Reaction conditions depicted in the following schemes, such as temperature, solvents, or co-reagents, are given by way of example only and are not limiting. Where representative or preferred experimental conditions (i.e., reaction temperature, time, moles of reagents, solvent, etc.) are given, it will be understood that other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by one of skill in the art using route optimization procedures. For complete protection and deprotection methods, see Philip J. Kocienski, "Protection Groups," Georg Thieme Verlag Stuttgart, New York, 1994, and Theodora W. Greene and Peter GM Wuts, "Protective Groups in Organic Synthesis," Wiley Interscience, 3rd Edition, 1999.

[0159] For the synthesis of compounds of formula (I), different synthetic strategies may be selected depending on the nature of R1, R2, R3, R4, R5, X and Y. In the processes illustrated in the following schemes, R1, R2, R3, R4, R5, X and Y are as defined in the preceding description unless otherwise stated.

[0160] According to one process, pyrimidine derivatives of general formula 4 (wherein R2 and R3 are as described above, R20 and R21 are H, substituted alkyl, heteroalkyl, or can together form a monocyclic or polycyclic alkyl or heteroalkyl, which may be substituted or unsubstituted, and R8 is COYR4R5, where Y, R4 and R5 are as described above or are CN) can be prepared according to the reaction scheme described in Scheme 1.

[0161] [ka]

[0162] Scheme 1 Pyrimidine 1 (wherein R3 and R8 are as previously described and LG1 is a halogen or a leaving group such as OMs, OTs, OTf) undergoes a substitution reaction with an amine NHR20R21 (wherein R20 and R21 are as previously described) by heating in a solvent such as, but not limited to, MeOH, EtOH, DMF, DMSO, in the presence or absence of a base such as TEA, DIEA, Cs2CO3, or K2CO3 to yield pyrimidines of general formula 2 (wherein R3, R20, R21, and R8 are as previously defined). Pyridine 2 is then subjected to halogenation conditions using, for example, NBS, NCS, or NIS to yield intermediates of general formula 3 (wherein R3, R20, R21, and R8 are as previously described and Hal is a halogen atom such as Cl, Br, or I). Finally, pyrimidine 3 undergoes a cross-coupling reaction using standard conditions well known to those skilled in the art to give pyrimidine 4. In some embodiments, the cross-coupling reaction is a Suzuki reaction, although other cross-coupling reactions may also be utilized.

[0163] Alternatively, pyrimidine derivatives of general formula 4 (wherein R2, R3, R20, R21, R8 are defined above) can be prepared according to the reaction scheme depicted in Scheme 2.

[0164] [ka]

[0165] Scheme 2 In this reaction sequence, thiomethyl compound 5 (wherein R3 and R8 are defined above) is first subjected to halogenation conditions and then to cross-coupling conditions to yield intermediate compound 7 (wherein R2, R3, R8 are defined above). The thiomethyl group is then oxidized to SO2Me using standard conditions well known to those skilled in the art, such as mCPBA or HO2, to yield intermediate 8 (wherein R2, R3, and R8 are defined above). Finally, intermediate 8 undergoes a substitution reaction with NHR20R21 (wherein R20 and R21 are defined above).

[0166] A final transformation of R8 is required to obtain the final compounds of general formula Ia.

[0167] When R8 is COOR19 (wherein R19 is H, alkyl, cycloalkyl), the final compounds of general formula I are produced when COOR19 is reacted with an amine HNR4R5 (wherein R4 and R5 are as previously described) using conditions well known to those skilled in the art for preparing amides from amines and carboxylic acids or carboxylic acid derivatives with standard coupling agents such as DIC, EDC, TBTU, DECP, etc., or others depicted in Scheme 3.

[0168] [ka]

[0169] Scheme 3 When R8 is CN, the final compound of general formula I (where R2, R3, R4, R20 and R21 are defined above) can be obtained by hydrolysis of a compound of general formula 4b (where R2, R3, R5 and R7 are defined above) to give an acid of general formula 9 (where R2, R3, R5 and R7 then undergo an amide coupling reaction as depicted in Scheme 4). Alternatively, compounds of general formula Ib can be obtained by direct hydrolysis of a compound of general formula 4b (where R2, R3, R5 and R7) using conditions well known to those skilled in the art, such as heating in the presence of NaOH and HO in DMF or DMSO.

[0170] [ka]

[0171] Scheme 4 For the synthesis of other compounds of general formula I, analogous synthetic schemes should be adapted with appropriate modifications tailored to the specific substituents of each molecule, such factors being understood by those skilled in the art.

[0172] According to a further general process, compounds of formula I can be converted to alternative compounds of formula I using suitable interconversion techniques, such as those illustrated in the Examples below.

[0173] All NMR experiments were recorded on a Bruker Avance III 400 NMR Spectrometer, equipped with a Bruker PABBO BB-1H / DZ GRD probe at 400 MHz for proton NMR, or a Bruker DPX-300 MHz. Most deuterated solvents typically contain 0.03%-0.05% v / v tetramethylsilane, which provides the reference signal ( 1 H and 13The peaks were used as reference signals (set at 0.00 for both C and C). When the deuterated solvent did not contain tetramethylsilane, the peak of the remaining non-deuterated solvent was used as the reference signal according to published guidelines (J. Org. Chem., Vol. 62, No. 21, 1997). Chemical shifts are expressed in parts per million (ppm, δ units). Coupling constants are in hertz (Hz). Splitting patterns indicate apparent multiplicity and are designated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), qt (quintet), or brs (broad singlet).

[0174] The following abbreviations refer to the abbreviations used below: Ac (acetyl); ACN (acetonitrile); atm (atmospheric pressure); DIEA (diisopropylethylamine); °C (degrees Celsius); DMF (dimethylformamide); DMSO (dimethyl sulfoxide); dppf (1,1 ’ -bis-diphenylphosphineferrocene; EtOAc (ethyl acetate); g (gram); h (hour); HATU (N-[(dimethylamino)(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methylmethanaminium hexafluorophosphate); HOBt (hydroxybenzotriazole); HPLC (high performance liquid chromatography); h (hour); LC (liquid chromatography); LDA (lithium diisopropylamide); MeOH (methanol); min (minute); mL (milliliter); mmol (millimol); MS (mass spectrometry); NBS (N-bromosuccinimide); NMR (nuclear magnetic resonance); O / N (overnight); PE (petroleum ether); RT (room temperature); TBDMS (tert-butyldimethylsilyl); TEA (triethylamine); TFA (trifluoroacetic acid); THF (tetrahydrofuran); TMS (trimethylsilyl).

[0175] UPLC / MS analysis was performed on a Waters AquityH equipped with an SQ detector (ESI), and LC / MS was performed on an Agilent 1200 Series equipped with a quadrupole detector or on a SHIMADZU LC-MS instrument consisting of a UFLC 20-AD system and an LCMS 2020 MS detector.

[0176] Microwave reactions were carried out using a Biotage Initiator Microwave Synthesizer using standard protocols known in the art.

[0177] The compounds of the present invention were prepared from readily available starting materials by several synthetic approaches. Exemplary synthetic routes are described below in the Examples. Unless otherwise specified, compounds of the present invention obtained as racemic mixtures can be separated to provide enantiomerically enriched mixtures or pure enantiomers.

[0178] Commercially available starting materials used in the following experimental descriptions were purchased from Sigma-Aldrich or Fisher unless otherwise stated.

[0179] Intermediate 1: tert-butyl (1-(5-bromo-4-cyanopyrimidin-2-yl)-4-methylpiperidin-4-yl)carbamate Step 1: tert-butyl (1-(4-cyanopyrimidin-2-yl)-4-methylpiperidin-4-yl)carbamate

[0180] [ka]

[0181] A solution of 2-chloropyrimidine-4-carbonitrile (2 g, 14.3 mmol), cesium carbonate (11.62 g, 35.7 mol), and tert-butyl (4-methylpiperidin-4-yl)carbamate (3.38 g, 15.8 mmol) in DMF (30 mL) was stirred at 110° C. overnight. The reaction mixture was filtered through a Celite pad. The pad was washed with EtOAc (50 mL), and the filtrate was washed with brine. The organic layer was dried over magnesium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (PE:EtOAc, 100:0 to 50:50 gradient) provided the title compound as a white solid (2 g, 66%). 1H NMR (400 MHz, DMSO-d6): 8.61 (s, 1H), 7.10 (s, 1H), 6.60 (brs, 1H), 4.06 (m, 2H), 3.38 (m, 2H), 2.07 (m, 2H), 1.42 (m, 2H), 1.39 (s, 9H), 1.25 (s, 3H).

[0182] Step 2: tert-butyl (1-(5-bromo-4-cyanopyrimidin-2-yl)-4-methylpiperidin-4-yl)carbamate

[0183] [ka]

[0184] To a solution of tert-butyl (1-(4-cyanopyrimidin-2-yl)-4-methylpiperidin-4-yl)carbamate (2 g, 6.31 mmol) in anhydrous acetonitrile (30 mL) was added N-bromo-succinimide (1.2 g, 6.93 mmol) in small portions at 0° C. The reaction mixture was stirred at room temperature for 1 h, then quenched with ice and extracted with EtOAc (50 mL). The organic layer was dried over sodium sulfate, filtered and concentrated. Purification by flash chromatography on silica (PE:EtOAc, 100:0-85:15 gradient) provided the title compound as a white solid (2 g, 80%). 1H NMR (400 MHz, DMSO-d6): 8.75 (s, 1H), 6.66 (brs, 1H), 4.01 (m, 2H), 3.35 (m, 2H), 2.08 (m, 2H), 1.43 (m, 2H), 1.39 (s, 9H), 1.22 (s, 3H).

[0185] Intermediate 2: tert-butyl N-[1-(4-amino-5-bromo-6-carbamoylpyrimidin-2-yl)-4-methylpiperidin-4-yl]carbamate Step 1: tert-butyl N-[1-(4-amino-6-carbamoylpyrimidin-2-yl)-4-methylpiperidin-4-yl]carbamate

[0186] [ka]

[0187] A mixture of 6-amino-2-chloropyrimidine-4-carboxamide (700 mg, 3.20 mmol), tert-butyl N-(4-methylpiperidin-4-yl)carbamate (1.3 g, 5.76 mmol), and TEA (822 mg, 7.72 mmol) in acetonitrile (11 mL) was heated in a sealed tube at 80° C. for 18 h. The solvent was then removed under reduced pressure, and the crude material was directly purified by flash chromatography on silica (PE:EtOAc, 90:10) to yield the title compound as a yellow solid (1.2 g, 100%). LC / MS (M+1): 351.2.

[0188] Step 2: tert-butyl N-[1-(4-amino-5-bromo-6-carbamoylpyrimidin-2-yl)-4-methylpiperidin-4-yl]carbamate

[0189] [ka]

[0190] NBS (243 mg, 1.30 mmol) was added portionwise to a solution of tert-butyl N-[1-(4-amino-6-carbamoylpyrimidin-2-yl)-4-methylpiperidin-4-yl]carbamate (400 mg, 1.14 mmol) in DMF (6 mL) maintained at 0° C. The reaction mixture was stirred at room temperature for 1 h, then quenched with ice and extracted with EtOAc. The organic layer was dried over sodium sulfate, filtered and concentrated to give the title compound as a yellow solid (420 mg, 80%). LC / MS (M+1): 429.2.

[0191] Intermediate 3: Methyl 5-bromo-2-(4-{[(tert-butoxy)carbonyl]amino}-4-methylpiperidin-1-yl)pyrimidine-4-carboxylate

[0192] [ka]

[0193] A mixture of methyl 5-bromo-2-chloropyrimidine-4-carboxylate (300 mg, 1.13 mmol), tert-butyl N-(4-methylpiperidin-4-yl)carbamate (307 mg, 1.36 mmol), and TEA (0.2 mL) in ACN (3 mL) was stirred in a sealed tube at 80° C. for 2 h. The solvent was then removed under reduced pressure, and the crude material was purified by flash chromatography on silica (PE:EtOAc, 73:27) to give the title compound as a yellow solid (495 mg, 96%). LC / MS (M+1): 429.2.

[0194] Intermediate 4: 6-amino-5-(2,3-dichloro-phenyl)-2-methanesulfonyl-pyrimidine-4-carbonitrile Step 1: 6-amino-2-(methylsulfanyl)pyrimidine-4-carbonitrile

[0195] [ka]

[0196] A mixture of 6-chloro-2-(methylsulfanyl)pyrimidin-4-amine (50 g, 285 mmol), KCN (37.1 g, 569 mmol), Pd(dba) (15.6 g, 17.1 mmol), DPPF (12.6 g, 22.8 mmol), and tributyl(chloro)stannane (5.56 g, 17.1 mmol) in ACN (500 mL) was stirred at 15 °C for 30 min and then heated at 80 °C for 16 h. The mixture was cooled to room temperature, poured into water (2.0 L), and extracted with EtOAc (1.5 L). The organic layer was washed with water (1.5 L), dried over sodium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (PE / EtOAc / DCM, gradient 8 / 1 / 0 to 4 / 1 / 1 with 0.1% NH4OH) provided the title compound as an off-white solid (28.6 g, 53%). 1 H NMR (400MHz DMSO-d6): 7.62 (brs, 2H), 6.63 (s, 1H), 2.40 (s, 3H).

[0197] Step 2: 6-amino-5-bromo-2-(methylsulfanyl)pyrimidine-4-carbonitrile

[0198] [ka]

[0199] NBS (11.2 g, 62.9 mmol) was added portionwise to a solution of 6-amino-2-(methylsulfanyl)pyrimidine-4-carbonitrile (10.0 g, 60.2 mmol) in DMF (90 mL) maintained at 5 °C. The reaction mixture was then stirred at the same temperature for 1 h. It was poured into water (300 mL) and extracted with EtOAc (300 mL). The organic layer was washed with 0.5 M NaHCO solution (300 mL × 2), dried over sodium sulfate, filtered, and concentrated to give the title compound as a yellow solid (7.78 g, 52.7%).

[0200] Step 3: 6-amino-5-(2,3-dichlorophenyl)-2-(methylsulfanyl)pyrimidine-4-carbonitrile

[0201] [ka]

[0202] A mixture of 6-amino-5-bromo-2-(methylsulfanyl)pyrimidine-4-carbonitrile (1.55 g, 6.32 mmol), 2,3-dichlorophenyl)boronic acid (3.02 g, 15.8 mmol), XPhos Palladacycle Gen 3 (267 mg, 316 mmol), and KPO (4.03 g, 18.9 mmol) in 1,4-dioxane (15 mL) and HO (3 mL) was stirred at 95 °C under nitrogen for 16 h. The mixture was cooled to room temperature, diluted with DCM (20 mL), and filtered. The filtrate was concentrated in vacuo and purified by RP-MPLC (TFA conditions) to give the title compound as a yellow solid (1.01 g, 48%). 1 H NMR (400MHz, CDCl3): 7.65 (dd, J=1.2, 8.0Hz, 1H), 7.41 (t, J=7.6Hz, 1H), 7.29 (dd, J=7.6, 8.0Hz, 1H), 5.04 (br, 2H), 2.57 (s, 3H). LC / MS (M+1): 311.1.

[0203] Step 4: 6-amino-5-(2,3-dichloro-phenyl)-2-methanesulfonyl-pyrimidine-4-carbonitrile

[0204] [ka]

[0205] mCPBA (2.83 g; 12.65 mmol) in DCM (40 mL) was added to a solution of 6-amino-5-(2,3-dichlorophenyl)-2-(methylsulfanyl)pyrimidine-4-carbonitrile (1.97 g; 6.32 mmol) in DCM (40 mL) maintained at 0° C. The reaction mixture was stirred at RT for 2 h and then cooled to 0° C. after which another solution of mCPBA (1.42 g; 6.32 mmol) in DCM (20 mL) was added, giving complete conversion.

[0206] The reaction mixture was stirred at RT for an additional 2 h. It was then filtered to remove a white precipitate. The filtrate was concentrated, redissolved in DCM, filtered, and concentrated. Purification by flash chromatography on silica (hexanes: EtOAc, gradient 60:40-80:20) provided the title compound as a white solid (1.5 g, 69%). 1H NMR (400 MHz, DMSO-d6) d 8.73 (s, 1H), 7.85 (dd, J=6.1, 3.5 Hz, 1H), 7.70 (s, 1H), 7.63-7.55 (m, 2H), 3.37 (s, 3H). LC / MS (M+1): 342.9.

[0207] Intermediate 5: {1-[4-amino-6-cyano-5-(2,3-dichloro-phenyl)-pyrimidin-2-yl]-4-methyl-piperidin-4-yl}-carbamic acid tert-butyl ester

[0208] [ka]

[0209] A solution of tert-butyl (4-methylpiperidin-4-yl)carbamate (Synthonix; 62 mg; 0.29 mmol) and potassium carbonate (101 mg; 0.73 mmol) in ACN (0.50 mL) and DMF (0.50 mL) was stirred at room temperature for 10 minutes, after which 6-amino-5-(2,3-dichloro-phenyl)-2-methanesulfonyl-pyrimidine-4-carbonitrile (Intermediate 4; 50 mg; 0.15 mmol) was added. The reaction mixture was then heated at 100° C. for 66 hours. It was diluted with EtOAc (40 mL) and washed with water (2×10 mL) and brine (10 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (hexane:EtOAc, 95:5-40:60 gradient) provided the title compound as a white foam. 1H NMR (400 MHz, DMSO-d6) 7.72 (dd, J=8.0, 1.6Hz, 1H), 7.45 (t, J=7.8Hz, 1H), 7.38 (dd, J=7.7, 1.6Hz, 1H), 6.56 (s, 2H), 4.08-3.93 (m, 2H), 3.40-3.24 (m, 2H), 2.04 (d, J=13.5Hz, 2H), 1.46-1.32 (m, 11H), 1.26 (s, 3H).

[0210] Intermediate 6: 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid

[0211] [ka]

[0212] A solution of tert-butyl N-[1-[4-amino-6-cyano-5-(2,3-dichlorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl]carbamate (Intermediate 5; 370 mg, 0.628 mmol) and NaOH (132 mg, 3.139 mmol) in water (5 mL) was stirred at 100 °C in an oil bath for 16 h. The pH was adjusted to 4 by adding 1 M HCl solution, and the solution was concentrated under reduced pressure. The residue was dissolved in MeOH (10 mL) and purified by C18 silica gel flash chromatography ((ACN:water-0.5% HCl), 10%-50% gradient in 10 min) to give the title compound as a yellow solid (250 mg, 94%). mp: 179-181 °C. 1H NMR (400 MHz, DMSO-d6) 8.18 (s, 3H), 7.63-7.57 (m, 1H), 7.39-7.31 (m, 2H), 7.22 (s, 1H), 7.15 (d, J=7.5Hz, 1H), 7.09 (s, 1H), 4.27 (d, J=13.9Hz, 1H), 2.55 (s, 0H), 1.71 (s, 4H), 1.39 (s, 3H). LC / MS (M+1): 396.1.

[0213] Intermediate 7: 6-amino-2-(4-{[(tert-butoxy)carbonyl]amino}-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxylic acid

[0214] [ka]

[0215] A solution of tert-butyl N-[1-[4-amino-6-cyano-5-(2,3-dichlorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl]carbamate (Intermediate 5, 200 mg, 0.34 mmol) in aqueous NaOH (1N solution, 4 mL) and EtOH (2 mL) was heated at 100° C. for 16 h. It was then diluted with water and extracted with EtOAc (3×20 mL). The combined organic layers were then washed with brine, dried over magnesium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (EtOAc:MeOH, 70:30) provided the title compound as a white solid (140 mg, 69%). LC / MS (M+1): 496.1.

[0216] Intermediate 8: tert-butyl N-[1-(5-bromo-4-cyano-6-methylpyrimidin-2-yl)-4-methylpiperidin-4-yl]carbamate Step 1: tert-butyl N-[1-(4-cyano-6-methylpyrimidin-2-yl)-4-methylpiperidin-4-yl]carbamate

[0217] [ka]

[0218] A solution of 2-chloro-6-methylpyrimidine-4-carbonitrile (1 g, 6.2 mmol), tert-butyl N-(4-methylpiperidin-4-yl)carbamate (1.7 g, 7.4 mmol), and TEA (0.1 mL) in ACN (15 mL) was heated at 80° C. for 2 h. The solvent was removed under reduced pressure, and the crude material was purified by flash chromatography (PE:EtOAc, 100:0 to 50:50 gradient) to afford the title compound as a yellow solid (1.9 g, 92%). LC / MS (M+1): 332.2.

[0219] Step 2: tert-butyl N-[1-(5-bromo-4-cyano-6-methylpyrimidin-2-yl)-4-methylpiperidin-4-yl]carbamate

[0220] [ka]

[0221] A solution of tert-butyl N-[1-(4-cyano-6-methylpyrimidin-2-yl)-4-methylpiperidin-4-yl]carbamate (1.9 g, 5.7 mmol) and NBS (1.6 g, 8.5 mmol) in DMF (10 mL) was stirred at room temperature for 1 h. The reaction mixture was then diluted with water (200 mL) and extracted with EtOAc (3×200 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give the title compound as a yellow solid (2.3 g, 96%). LC / MS (M+1): 410.2.

[0222] Intermediate 9: 7-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole [ka]

[0223] A mixture of 6-bromo-7-chloro-1H-indazole (300 mg, 1.23 mmol), Pd(dppf)Cl.sub.2·DCM (53 mg, 0.062 mmol), BPD (497 mg, 1.859 mmol), and KOAc (381 mg, 3.7 mmol) in dioxane (5 mL) was flushed with nitrogen and heated at 120 °C in a sealed tube for 2 h. The solvent was then removed under reduced pressure, and the residue was purified by flash chromatography on silica (PE:EtOAc, 50:50) to afford the title compound as a yellow oil (300 mg, 44%). LC / MS (M+1): 279.2.

[0224] Intermediate 10: 6-amino-5-(7-chloro-1H-indazol-6-yl)-2-methanesulfonyl-pyrimidine-4-carbonitrile

[0225] [ka]

[0226] The title compound was obtained as a yellow oil following a procedure similar to that described for Intermediate 4, but starting from 7-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (Intermediate 9). LC / MS (M+1): 349.0.

[0227] Intermediate 11: tert-butyl N-[(3S,4S)-8-(5-bromo-4-cyano-6-methylpyrimidin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate Step 1: tert-butyl N-[(3S,4S)-8-(4-cyano-6-methylpyrimidin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate

[0228] [ka]

[0229] A solution of 2-chloro-6-methylpyrimidine-4-carbonitrile (106 mg; 0.69 mmol), tert-butyl N-[(3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (125 mg; 0.46 mmol), and DIEA (0.4 mL, 2.31 mmol) in anhydrous DMSO (2.5 mL) was stirred at 70 °C for 24 h. The reaction mixture was diluted with water (10 mL) and EtOAc (25 mL). The organic layer was washed with water (2x) and brine, dried over sodium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (hexane:EtOAc, 95:5-20:80 gradient) provided the title compound as a yellow foam (175 mg, 98%). 1H NMR (Bruker 400 MHz, DMSO-d6): 7.03 (s, 1H), 6.98 (d, J=10.4Hz, 1H), 4.23-4.11 (m, 1H), 3.88 (dd, J=10.5, 5.1Hz, 1H), 3.85-3.78 (m, 1H), 3.78-3.63 (m, 3H), 3.63-3.53 (m, 1H), 3.50 (d, J=8.4Hz, 1H), 2.34 (s, 3H), 1.69-1.51 (m, 3H), 1.51-1.42 (m, 1H), 1.39 (s, 9H), 1.02 (d, J=6.3Hz, 3H); LC / MS (M+1): 388.2.

[0230] Step 2: tert-Butyl N-[(3S,4S)-8-(5-bromo-4-cyano-6-methylpyrimidin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate

[0231] [ka]

[0232] A solution of N-bromosuccinimide (121 mg; 0.68 mmol) in DMF (1.75 mL) was slowly added to a solution of tert-butyl N-[(3S,4S)-8-(4-cyano-6-methylpyrimidin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (175 mg; 0.45 mmol) in DMF (1.75 mL) maintained at 0 °C. The reaction mixture was stirred at RT for 2 h. It was then diluted with EtOAc (50 mL), washed with water (2 × 25 mL) and brine (25 mL), dried over sodium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (hexane:EtOAc; 95:5-50:50 gradient) provided the title compound as a white foam (158 mg, 75%). 1H NMR (Bruker 400 MHz, DMSO-d6): 6.99 (d, J=10.5Hz, 1H), 4.22-4.12 (m, 1H), 3.88 (dd, J=10.5, 5.1Hz, 1H), 3.85-3.76 (m, 1H), 3.76-3.63 LC / MS (M+1): 466.1, 468.1.

[0233] Intermediate 12: tert-butyl N-[(1R)-8-(4-cyano-6-methylpyrimidin-2-yl)-3,3-difluoro-8-azaspiro[4.5]decan-1-yl]carbamate Step 1: tert-butyl N-[(1R)-8-(4-cyano-6-methylpyrimidin-2-yl)-3,3-difluoro-8-azaspiro[4.5]decan-1-yl]carbamate

[0234] [ka]

[0235] The title compound was obtained as a yellow foam (172 mg, 98%) according to the procedure described in Intermediate 12, Step 1, but starting from 2-chloro-6-methylpyrimidine-4-carbonitrile (99 mg; 0.65 mmol) and tert-butyl N-[(1R)-3,3-difluoro-8-azaspiro[4.5]decan-1-yl]carbamate (125 mg; 0.43 mmol). 1H NMR (400 MHz, DMSO-d6): 7.09-7.00 (m, 2H), 4.51-4.26 (m, 2H), 3.85 (q, J=9.3Hz, 1H), 3.18-2.94 (m, 2H), 2.48-2.36 (m, 2H), 2.34 (s, 3H), 2.31-1.95 (m, 2H), 1.62-1.38 (m, 4H), 1.34 (s, 9H). LC / MS (M+1): 408.1.

[0236] Step 2: tert-butyl N-[(1R)-8-(5-bromo-4-cyano-6-methylpyrimidin-2-yl)-3,3-difluoro-8-azaspiro[4.5]decan-1-yl]carbamate

[0237] [ka]

[0238] The title compound was obtained as a yellow solid (150 mg, 74%) according to the procedure described in Intermediate 12, Step 2, but starting from tert-butyl N-[(1R)-8-(4-cyano-6-methylpyrimidin-2-yl)-3,3-difluoro-8-azaspiro[4.5]decan-1-yl]carbamate (170.00 mg; 0.42 mmol). LC / MS (M+1): 486.1, 488.1.

[0239] Intermediate 13: tert-butyl N-[(1R)-8-(5-bromo-4-cyano-6-methylpyrimidin-2-yl)-8-azaspiro[4.5]decan-1-yl]carbamate Step 1: tert-butyl N-[(1R)-8-(4-cyano-6-methylpyrimidin-2-yl)-8-azaspiro[4.5]decan-1-yl]carbamate

[0240] [ka]

[0241] The title compound was obtained as a yellow foam (295 mg, 94%) according to the procedure described in Intermediate 12, Step 1, but starting from 2-chloro-6-methylpyrimidine-4-carbonitrile (258 mg; 1.68 mmol) and tert-butyl N-[(1R)-8-azaspiro[4.5]decan-1-yl]carbamate (214 mg; 0.84 mmol). 1H NMR (Bruker 400 MHz, DMSO-d6): 7.00 (s, 1H), 6.73 (d, J=9.3Hz, 1H), 4.45-4.13 (m, 2H), 3.57 (q, J=8.3Hz, 1H), 3.24-3.06 (m, 2H), 2.34 (s, 3H), 1.93-1.78 (m, 1H), 1.78-1.58 (m, 2H), 1.58-1.40 (m, 4H), 1.41-1.20 (m, 12H). LC / MS (M+1): 372.0.

[0242] Step 2: tert-butyl N-[(1R)-8-(5-bromo-4-cyano-6-methylpyrimidin-2-yl)-8-azaspiro[4.5]decan-1-yl]carbamate

[0243] [ka]

[0244] The title compound was obtained as a yellow foam (270 mg, 75%) according to the procedure described in Intermediate 12, Step 2, but starting from tert-butyl N-[(1R)-8-(4-cyano-6-methylpyrimidin-2-yl)-8-azaspiro[4.5]decan-1-yl]carbamate (295 mg; 0.79 mmol). LC / MS: 450.0, 452.0.

[0245] Intermediate 14: (3R)-3H-spiro[1-benzofuran-2,4'-piperidine]-3-amine hydrochloride Step 1: 2-(2-fluorophenyl)-1,3-dithiane

[0246] [ka]

[0247] BF3·Et2O (25 mL, 197 mmol) was added to a solution of 2-fluoro-benzaldehyde (10.0 g, 76.5 mmol) and 1,3-propanediol (17.4 g, 153.1 mmol) in DCM (100 mL) at 25 °C. The resulting mixture was stirred at 25 °C for 16 h. It was then concentrated in vacuo and purified by flash chromatography on silica (PE:EtOAc, 5:1) to afford the title compound as an off-white solid (16.0 g, 95%). LC / MS (M+1): 215.

[0248] Step 2: 4-(2-fluorobenzoyl)piperidin-4-ol

[0249] [ka]

[0250] A solution of 2-(2-fluorophenyl)-1,3-dithiane (10.0 g, 40.7 mmol) in THF (5 mL) was added to a solution of LDA in THF (41 mL, 2 M) maintained at −78° C. under a nitrogen atmosphere. The resulting mixture was stirred at −20° C. for 30 minutes. Then, a solution of tert-butyl 4-oxopiperidine-1-carboxylate (12.8 g, 61.1 mmol) in THF (5 mL) was added dropwise at −78° C. After stirring at −78° C. for 1 h, the reaction mixture was poured into saturated NH4Cl solution (100 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with brine (1×100 mL), dried over anhydrous Na2SO4, filtered, and concentrated. Purification by flash chromatography on silica (PE: EtOAc, 1:1) gave tert-butyl 4-[2-(2-fluorophenyl)-1,3-dithian-2-yl]-4-hydroxypiperidine-1-carboxylate as an off-white solid (15.0 g, 78%). LC / MS (M+1): 314.

[0251] A solution of tert-butyl 4-[2-(2-fluorophenyl)-1,3-dithian-2-yl]-4-hydroxypiperidine-1-carboxylate (15.0 g, 47.9 mmol), TBAB (4.63 g, 14.4 mmol), pyridine hydrobromide (15.3 g, 95.8 mmol), and pyridine (7.7 mL, 95.8 mmol) in DCM (200 mL) and HO (40 mL) was stirred at 25 °C for 16 h. The resulting mixture was concentrated under reduced pressure and purified by flash chromatography on silica (DCM:MeOH, 1:1) to provide the title compound as a brown oil (10.4 g, 97%). LC / MS (M+1): 224.

[0252] Step 3: Spiro[1-benzofuran-2,4'-piperidin]-3-one

[0253] [ka]

[0254] A solution of 4-(2-fluorobenzoyl)piperidin-4-ol (10.0 g, 40.3 mmol), t-BuOK (9.52 g, 80.6 mmol), and dioxane (100 mL) was stirred at 120 °C for 2 h. The reaction mixture was cooled to room temperature, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica (DCM:MeOH, 1:1) to provide the title compound as a brown solid (8.0 g, 96%). LC / MS (M1): 204.

[0255] Step 4: (S)-2-methyl-N-[1'-[(S)-2-methylpropane-2-sulfinyl]spiro[1-benzofuran-2,4'-piperidin]-3-ylidene]propane-2-sulfinamide

[0256] [ka]

[0257] A mixture of Ti(OEt) (50 mL), (R)-2-methylpropane-2-sulfinamide (18.0 g, 140.7 mmol), and spiro[1-benzofuran-2,4-piperidin]-3-one (5.00 g, 23.4 mmol) was stirred at 90 °C for 16 h. It was then diluted with water (120 mL) and extracted with EtOAc (3 × 120 mL). The combined organic layers were washed with brine (1 × 100 mL), dried over anhydrous NaSO, filtered, and concentrated. Purification by flash chromatography on silica (PE:EtOAc, 1:1) provided the title compound as a yellow solid (6.0 g, 60%). LC / MS (M+1): 411.

[0258] Step 5: (S)-2-methyl-N-[(3S)-1'-[(S)-2-methylpropane-2-sulfinyl]-3H-spiro[1-benzofuran-2,4'-piperidin]-3-yl]propane-2-sulfinamide

[0259] [ka]

[0260] NaBH (1.87 g, 46.9 mmol) was added to a solution of (S)-2-methyl-N-[1-[(S)-2-methylpropane-2-sulfinyl]spiro[1-benzofuran-2,4-piperidin]-3-ylidene]propane-2-sulfinamide (4.00 g, 9.38 mmol) in THF (100 mL) and HO (2.00 mL) at −50° C. The resulting mixture was stirred at 25° C. for 2 h. It was then quenched with saturated aqueous NH Cl at 0° C. and extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with brine (1 × 100 mL), dried over anhydrous Na SO , filtered, and concentrated. Purification by flash chromatography on silica (PE: EtOAc, 1:1) provided the title compound as a yellow solid (2 g, 52%). LC / MS (M+1): 413.

[0261] Step 6: (3R)-3H-spiro[1-benzofuran-2,4'-piperidine]-3-amine hydrochloride

[0262] [ka]

[0263] A mixture of HCl / MeOH (10 mL, 6 M) and (S)-2-methyl-N-[(3S)-1-[(S)-2-methylpropane-2-sulfinyl]-3H-spiro[1-benzofuran-2,4-piperidin]-3-yl]propane-2-sulfinamide (700 mg, 1.70 mmol) was stirred at 25 °C for 2 h. The resulting mixture was concentrated under reduced pressure. The solid was collected by filtration and washed with EtO (3 × 10 mL) to give the title compound as an off-white solid (300 mg, 85%). LC / MS (M+1): 205.

[0264] Intermediate 15: 3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine]-3-amine Step 1: 3-(1,3-dithian-2-yl)-2-fluoropyridine

[0265] [ka]

[0266] To a solution of 2-fluoropyridine-3-carbaldehyde (46.0 g, 349.3 mmol) and 1,3-propanedithiol (43.8 g, 384.2 mmol) in DCM (500 mL) was added BF Et O (29 mL, 107.6 mmol, 0.31 equiv, 47%) dropwise at room temperature. The resulting mixture was stirred at room temperature for 16 h. The reaction was quenched with saturated NaHCO (200 mL) and extracted with EtOAc (3 × 200 mL). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated. Purification by flash chromatography on silica (PE:EtOAc, 10:1) afforded the title compound as a white solid (59 g, 63%). LC / MS (M+1): 216.

[0267] Step 2: tert-butyl 4-[2-(2-fluoropyridin-3-yl)-1,3-dithian-2-yl]-4-hydroxypiperidine-1-carboxylate

[0268] [ka]

[0269] A solution of LDA (240 mL, 2 M in THF) was added dropwise to a solution of 3-(1,3-dithian-2-yl)-2-fluoropyridine (59.0 g, 220.3 mmol) in THF (150 mL) maintained at −78° C. The resulting mixture was then stirred at −20° C. for 60 minutes, after which a solution of tert-butyl 4-oxopiperidine-1-carboxylate (92.4 g, 440.6 mmol) in THF (30 mL) was added at −78° C. The resulting mixture was stirred at −78° C. for an additional 1 h and quenched at 0° C. with saturated NH4Cl (500 mL). It was extracted with EtOAc (3×300 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated. Purification by flash chromatography on silica (PE: EtOAc, 5:1) provided the title compound as a white solid (80 g, 87%). LC / MS: 359 (M+H-56).

[0270] Step 3: tert-butyl 4-(2-fluoropyridine-3-carbonyl)-4-hydroxypiperidine-1-carboxylate

[0271] [ka]

[0272] A solution of tert-butyl 4-[2-(2-fluoropyridin-3-yl)-1,3-dithian-2-yl]-4-hydroxypiperidine-1-carboxylate (90.0 g, 213.6 mmol), TBAB (21.7 g, 64.1 mmol), 21^[2]-pyridine tribromate (143.8 g, 427.2 mmol), and pyridine (27.2 mL, 320.4 mmol, 1.50 equiv) in DCM (1 L) and HO (200 mL) was stirred at room temperature for 10 h. The reaction mixture was then extracted with DCM (3 × 300 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated. Purification by flash chromatography on silica (PE:EtOAc, 2:1) provided the title compound as a yellow solid (50.0 g, 71%). LC / MS: 269 (M+H-56).

[0273] Step 4: tert-Butyl 3-oxospiro[furo[2,3-b]pyridine-2,4-piperidine]-1-carboxylate

[0274] [ka]

[0275] t-BuOK (6.51 g, 55.1 mmol) was added to a solution of tert-butyl 4-(2-fluoropyridine-3-carbonyl)-4-hydroxypiperidine-1-carboxylate (17.0 g, 50.1 mmol) in dioxane (170 mL) at room temperature. After stirring for 2 h, the resulting mixture was poured into water (200 mL) and extracted with EtOAc (3 × 200 mL). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated. Purification by flash chromatography on silica (PE:EtOAc, 5:1) provided the title compound as a white solid (8.5 g, 53%). LC / MS: 249 (M+H-56).

[0276] Step 5: tert-Butyl 3-[[(R)-2-methylpropane-2-sulfinyl]imino]spiro[furo[2,3-b]pyridine-2,4'-piperidine]-1'-carboxylate

[0277] [ka]

[0278] A mixture of tert-butyl 3-oxospiro[furo[2,3-b]pyridine-2,4-piperidine]-1-carboxylate (8.50 g, 26.8 mmol), (R)-2-methylpropane-2-sulfinamide (20.5 g, 160.7 mmol), and Ti(OEt) (60 mL) was stirred at 90 °C for 2 h. The resulting mixture was cooled to room temperature and poured into H O (150 mL). It was filtered, and the filtrate was extracted with EtOAc (3 × 150 mL). The combined organic layers were dried over anhydrous Na SO , filtered, and concentrated. Purification by flash chromatography on silica (PE: EtOAc, 5:1) provided the title compound as a yellow solid (11 g, 96%). LC / MS (M+1): 408.0.

[0279] Step 6: tert-butyl-3-[[(S)-2-methylpropane-2-sulfinyl]amino]-3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine]-1'-carboxylate

[0280] [ka]

[0281] Sodium borohydride (4.66 g, 117 mmol) was added in one portion to a stirred solution of tert-butyl 3-[[(R)-2-methylpropane-2-sulfinyl]imino]spiro[furo[2,3-b]pyridine-2,4-piperidine]-1-carboxylate (10.0 g, 23.4 mmol) in THF (100 mL) and MeOH (100 mL) at −50° C. The resulting mixture was stirred at −50° C. for 1 h and quenched with water (10 mL). The solvent was removed under reduced pressure, and the mixture was diluted with water (100 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to provide the title compound as a yellow solid (10 g, 62%). LC / MS (M+1): 410.0.

[0282] Step 7: 3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine]-3-amine

[0283] [ka]

[0284] A solution of HCl (gas) in 1,4-dioxane (100 mL) was added dropwise to a solution of tert-butyl-3-[[(S)-2-methylpropane-2-sulfinyl]amino]-3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine]-1'-carboxylate (10.0 g, 24.4 mmol) in DCM (60 mL) maintained at 0 °C. After stirring for 1 h at room temperature, the resulting mixture was concentrated under reduced pressure. The resulting HCl salt was loaded onto a SiliaBond propylsulfonic acid (SCX-2) resin prewetted with methanol and eluted with methanol until no HCl was detected. The free amine was then washed with 7 M NH3 in methanol. The eluent was concentrated under vacuum to give the title compound as an orange oil (4.0 g, 77.7%). LC / MS (M+1): 206.

[0285] Intermediate 16: (4S)-4,6-Dihydrospiro[cyclopenta[d][1,3]thiazole-5,4'-piperidine]-4-amine Step 1: tert-butyl (4Z)-2-chloro-4-{[(R)-2-methylpropane-2-sulfinyl]imino}-4,6-dihydrospiro[cyclopenta[d][1,3]thiazole-5,4'-piperidine]-1'-carboxylate

[0286] [ka]

[0287] A mixture of tert-butyl 2-chloro-4-oxo-6H-spiro[cyclopenta[d][1,3]thiazole-5,4-piperidine]-1-carboxylate (300 mg, 0.845 mmol) and (R)-2-methylpropane-2-sulfinamide (647 mg, 5.07 mmol) in Ti(OEt) (3.39 g, 14.1) was stirred at 90 °C for 19 h under a nitrogen atmosphere. The reaction was then quenched by the addition of water (50 mL) and filtered. The filtrate was extracted with EtOAc (3 × 150 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (PE:EtOAc, 1:0-1:1 gradient) provided the title compound as a yellow solid (280 mg, 74%). LC / MS (M+1): 446.1.

[0288] Step 2: tert-butyl (4S)-2-chloro-4-{[(R)-2-methylpropane-2-sulfinyl]amino}-4,6-dihydrospiro[cyclopenta[d][1,3]thiazole-5,4'-piperidine]-1'-carboxylate

[0289] [ka]

[0290] Sodium borohydride (70 mg, 1.78 mmol) was added portionwise to a solution of tert-butyl-(4Z)-2-chloro-4-[[(R)-2-ethylpropane-2-sulfinyl(imino)]imino]-6H-spiro[cyclopenta[d][1,3]thiazole-5,4-piperidine]-1-carboxylate (400 mg, 0.892 mmol) in THF (4.4 mL) and water (1.3 mL) maintained at −50° C. under an argon atmosphere. The resulting mixture was stirred at −50° C. under an argon atmosphere for 2 h, quenched by the addition of water (50 mL), and filtered. The filtrate was extracted with EtOAc (3×50 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (PE: EtOAc, gradient 1:0 to 0:1) provided the title compound as a yellow solid (200 mg, 50%). LC / MS (M+1): 448.1.

[0291] Step 3: tert-butyl (4S)-4-{[(R)-2-methylpropane-2-sulfinyl]amino}-4,6-dihydrospiro[cyclopenta[d][1,3]thiazole-5,4'-piperidine]-1'-carboxylate

[0292] [ka]

[0293] A suspension of tert-butyl (4S)-2-chloro-4-[[(R)-2-methylpropane-2-sulfinyl]amino]-4,6-dihydrospiro[cyclopenta[d][1,3]thiazole-5,4-piperidine]-1-carboxylate (0.20 g, 0.446 mmol), Pd / C (0.10 g, 0.094 mmol, 10%) in MeOH (10 mL) under H atmosphere was stirred at 100 °C for 12 h. The mixture was filtered through a Celite pad, and the filtrate was concentrated to give the title compound as a yellow solid (130 mg, 66%). LC / MS (M+1): 414.2.

[0294] Step 4: (4S)-4,6-Dihydrospiro[cyclopenta[d][1,3]thiazole-5,4'-piperidine]-4-amine

[0295] [ka]

[0296] A solution of tert-butyl (4S)-4-[[(R)-2-methylpropane-2-sulfinyl]amino]-4,6-dihydrospiro[cyclopenta[d][1,3]thiazole-5,4-piperidine]-1-carboxylate (150 mg, 0.337 mmol) in MeOH / HCl (4 mL, 26 mmol, 20%) was stirred at room temperature for 30 minutes. The solvent was removed under reduced pressure, and the residue was loaded onto SiliaBond propylsulfonic acid (SCX-2) resin pre-wetted with methanol. The resin was eluted with MeOH, and the free amine was released with MeOH / NH3 (7 M). MeOH was removed under reduced pressure to provide the title compound as an off-white solid (65 mg, 89%). LC / MS (M+1): 210.1.

[0297] Compound 1: 2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide Step 1: Synthesis of tert-butyl (1-(4-cyano-5-(2,3-dichlorophenyl)pyrimidin-2-yl)-4-methylpiperidin-4-yl)carbamate

[0298] [ka]

[0299] A solution of tert-butyl (1-(5-bromo-4-cyanopyrimidin-2-yl)-4-methylpiperidin-4-yl)carbamate (Intermediate 1, 2 g, 5.06 mmol), 2,3-dichlorophenylboronic acid (0.967 g, 5.06 mmol), and cesium carbonate (4.1 g, 12.6 mmol) in a dioxane / water mixture (15:5 mL) was degassed with nitrogen for 3 minutes. Pd(PPh3)4 (0.58 g, 0.51 mmol) was added, and the reaction mixture was heated at 100 °C overnight under an inert atmosphere. The reaction mixture was dissolved in EtOAc (50 mL) and washed with water (30 mL) and brine solution (30 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (PE:AcOEt, 100:0-80:20 gradient) provided the title compound as a white solid (1.6 g, 70%). 1H NMR (400 MHz, DMSO-d6): 8.68 (s, 1H), 8.80 (dd, J=2.0, 7.6 Hz, 1H), 4.56 (m, 2H), 6.69 (brs, 1H), 4.06 (m, 2H), 3.45 (m, 2H), 2.12 (m, 2H), 1.48 (m. 2H), 1.40 (s, 9H), 1.27 (s, 3H).

[0300] Step 2: tert-butyl N-{1-[4-carbamoyl-5-(2,3-dichlorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl}carbamate

[0301] [ka]

[0302] To a solution of tert-butyl (1-(4-cyano-5-(2,3-dichlorophenyl)pyrimidin-2-yl)-4-methylpiperidin-4-yl)carbamate (0.2 g, 0.432 mmol) in DMSO (8 mL) were added hydrogen peroxide (0.4 mL, 30% in water) and potassium carbonate (0.119 g, 0.86 mmol) at 0° C. The reaction mixture was stirred at room temperature for 1 h, then quenched with water and extracted with ethyl acetate (2×20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to provide the title compound (0.18 g, 87%). LC / MS (M+1): 480.2.

[0303] Step 3: 2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide hydrochloride

[0304] [ka]

[0305] A solution of HCl (2 mL of a 4 M solution in dioxane) was added to a solution of tert-butyl N-{1-[4-carbamoyl-5-(2,3-dichlorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl}carbamate (180 mg, 0.375 mmol) in anhydrous dichloromethane (5 mL) maintained at 0° C. The reaction mixture was stirred at room temperature for 1 h. It was then concentrated under reduced pressure to yield the title compound as a white solid (75 mg, 50%). 1H NMR (400 MHz, DMSO-d6): 8.36 (s, 1H), 8.14 (m, 4H), 7.59 (m, 2H), 7.37 (t, J=9.2Hz, 1H), 7.26 (d, J=7.2Hz, 1H), 4.40 (m, 2H), 3.52 (m, 2H), 1.76 (m, 4H), 1.41 (s, 3H).

[0306] Compound 2: 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(3-chloro-phenyl)-pyrimidine-4-carboxylic acid amide Step 1: tert-butyl N-{1-[4-amino-6-carbamoyl-5-(3-chlorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl}carbamate

[0307] [ka]

[0308] A mixture of tert-butyl N-[1-(4-amino-5-bromo-6-carbamoylpyrimidin-2-yl)-4-methylpiperidin-4-yl]carbamate (Intermediate 2, 250 mg, 0.41 mmol), (3-chlorophenyl)boronic acid (137 mg, 0.83 mmol), Pd(PPh3)4 (34 mg, 0.03 mmol), and sodium carbonate (84 mg, 0.75 mmol) in water (2 mL) and dioxane (6 mL) was heated at 130 °C for 30 min under an inert atmosphere. The solvent was then removed under reduced pressure, and the crude material was purified by flash chromatography on silica (PE: EtOAc, 50:50) to yield the title compound as a yellow solid (110 mg, 47%). LC / MS (M+1): 461.2.

[0309] Step 2: 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(3-chloro-phenyl)-pyrimidine-4-carboxylic acid amide

[0310] [ka]

[0311] A solution of tert-butyl N-[1-[4-amino-6-carbamoyl-5-(3-chlorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl]carbamate (200 mg, 0.37 mmol) and HCl (0.6 mL of a 1.25 M solution in MeOH) in MeOH (6 mL) was stirred at room temperature for 2 h. The solvent was removed under reduced pressure and the crude material was purified by preparative HPLC (XBridge Prep C18 OBD column, 5 μm, 19 × 150 mm; mobile phase, water (10 mM NH4HCO3 + 0.1% NH4OH) and ACN (gradient from 18% ACN to 48% in 8 min) to provide the title compound as a white solid (31 mg, 23%). mp: 118-120 °C. 1H NMR (300 MHz, CD3OD); 7.43-7.27 (m, 2H), 7.28-7.20 (m, 1H), 7.16 (m, 1H), 4.07-3.95 (m, 2H), 3.70 (m, 2H), 1.58 (m, 4H), 1.25 (d, J = 1.3 Hz, 3H). LC / MS (M+1): 361.3.

[0312] Compound 3: 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid amide Step 1: 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carbonitrile bis-trifluoroacetic acid ester

[0313] [ka]

[0314] A solution of {1-[4-amino-6-cyano-5-(2,3-dichloro-phenyl)-pyrimidin-2-yl]-4-methyl-piperidin-4-yl}-carbamic acid tert-butyl ester (Intermediate 5; 34 mg; 0.07 mmol) and TFA (0.34 mL) in DCM (0.68 mL) was stirred at room temperature for 1 h. The solvent was then removed under reduced pressure, and excess TFA was removed by azeotropy with toluene to give the title compound as a white foam (42 mg, 97%). LC / MS (M+1): 377.1.

[0315] Step 2: 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid amide

[0316] [ka]

[0317] A solution of 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carbonitrile bis-trifluoroacetate (35 mg; 0.06 mmol), sodium hydroxide (0.1 mL of a 6 M solution in water, 0.58 mmol) and hydrogen peroxide (30% by weight, 70 μL; 0.58 mmol) in DMF (1.40 mL) was heated at 100° C. for 1 h in a microwave reactor. Hydrogen peroxide and sodium hydroxide were added twice (equal amounts) and the reaction mixture was again heated at 100° C. to obtain complete conversion. The reaction mixture was filtered through a pad of Celite and then purified by preparative HPLC (XBridge Prep C-18 OBD, 10 uM, 30×250, 30-80% gradient of water (0.1% ammonium hydroxide) and ACN in 15 min) to provide the title compound as a white amorphous foam (mixture of two atropisomers, 12 mg, 48%). 1H NMR (400 MHz, DMSO-d6) 7.70 (s, 1H), 7.51 (dd, J=8.1, 1.6Hz, 1H), 7.28 (t, J=7.8Hz, 1H), 7.14 (s, 1H), 7.10 (dd, J=7.6, 1.6Hz, 1H), 6.05 (s, 2H), 3.99-3.87 (m, 2H), 3.68-3.54 (m, 2H), 1.47-1.31 (m, 4H), 1.08 (s, 3H). LC / MS (M+1): 395.2.

[0318] Compounds 26 and 27: (4M)-6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid amide and (4P)-6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid amide

[0319] [ka]

[0320] The mixture of Atoropolymer 3 (200mg) and SFC ((R,R)WHELK-01, 4.6×150mm, 5um, EtOH+0.1% DEA:CO2, 0-50%) were separated.

[0321] First-eluting isomer (Compound 26): White solid, 76 mg, RT = 3.42 min, ed = 99.7%. 1H NMR (300 MHz, DMSO-d6): 7.75-7.68 (m, 1H), 7.49 (dd, J = 8.0, 1.6 Hz, 1H), 7.27 (t, J = 7.8 Hz, 1H), 7.15 (s, 1H), 7.08 (dd, J = 7.7, 1.6 Hz, 1H), 6.07 (s, 2H), 3.96-3.85 (m, 2H), 3.68-3.53 (m, 2H), 1.59 (brs, 1H), 1.37 (q, J = 4.9, 4.4 Hz, 4H), 1.07 (s, 3H). mp: 126-128℃.

[0322] Second-eluting isomer Compound 27: White solid, 76 mg, RT = 3.79 min, ed = 98.2%. 1H NMR (300 MHz, DMSO-d6) 7.71 (s, 1H), 7.49 (dd, J = 8.1, 1.5 Hz, 1H), 7.27 (t, J = 7.8 Hz, 1H), 7.16 (s, 1H), 7.08 (dd, J = 7.7, 1.6 Hz, 1H), 3.91 (d, J = 13.6 Hz, 2H), 3.61 (dt, J = 13.1, 6.4 Hz, 2H), 1.61 (brs, 2H), 1.46-1.34 (m, 4H), 1.07 (s, 3H). mp: 130-132°C.

[0323] Compound 4: 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(3-fluoro-phenyl)-pyrimidine-4-carboxylic acid amide

[0324]

change

[0325] The title compound was obtained as an off-white solid according to the procedure previously described, but starting from tert-butyl N-[1-(4-amino-5-bromo-6-carbamoylpyrimidin-2-yl)-4-methylpiperidin-4-yl]carbamate (Intermediate 2, 500 mg, 1.1 mmol) and (3-fluorophenyl)boronic acid (243 mg, 1.7 mmol). 1H NMR (400 Mz, DMSO-d6) 7.61 (s, 1H), 7.37 (q, J=7.6Hz, 1H), 7.16 (s, 1H), 7.09 (t, J=8.6Hz, 1H), 7.03-6.94 (m, 2H), 6.00 (brs, 2H), 3.90-3.90 (m, 2H), 3.62-3.45 (m, 2H), 1.75 (brs, 1H), 1.39-1.36 (m, 4H), 1.09 (s, 3H). LC / MS (M+1): 345.2.

[0326] Compound 5: 6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide

[0327] [ka]

[0328] The title compound was obtained as a white powder (30 mg, 20%, 3 steps) according to the procedure described previously, but starting from ((3S,4S)-3-methyl-2-oxa-8-aza-spiro[4.5]dec-4-yl)-carbamic acid tert-butyl ester (WUXI, 130 mg, 0.5 mmol) and 6-amino-5-(2,3-dichloro-phenyl)-2-methanesulfonyl-pyrimidine-4-carbonitrile (Intermediate 5, 110 mg, 0.3 mmol). 1H NMR (400 MHz, DMSO-d6) 7.71 (s, 1H), 7.51 (dd, J=8.0, 1.5Hz, 1H), 7.28 (t, J=7.8Hz, 1H), 7.15 (s, 1H), 7.10 (dd, J=7.6, 1.5Hz, 1H), 6.08 (s, 2H), 4.12 (m, 3H), 3.68 (d, J=8.4Hz, 1H), 3.49 (d, J=8.4Hz, 1H), 3.47-3.32 (m, 2H), 2.89 (d, J=5.2Hz, 1H), 1.75-1.63 (m, 1H), 1.63-1.52 (m, 1H), 1.52-1.38 (m, 2H), 1.38-1.20 (m, 2H), 1.08 (d, J=6.4Hz, 3H). LC / MS (M+1): 451.1.

[0329] Compound 6: 6-amino-2-{9-amino-3-azabicyclo[3.3.1]nonan-3-yl}-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide

[0330] [ka]

[0331] The title compound was obtained as a white powder (1:1 mixture of isomers) according to the procedure described above, but starting from N-(3-azabicyclo[3.3.1]nonan-9-yl)carbamate tert-butyl (Achemblock) and 6-amino-5-(2,3-dichloro-phenyl)-2-methanesulfonyl-pyrimidine-4-carbonitrile (Intermediate 4). LC / MS (M+1): 421.3.

[0332] Compound 7: 6-amino-2-[(1R)-1-amino-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide

[0333] [ka]

[0334] The title compound was obtained as a white powder according to the procedure previously described, but starting from (R)-(8-aza-spiro[4.5]dec-1-yl)-carbamic acid tert-butyl ester (WUXI) and 6-amino-5-(2,3-dichloro-phenyl)-2-methanesulfonyl-pyrimidine-4-carbonitrile (Intermediate 4). 1H NMR (400 MHz, DMSO-d6) 7.50 (dd, J=8.1, 1.6Hz, 1H), 7.28 (t, J=7.9Hz, 1H), 7.09 (dd, J=7.6, 1.5Hz, 1H), 4.44 (t, J=12.2Hz, 2H), 3.00 (q, J=10.4Hz, 2H), 2.65 (t, J=7.3Hz, 1H), 1.91-1.71 (m, 2H), 1.69-1.56 (m, 1H), 1.56-1.42 (m, 3H), 1.42-1.25 (m, 2H), 1.25-1.08 (m, 2H). LC / MS (M+1): 435.1.

[0335] Compound 8: 6-amino-2-[(1R)-1-amino-3,3-difluoro-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide

[0336] [ka]

[0337] The title compound was obtained as a white powder according to the procedure described previously, but starting from ((R)-3,3-difluoro-8-aza-spiro[4.5]dec-1-yl)-carbamic acid tert-butyl ester (WUXI) and 6-amino-5-(2,3-dichloro-phenyl)-2-methanesulfonyl-pyrimidine-4-carbonitrile (Intermediate 4). 1H NMR (400 MHz, DMSO-d6) d 7.72 (s, 1H), 7.51 (dd, J=8.0, 1.5Hz, 1H), 7.28 (t, J=7.8Hz, 1H), 7.20-7.13 (m, 1H), 7.10 (dt, J=7.6, 1.4Hz, 1H), 6.09 (s, 2H), 4.54 (t, J=16.4Hz, 2H), 3.13-2.84 (m, 3H), 2.47-2.28 (m, 2H), 2.14-1.85 (m, 2H), 1.74-1.43 (m, 4H), 1.30 (dd, J=27.6, 13.3Hz, 2H). LC / MS (M+1): 471.1.

[0338] Compound 9: 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid methylamide

[0339] [ka]

[0340] A solution of 6-amino-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxylic acid (Intermediate 6, 110 mg, 0.27 mmol) and SO2Cl2 (0.5 mL) in MeOH (5 mL) was heated at 80 °C for 4 h under a nitrogen atmosphere. The solvent was removed under reduced pressure, and the residue was redissolved in a 2 M solution of methylamine in THF (2 mL) and heated in a sealed reactor at 90 °C for 16 h. The solvent was removed under reduced pressure, and the crude material was purified by preparative HPLC (XBridge Shield RP18 OBD column, 5 μm, 19 × 150 mm; water (10 mM NH4HCO3):ACN gradient 38%-68% in 8 min) to provide the title compound as a white solid (12 mg, 24%). mp: 147-149℃;δ 1H NMR (300 MHz, DMSO-d6) 8.32 (d, J=5.0Hz, 1H), 7.49 (dd, J=8.1, 1.5Hz, 1H), 7.26 (t, J=7.9Hz, 1H), 7.05 (dd, J=7.6, 1.6Hz, 1H), 6.07 (s, 2H), 4.02-3.92 (m, 2H), 3.64-3.53 (m, 2H), 2.71 (d, J=1.5Hz, 3H), 1.44-1.39 (m, 6H), 1.07 (s, 3H). LC / MS (M+1): 409.1.

[0341] Compound 10: 6-amino-2-[6-amino-7-hydroxy-1-(propan-2-yl)-2-azaspiro[3.4]octan-2-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide

[0342] [ka]

[0343] The title compound was obtained as a white powder (mixture of two diastereoisomers) according to the procedure previously described, but starting from rac-tert-butyl n-[(6r,7r)-7-hydroxy-1-(propan-2-yl)-2-azaspiro[3.4]octan-6-yl]carbamate hydrochloride (enamine) and 6-amino-5-(2,3-dichloro-phenyl)-2-methanesulfonyl-pyrimidine-4-carbonitrile (Intermediate 4). LC / MS (M+1): 465.2.

[0344] Compound 11: 6-amino-2-[8-(aminomethyl)-6-azaspiro[3.4]octan-6-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide

[0345] [ka]

[0346] The title compound was obtained as a white powder (mixture of isomers) according to the procedure described previously, but starting from tert-butyl n-((6-azaspiro[3.4]octan-8-yl)methyl)carbamate (enamine) and 6-amino-5-(2,3-dichloro-phenyl)-2-methanesulfonyl-pyrimidine-4-carbonitrile (Intermediate 4). 1H NMR (400 MHz, DMSO-d6) 7.70 (s, 1H), 7.54-7.47 (m, 1H), 7.32-7.23 (m, 1H), 7.17 (s, 1H), 7.13-7.05 (m, 1H), 6.03 (s, 2H), 3.76-3.38 (m, 4H), 2.84 (d, J=12.0Hz, 1H), 2.41-2.29 (m, 1H), 2.28-1.64 (m, 7H). LC / MS (M+1): 421.2.

[0347] Compound 12: 6-amino-2-[3-(aminomethyl)-8-azabicyclo[3.2.1]octan-8-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide

[0348] [ka]

[0349] The title compound was obtained as a white powder according to the procedure described previously, but starting from tert-butyl n-((8-azabicyclo[3.2.1]octan-3-yl)methyl)carbamate (enamine) and 6-amino-5-(2,3-dichloro-phenyl)-2-methanesulfonyl-pyrimidine-4-carbonitrile (Intermediate 4). 1H NMR (400 MHz, methanol-d4) d 7.49 (dd, J=8.0, 1.6Hz, 1H), 7.29 (t, J=7.8Hz, 1H), 7.16 (dd, J=7.6, 1.6Hz, 1H), 4.80-4.74 (m, 2H), 2.48 (d, J=6.7Hz, 2H), 2.15-1.95 (m, 3H), 1.84 (d, J=7.5Hz, 2H), 1.73-1.62 (m, 2H), 1.48 (td, J=13.5, 2.9Hz, 2H). LC / MS (M+1): 421.2.

[0350] Compounds 13 and 14: 6-amino-5-(2,3-dichlorophenyl)-2-[(1R,7S,11s)-11-amino-9-azabicyclo[5.3.1]undecan-9-yl]pyrimidine-4-carboxamide and 6-amino-5-(2,3-dichlorophenyl)-2-[(1R,7S,11r)-11-amino-9-azabicyclo[5.3.1]undecan-9-yl]pyrimidine-4-carboxamide

[0351] [ka]

[0352] The title compound was obtained as a mixture of two diastereoisomers according to the procedure described previously, but starting from tert-butyl n-(9-azabicyclo[5.3.1]undecan-11-yl)carbamate oxalate (enamine) and 6-amino-5-(2,3-dichlorophenyl)-2-methanesulfonyl-pyrimidine-4-carbonitrile (Intermediate 4). The two isomers were separated by preparative HPLC (XBridge Prep C-18 OBD, 10 μM, 30×250, 30-80% ACN / water / (0.1% ammonium hydroxide) / ACN gradient 30-80% in 15 min).

[0353] First-eluting isomer (arbitrarily assigned): 6-amino-5-(2,3-dichlorophenyl)-2-[(1R,7S,11s)-11-amino-9-azabicyclo[5.3.1]undecan-9-yl]pyrimidine-4-carboxamide; white powder (8.2 mg, 17%). 1H NMR (400 MHz, DMSO-d6) 7.66 (s, 1H), 7.51 (dd, J=8.0, 1.5Hz, 1H), 7.28 (t, J=7.8Hz, 1H), 7.23-7.08 (m, 2H), 6.10 (s, 2H), 4.81 (dd, J=13.3, 6.3Hz, 2H), 3.09 (t, J=6.0Hz, 1H), 2.85 (dd, J=13.5, 4.5Hz, 2H), 2.02 (d, J=3.1Hz, 1H), 1.95-1.73 (m, 3H), 1.73-1.56 (m, 3H), 1.51 (dt, J=14.9, 7.5Hz, 2H), 1.29 (q, J=12.9, 12.5Hz, 2H), 1.19-1.00 (m, 1H). LC / MS (M+1): 449.5.

[0354] Second-eluting isomer (arbitrarily assigned) : 6-amino-5-(2,3-dichlorophenyl)-2-[(1R,7S,11r)-11-amino-9-azabicyclo[5.3.1]undecan-9-yl]pyrimidine-4-carboxamide, white powder (4.7 mg, 10%). 1H NMR (400 MHz, methanol-d4) 7.48 (dd, J=8.0, 1.6Hz, 1H), 7.29 (t, J=7.8Hz, 1H), 7.17 (dd, J=7.6, 1.6Hz, 1H), 4.59-4.52 (m, 2H), 3.47-3.42 (m, 1H), 3.28-3.24 (m, 1H), 2.01-1.90 (m, 2H), 1.88-1.71 (m, 4H), 1.61-1.39 (m, 4H), 1.37-1.19 (m, 2H). LC / MS: 449.2.

[0355] Compound 15: 2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)-6-hydroxypyrimidine-4-carboxamide Step 1: tert-butyl N-{1-[4-amino-6-carbamoyl-5-(2,3-dichlorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl}carbamate

[0356] [ka]

[0357] A solution of tert-butyl N-[1-[4-amino-6-cyano-5-(2,3-dichlorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl]carbamate (Intermediate 5, 371 mg, 0.78 mmol) in EtOH (5 mL) and aqueous NaOH (0.8 mL of a 2.2 M solution) was heated at 100° C. for 16 h. The reaction mixture was cooled to RT, and the pH was adjusted to 7 by the addition of 3 M HCl solution. The resulting solution was extracted with EtOAc (30 mL), and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (EtOAc:MeOH, 100:0-80:20 gradient) provided the title compound as an off-white solid (180 mg, 49%). LC / MS: 495.1.

[0358] Step 2: 2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)-6-hydroxypyrimidine-4-carboxamide

[0359] [ka]

[0360] A solution of tert-butyl N-[1-[4-amino-6-carbamoyl-5-(2,3-dichlorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl]carbamate (60 mg, 0.122 mmol) and NaNO (88 mg, 1.3 mmol) in THF (5 mL), water (3 mL), and concentrated HCl (1 mL) was stirred at 0 °C for 4 h. The solvent was removed under reduced pressure, and the residue was diluted with aqueous HCl (5 M, 2 mL) and stirred at room temperature for 30 min. It was then poured onto ice and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated. Purification by preparative HPLC (XBridge OBD C18 column, 19 x 250 mm, 5 μm; 58%-80% gradient of water (10 mM NH4HCO3) and ACN over 8 min) gave the title compound as a yellow solid (4 mg, 8%). 1H NMR (400 MHz, methanol-d4) 7.48-7.47 (m, 1H), 7.45-7.44 (m, 1H), 7.28-7.23 (m, 1H), 4.41-4.20 (m, 2H), 3.51-3.38 (m, 2H), 1.92-1.81 (m, 4H), 1.54-1.50 (m, 3H). LC / MS (M+1): 396.1.

[0361] Compound 16: 2-(4-amino-4-methyl-piperidin-1-yl)-6-chloro-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid amide

[0362] [ka]

[0363] A solution of NaNO (197 mg, 2.7 mmol) in water (1 mL) was added to a solution of tert-butyl N-[1-[4-amino-6-cyano-5-(2,3-dichlorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl]carbamate (Intermediate 5, 440 mg, 0.90 mmol) in aqueous HCl (6 M solution, 5 mL, 29.6 mmol) maintained at 0 °C. The reaction mixture was stirred at 0 °C for 30 min and then at room temperature for 4 h. The reaction mixture was poured onto ice, and the pH was adjusted to 9 by the addition of aqueous NaOH (2 M). This was extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (PE:EtOAc, 50:50) gave a yellow solid (210 mg), which was redissolved in ACN (4 mL) and aqueous NaOH (0.5 M, 4 mL). The reaction mixture was heated at 70 °C for 1 h. It was then diluted with water (15 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over magnesium sulfate, filtered, and concentrated. Purification by flash chromatography (PE:EtOAc, 50:50) gave the title compound as a yellow solid (80 mg, 51%). 1H NMR (400 MHz, methanol-d4) 7.53 (dd, J=8.0, 1.6Hz, 1H), 7.30 (t, J=7.9Hz, 1H), 7.17 (dd, J=7.6, 1.6Hz, 1H), 4.09-4.01 (m, 2H), 3.89 (d, J=5.5Hz, 2H), 1.65 (qdd, J=13.2, 7.5, 4.3Hz, 4H), 1.27 (s, 3H). LC / MS (M+1): 415.0.

[0364] Compound 17: 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid (2-hydroxy-ethyl)-amide

[0365] [ka]

[0366] The title compound was obtained as a white solid according to the procedure described previously, but starting from 6-amino-2-(4-[[(tert-butoxy)carbonyl]amino]-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxylic acid (Intermediate 7) and 2-aminoethan-1-ol. mp: 125-127°C. 1H NMR (400 MHz, methanol-d4) 7.54-7.47 (m, 1H), 7.31 (t, J=7.8Hz, 1H), 7.18-7.12 (m, 1H), 4.08-3.97 (m, 2H), 3.82-3.71 (m, 2H), 3.62-3.55 (m, 2H), 3.30 (d, J=5.6Hz, 2H), 1.68-1.53 ​​(m, 3H), 1.25 (s, 3H). LC / MS (M+1): 439.2.

[0367] Compound 18: 2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide Step 1: tert-butyl N-{1-[4-cyano-5-(2,3-dichlorophenyl)-6-methylpyrimidin-2-yl]-4-methylpiperidin-4-yl}carbamate

[0368] [ka]

[0369] A mixture of tert-butyl N-[1-(5-bromo-4-cyano-6-methylpyrimidin-2-yl)-4-methylpiperidin-4-yl]carbamate (Intermediate 8, 2.3 g, 5.5 mmol), (2,3-dichlorophenyl)boronic acid (2.2 g, 11 mmol), Pd(PPh) (1.34 g, 1.1 mmol), and NaHCO (2.43 g, 27.4 mmol) in dioxane (9 mL) and water (3 mL) was heated in a sealed reactor at 110 °C under a nitrogen atmosphere for 2 h. The solvent was removed under reduced pressure, and the crude material was purified by flash chromatography on silica (PE:EtOAc, 100:0 to 50:50 gradient) to afford the title compound as a yellow solid (3 g, 100%). LC / MS (M+1): 476.4.

[0370] Step 2: 2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide

[0371] [ka]

[0372] A solution of tert-butyl N-[1-[4-cyano-5-(2,3-dichlorophenyl)-6-methylpyrimidin-2-yl]-4-methylpiperidin-4-yl]carbamate (100 mg, 0.199 mmol) in concentrated HCl (3 mL) was stirred at room temperature under a nitrogen atmosphere for 16 h. The crude mixture was directly purified by preparative HPLC (XBridge Prep OBD C18 column, 30 × 150 mm, 5 μm; 32%-62% gradient of water (10 mM NH4HCO3) and ACN over 8 min). The title compound was isolated as a yellow solid (25 mg, 31%). mp: 103-105 °C. 1H NMR (400 MHz, methanol-d4) 9.38 (s, 1H), 8.07 (d, J=1.5Hz, 1H), 7.77 (d, J=3.1Hz, 1H), 7.72 (d, J=3.1Hz, 1H), 7.64 (d, J=1.8Hz, 1H), 4.46 (d, J=12.7Hz, 2H), 3.67 (s, 2H), 2.03 (d, J=13.7Hz, 4H), 1.58 (s, 3H). LC / MS (M+1): 394.1.

[0373] Compounds 30 and 31: (4M)-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide and (4P)-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide

[0374] [ka]

[0375] The atropisomer mixture of compound 18 (250 mg) was separated by preparative HPLC (column: CHIRALPAK IG, 2 × 25 cm, 5 μm, hexane + 8 mmol / L NH3·MeOH:EtOH-50%).

[0376] First-eluting isomer (Compound 30): White solid, 60 mg, RT=6.96 min. 1H NMR (300 MHz, DMSO-d6): 7.91 (s, 1H), 7.56 (dd, J=8.0, 1.6Hz, 1H), 7.40- 7.28 (m, 2H), 7.18 (dd, J=7.6, 1.6Hz, 1H), 4.01 (d, J=13.7Hz, 2H), 3.70 (dt, J=12.8, 6.3Hz, 2H), 1.98 (s, 4H), 1.42 (d, J=5.4Hz, 4H), 1.10 (s, 3H). LC / MS (M+1): 394.1. mp: 160-162℃.

[0377] The second eluting isomer (compound 31 ): white solid, 40 mg, RT=14.5 min. 1H NMR (300 MHz, DMSO-d6): 7.91 (s, 1H), 7.56 (dd, J=8.0, 1.6Hz, 1H), 7.40- 7.29 (m, 2H), 7.18 (dd, J=7.6, 1.6Hz, 1H), 4.03 (d, J=13.4Hz, 2H), 3.68 (dt, J=13.1, 6.4Hz, 2H), 1.98 (s, 3H), 1.78 (d, J=9.2Hz, 2H), 1.41 (d, J=5.3Hz, 4H), 1.09 (s, 4H). LC / MS (M+1): 394.1. mp: 190-192℃.

[0378] Compound 19: 2-(4-amino-4-methyl-piperidin-1-yl)-6-chloro-5-(3-fluoro-phenyl)-pyrimidine-4-carboxylic acid amide Step 1: tert-butyl N-{1-[4-amino-6-carbamoyl-5-(3-fluorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl}carbamate

[0379] [ka]

[0380] The title compound was obtained as a brown solid following the procedure described for compound 2, but starting from tert-butyl N-[1-(4-amino-5-bromo-6-carbamoylpyrimidin-2-yl)-4-methylpiperidin-4-yl]carbamate (Intermediate 2) and (3-fluorophenyl)boronic acid. LC / MS (M+1): 445.2.

[0381] Step 2: 2-(4-amino-4-methyl-piperidin-1-yl)-6-chloro-5-(3-fluoro-phenyl)-pyrimidine-4-carboxylic acid amide

[0382] [ka]

[0383] The title compound was obtained following a procedure similar to that described for compound 16, but starting from tert-butyl N-[1-[4-amino-6-carbamoyl-5-(3-fluorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl]carbamate. The title compound was isolated as a white solid. mp: 110-112 °C. 1H NMR (400 MHz, methanol-d4) 7.53-7.39 (m, 1H), 7.42-7.36 (m, 1H), 7.16-6.99 (m, 5H), 4.55-4.45 (m, 3H), 3.54 (ddd, J=14.1, 9.7, 3.9Hz, 3H), 2.05 (s, 1H), 2.00-1.87 (m, 1H), 1.85 (ddd, J=18.0, 8.3, 3.8Hz, 5H), 1.54 (s, 4H). LC / MS (M+1): 364.0.

[0384] Compound 20: 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid hydroxyamide Step 1: Methyl 6-amino-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxylate

[0385] [ka]

[0386] A solution of 6-amino-2-(4-[[(tert-butoxy)carbonyl]amino]-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxylic acid (Intermediate 7, 40 mg, 0.073 mmol) and SOCl (1 mL, 13.1 mmol) in MeOH (4 mL) was stirred at 70 °C for 2 h. The solvent was then removed under reduced pressure to provide the title compound as a brown solid (38 mg, 96%). LC / MS (M+1): 410.2.

[0387] Step 2: 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid hydroxyamide

[0388] [ka]

[0389] A solution of methyl 6-amino-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxylate (33 mg, 0.1 mmol) and NHOH (20 μL, 50% in water) in MeOH (1 mL) was stirred at room temperature for 16 h. The solvent was removed under reduced pressure and the crude material was purified by preparative HPLC (XBridge Shield RP18 OBD column, 5 μm, 19 × 150 mm; 25%-55% gradient of water (10 mM NHHCO) and ACN over 8 min) to give the title compound as a white solid (9 mg, 33%). 1H NMR (400 MHz, DMSO-d6) 7.56-7.49 (m, 2H), 7.29 (t, J=7.9Hz, 2H), 7.12 (s, 1H), 7.12 (d, J=7.8Hz, 1H), 6.10 (s, 4H), 3.91 (d, J=12.6Hz, 4H), 3.64 (s, 5H), 1.39 (d, J=9.5Hz, 10H), 1.24 (s, 1H), 1.09 (s, 6H). LC / MS (M+1): 411.1.

[0390] Compound 21: 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid hydrazide Step 1: tert-butyl N-{1-[4-amino-5-(2,3-dichlorophenyl)-6-(hydrazinecarbonyl)-pyrimidin-2-yl]-4-methylpiperidin-4-yl}carbamate

[0391] [ka]

[0392] A solution of 6-amino-2-(4-{[(tert-butoxy)carbonyl]amino}-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxylic acid (Intermediate 7, 50 mg, 0.084 mmol), HATU (50 mg, 0.126 mmol), DIEA (34 mg, 0.25 mmol) and hydrazine (6 ul) in DMF (5.0 mL) was stirred at 80° C. for 24 h. The reaction mixture was then diluted with water / ice (25 mL) and extracted with EtOAc (3×30 mL). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated. Purification by flash chromatography on silica (PE:EtOAc, 90:10) provided the title compound as a yellow solid (40 mg, 88%).

[0393] Step 2: 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid hydrazide

[0394] [ka]

[0395] A solution of tert-butyl N-[1-[4-amino-5-(2,3-dichlorophenyl)-6-(hydrazinecarbonyl)-pyrimidin-2-yl]-4-methylpiperidin-4-yl]carbamate (40 mg, 0.074 mmol) in HCl (2 mL of a 4N solution in dioxane) was stirred at room temperature for 4 h. The solvent was then removed under reduced pressure, and the crude material was purified by preparative HPLC (XBridge Prep OBD C18 column, 30 × 150 mm, 5 μm; 30%-60% gradient of water (10 mM NH4HCO3) and ACN over 8 min). The title compound was isolated as a white solid (4.3 mg, 13%). mp: 171-173 °C. 1H NMR (300 MHz, methanol-d4) 7.50 (d, J=7.8Hz, 1H), 7.30 (t, J=7.8Hz, 1H), 7.15 (d, J=7.5Hz, 1H), 4.05 (dt, J=13.9, 5.2Hz, 2H), 3.69 (ddd, J=13.1, 7.7, 4.3Hz, 2H), 1.69-1.50 (m, 4H), 1.26 (s, 3H). LC / MS (M+1): 410.1.

[0396] Compound 22: 2-(4-amino-4-methyl-piperidin-1-yl)-6-fluoro-5-(3-fluoro-phenyl)-pyrimidine-4-carboxylic acid amide

[0397] [ka]

[0398] A mixture of tert-butyl N-[1-[4-amino-6-carbamoyl-5-(3-fluorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl]carbamate (prepared in Step 1 from compound 4, 179 mg, 0.396 mmol), phenylboronic acid (3.0 mL), NaNO (139 mg, 1.9 mmol), and KF (117 mg, 1.9 mmol) was stirred at 0 °C for 1 h. The reaction was then quenched by the addition of aqueous NH Cl (10 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated. The crude product (50 mg) was purified by preparative HPLC (XBridge Prep OBD C18 column, 19 × 250 mm, 5 μm; water (10 mM NH4HCO3) and ACN, 30%-45% gradient in 8 minutes) to give the title compound as a white solid (8 mg, 5%). mp: 90-92 °C. 1H NMR (400 MHz, methanol-d4) 7.45-7.35 (m, 1H), 7.17-7.05 (m, 3H), 4.03 (s, 2H), 3.85 (s, 2H), 1.72-1.55 (m, 4H), 1.28 (s, 3H). LC / MS (M+1): 348.1.

[0399] Compound 23: 6-amino-2-[4-(aminomethyl)-8-oxa-2-azaspiro[4.5]decan-2-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide

[0400] [ka]

[0401] The title compound was obtained as a white powder according to the procedure described previously, but starting from 6-amino-5-(2,3-dichloro-phenyl)-2-methanesulfonyl-pyrimidine-4-carbonitrile (Intermediate 4) and tert-butyl n-((8-oxa-2-azaspiro[4.5]decan-4-yl)methyl)carbamate (enamine). 1H NMR (400 MHz, DMSO-d6) 7.78 (s, 1H), 7.51 (dd, J=8.1, 1.6Hz, 1H), 7.28 (t, J=7.8Hz, 1H), 7.18 (s, 1H), 7.10 (dt, J=7.6, 1.5Hz, 1H), 6.04 (s, 2H), 3.84-3.64 (m, 4H), 2.72-2.61 (m, 2H), 1.98-1.84 (m, 2H), 1.77 (dd, J=18.1, 6.4Hz, 2H), 1.55 (t, J=10.6Hz, 2H), 1.36 (t, J=16.2Hz, 3H). LC / MS (M+1): 451.3.

[0402] Compound 24: 2-[3a-(aminomethyl)-octahydro-1H-isoindol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide

[0403] [ka]

[0404] The title compound was obtained as a white powder (mixture of isomers) according to the procedure described previously, but starting from 6-amino-5-(2,3-dichloro-phenyl)-2-methanesulfonyl-pyrimidine-4-carbonitrile (Intermediate 4) and tert-butyl n-(octahydro-1h-isoindol-3a-ylmethyl)-carbamate (enamine). 1H NMR (400 MHz, DMSO-d6) 7.68 (s, 1H), 7.51 (dd, J=8.1, 1.6Hz, 1H), 7.28 (t, J=7.8Hz, 1H), 7.16 (s, 1H), 7.13-7.07 (m, 1H), 6.00 (s, 2H), 3.71-3.35 (m, 4H), 2.64 (s, 1H), 2.10-1.99 (m, 1H), 1.66-1.22 (m, 9H). LC / MS (M+1): 435.

[0405] Compound 25: 2-(4-amino-4-methylpiperidin-1-yl)-5-(3-fluorophenyl)-6-hydroxypyrimidine-4-carboxamide hydrochloride

[0406] [ka]

[0407] A solution of 2-(4-amino-4-methylpiperidin-1-yl)-6-fluoro-5-(3-fluorophenyl)-pyrimidine-4-carboxamide (Example 36, 50 mg, 0.072 mmol) in concentrated HCl (1.0 mL) and water (2.0 mL) was stirred for 2 h at 50° C. The resulting mixture was concentrated under reduced pressure and purified directly by preparative HPLC (XBridge Prep OBD C18 column, 19 × 250 mm, 5 μm; water (10 mM NH4HCO3) and ACN (gradient 58%-80% in 8 min)) to yield the title compound as a white solid (8.6 mg, 31%). 1H NMR (400 MHz, DMSO-d6) 7.63 (s, 1H), 7.33-7.23 (m, 2H), 7.12-7.02 (m, 2H), 7.04-6.96 (m, 1H), 4.06 (s, 1H), 3.81 (s, 2H), 3.61 (s, 2H), 1.48 (s, 4H), 1.17 (s, 3H). LC / MS (M+1): 346.1.

[0408] Compounds 66 and 67: (5P)-6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide and (5M)-6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Step 1: tert-butyl N-[(3S,4S)-8-[4-amino-6-cyano-5-(2,3-dichlorophenyl)pyrimidin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate

[0409] [ka]

[0410] A solution of 6-amino-5-(2,3-dichloro-phenyl)-2-methanesulfonyl-pyrimidine-4-carbonitrile (Intermediate 4, 1.50 g; 4.37 mmol), tert-butyl N-[(3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (WUXI; 1.77 g; 6.56 mmol), and DIEA (2.27 mL) in anhydrous DMSO (60 mL) was stirred at 70 °C for 6 h. The reaction mixture was then diluted with water (300 mL) and EtOAc (800 mL). The organic layer was washed with water (2 × 300 mL) and brine (300 mL), dried over sodium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (hexanes: EtOAc, gradient 95:5 to 20:80) provided the title compound as a white solid (2.07 g, 89%). 1H NMR (400 MHz, DMSO-d6): 7.72 (dd, J=8.0, 1.6Hz, 1H), 7.45 (t, J=7.8Hz, 1H), 7.39 (dd, J=7.7, 1.7Hz, 1H), 6.97 (d, J=10.5Hz, 1H), 4.17 (p, J=6.2Hz, 1H), 3.89 (dd, J=10.6, 5.1Hz, 1H), 3.86-3.75 (m, 1H), 3.75-3.61 (m, 3H), 3.57-3.43 (m, 2H), 1.68-1.50 (m, 3H), 1.50-1.31 (m, 10H), 1.03 (d, J=6.3Hz, 3H);LC / MS (M+1): 533.1.

[0411] Step 2: tert-butyl N-[(3S,4S)-8-[4-amino-6-carbamoyl-5-(2,3-dichlorophenyl)pyrimidin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate

[0412] [ka]

[0413] A solution of tert-butyl N-[(3S,4S)-8-[4-amino-6-cyano-5-(2,3-dichlorophenyl)pyrimidin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (Intermediate 4; 2.0 g; 3.75 mmol), potassium carbonate (2.59 g; 18.75 mmol), and hydrogen peroxide, 30 wt% (7.65 mL; 67.49 mmol) in DMSO (50 mL) was stirred for 4.5 h at 50° C. The reaction mixture was diluted with EtOAc (800 mL) and washed with a solution of sodium thiosulfate pentahydrate (50.25 g; 202.46 mmol) in water (500 mL). The organic layer was washed with water (2×400 mL) and brine (400 mL), dried over sodium sulfate, filtered and concentrated to give the title compound as a white solid (2.2 g, 95.8%). 1H NMR (Bruker 400 MHz, DMSO-d6): 7.73 (s, 1H), 7.51 (dd, J=8.0, 1.5Hz, 1H), 7.28 (t, J=7.8Hz, 1H), 7.14 (s, 1H), 7.10 (dd, J=7.4, 1.2Hz, 1H), 6.97 (d, J=10.5Hz, 1H), 6.08 (s, 2H), 4.22-4.11 (m, 1H), 3.96-3.78 (m, 2H), 3.78-3.64 (m, 3H), 3.61-3.47 (m, 2H), 1.69-1.50 (m, 4H), 1.40 (s, 9H), 1.03 (d, J=6.3Hz, 3H). LC / MS (M+1): 551.2.

[0414] Step 3: (5P)-6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide and (5M)-6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide

[0415] [ka]

[0416] A solution of tert-butyl N-[(3S,4S)-8-[4-amino-6-carbamoyl-5-(2,3-dichlorophenyl)pyrimidin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (2.20 g; 3.59 mmol; 1.00 equiv.) in dichloromethane (44 mL) and TFA (22 mL) was stirred at room temperature for 1 h. Toluene was added, and the mixture was concentrated under reduced pressure. This procedure was repeated twice. The crude residue (3.3 g) was purified by preparative SFC (column Amylose 2, 250 × 21 mm, 5 microns, methanol + 20 mM NH4OH:CO2; 45-55).

[0417] First-eluting fraction (Compound 67): (5M)-6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide: white amorphous solid; 637 mg (40%). RT=4.04 min;ed=100%;1H NMR (400 MHz, DMSO-d6): 7.71 (s, 1H), 7.51 (dd, J=8.1, 1.5Hz, 1H), 7.28 (t, J=7.8Hz, 1H), 7.15 (s, 1H), 7.10 (dd, J=7.6, 1.5Hz, 1H), 6.08 (s, 2H), 4.16-3.99 (m, 3H), 3.68 (d, J=8.4Hz, 1H), 3.50 (d, J=8.4Hz, 1H), 3.48-3.25 (m, 4H), 2.91 (d, J=5.1Hz, 1H), 1.77-1.34 (m, 6H), 1.09 (d, J=6.4Hz, 3H); LC / MS (M+1):451.0.

[0418] Second eluting fraction(Compound 66): (5P)-6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide: white solid; 603 mg (37%). RT=4.53 min;ed=95%;1H NMR (Bruker 400 MHz, DMSO-d6): 7.72 (s, 1H), 7.51 (dd, J=8.0, 1.6Hz, 1H), 7.28 (t, J=7.8Hz, 1H), 7.15 (s, 1H), 7.10 (dd, J=7.7, 1.6Hz, 1H), 6.08 (s, 2H), 4.15-3.99 (m, 3H), 3.68 (d, J=8.4Hz, 1H), 3.50 (d, J=8.4Hz, 1H), 3.48-3.34 (m, 4H), 2.90 (d, J=5.2Hz, 1H), 1.75-1.63 (m, 1H), 1.63-1.53 ​​(m, 1H), 1.53-1.29 (m, 4H), 1.08 (d, J=6.4Hz, 3H). LC / MS (M+1):451.0.

[0419] Compound 85: 2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Step 1: tert-butyl N-[(3S,4S)-8-[4-cyano-5-(2,3-dichlorophenyl)-6-methylpyrimidin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate

[0420] [ka]

[0421] Under a N atmosphere, tert-butyl N-[(3S,4S)-8-(5-bromo-4-cyano-6-methylpyrimidin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (108 mg; 0.23 mmol) was combined with 2,3-dichlorophenylboronic acid (66 mg; 0.35 mmol) and cesium carbonate (151 mg; 0.46 mmol) in 1,4-dioxane (2.2 mL) and water (0.54 mL). The mixture was degassed for 10 min, after which tetrakis(triphenylphosphine)palladium(0) (53 mg; 0.05 mmol) was added and stirred at 100 °C for 2 h. The reaction mixture was cooled to room temperature and diluted with EtOAc (10 mL). It was filtered through a pad of Celite rinsed with EtOAc (10 mL) and the filtrate was concentrated and purified by flash chromatography on silica (hexane: EtOAc, gradient 95:5-20:80) to provide the title compound as a white solid (72 mg, 58%). 1H NMR (Bruker 400 MHz, DMSO-d6): 7.80 (dd, J=6.4, 3.2Hz, 1H), 7.60-7.47 (m, 2H), 7.01 (d, J=10.5Hz, 1H), 4.18 (p, J=6.2Hz, 1H), 3.96-3.84 (m, 2H), 3.84-3.73 (m, 2H), 3.70 (d, J=8.5Hz, 1H), 3.66-3.58 (m, 1H), 3.54 (d, J=8.2Hz, 1H), 2.12 (s, 3H), 1.75-1.44 (m, 4H), 1.40 (s, 9H), 1.03 (d, J=6.3Hz, 3H). LC / MS (M+1): 532.2.

[0422] Step 2: tert-butyl N-[(3S,4S)-8-[4-carbamoyl-5-(2,3-dichlorophenyl)-6-methylpyrimidin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate

[0423] [ka]

[0424] A solution of tert-butyl N-[(3S,4S)-8-[4-cyano-5-(2,3-dichlorophenyl)-6-methylpyrimidin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (100 mg; 0.19 mmol), potassium carbonate (130 mg; 0.94 mmol), and hydrogen peroxide, 30 wt% (0.38 mL; 3.38 mmol) in DMSO (2.5 mL) was stirred at 50 °C for 6 h. The reaction mixture was diluted with EtOAc (50 mL) and washed with a solution of sodium thiosulfate pentahydrate (2.52 g; 10.1 mmol) in water (25 mL). The organic layer was washed with water (2 × 25 mL) and brine (25 mL), dried over sodium sulfate, filtered, and concentrated to yield the title compound as a white solid (103 mg, 94%). LC / MS (M+1): 550.2.

[0425] Step 3: 2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide

[0426] [ka]

[0427] A solution of tert-butyl N-[(3S,4S)-8-[4-carbamoyl-5-(2,3-dichlorophenyl)-6-methylpyrimidin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (100.00 mg; 0.18 mmol; 1.00 equiv.) in dichloromethane (2 mL) and TFA (1 mL) was stirred at room temperature for 1 hour. Toluene was added, and the mixture was concentrated under reduced pressure. This procedure was repeated twice. The crude material was then purified by preparative HPLC (XBridge Prep C-18 OBD, 10 μM, 30×250; ACN:water containing 0.1% ammonium hydroxide, 20-60% gradient in 15 minutes) to provide the title compound as a white powder (70 mg, 86%). 1H NMR (Bruker 400 MHz, DMSO-d6): 7.93 (s, 1H), 7.58 (dd, J=8.0, 1.6Hz, 1H), 7.43-7.29 (m, 2H), 7.20 (dd, J=7.7, 1.6Hz, 1H), 4.23-4.10 (m, 2H), 4.08 (dd, J=6.5, 5.2Hz, 1H), 3.70 (d, J=8.4Hz, 1H), 3.61-3.42 (m, 3H), 2.93 (d, J=5.2Hz, 1H), 2.00 (s, 3H), 1.77-1.68 (m, 1H), 1.68-1.42 (m, 5H), 1.09 (d, J=6.4Hz, 3H); LC / MS (M+1): 450.1.

[0428] Compounds 94 and 95: (5P)-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide and (5M)-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide

[0429] [ka]

[0430] The two atropisomers from compound 85 were separated by preparative SFC (Column IA, 250 x 21 mm, 5 micron, methanol + 20 mM NH4OH:CO2, 30-70).

[0431] First-eluting isomer(Compound 94): white amorphous solid, 24 mg, RT = 3.32 min, ed = 100%. 1H NMR (Bruker 400 MHz, DMSO-d6): 7.93 (s, 1H), 7.58 (dd, J=8.0, 1.5Hz, 1H), 7.42-7.29 (m, 2H), 7.20 (dd, J=7.6, 1.6Hz, 1H), 4.24-4.02 (m, 3H), 3.70 (d, J=8.4Hz, 1H), 3.62-3.41 (m, 3H), 2.92 (d, J=5.2Hz, 1H), 2.00 (s, 3H), 1.80-1.33 (m, 6H), 1.09 (d, J=6.4Hz, 3H). LC / MS (M+1): 450.2.

[0432] Second-eluting isomer (Compound 95): white solid, 22 mg, RT = 3.67 min, ed = 100%. 1H NMR (400 MHz, DMSO-d6): 7.93 (s, 1H), 7.58 (dd, J=8.0, 1.6Hz, 1H), 7.41-7.30 (m, 2H), 7.20 (dd, J=7.7, 1.6Hz, 1H), 4.27-3.99 (m, 3H), 3.71 (d, J=8.5Hz, 1H), 3.65-3.39 (m, 3H), 2.94 (d, J=5.2Hz, 1H), 2.00 (s, 3H), 1.81-1.35 (m, 5H), 1.35-1.17 (m, 1H), 1.09 (d, J=6.4Hz, 3H). LC / MS (M+1): 450.2.

[0433] Compounds 96 and 97: (5M)-2-[(1R)-1-amino-3,3-difluoro-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide and (5P)-2-[(1R)-1-amino-3,3-difluoro-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide

[0434]

change

[0435] The title compound was obtained as a white powder (65 mg, 44% for three steps, mixture of two atropisomers) following the procedure described for compound 85, but starting from tert-butyl N-[(1R)-8-(5-bromo-4-cyano-6-methylpyrimidin-2-yl)-3,3-difluoro-8-azaspiro[4.5]decan-1-yl]carbamate (150.00 mg; 0.31 mmol) and 2,3-dichlorophenylboronic acid (88.28 mg; 0.46 mmol). The two atropisomers were separated by preparative SFC (column Cel4, 250 × 21 mm, 5 microns, methanol + 20 mM NHOH:CO).

[0436] First-eluting isomer (Compound 96): White solid, 31 mg, RT=, ed=. 1H NMR (Bruker 400 MHz, DMSO-d6): 7.93 (s, 1H), 7.58 (d, J=8.0Hz, 1H), 7.42-7.28 (m, 2H), 7.20 (d, J=7.6Hz, 1H), 4.61 (dd, J=17.5, 13.3Hz, 2H), 3.18-2.94 (m, 3H), 2.46-2.29 (m, 2H), 2.12-1.91 (m, 5H), 1.78-1.54 (m, 4H), 1.36 (dd, J=26.1, 13.4Hz, 2H). LC / MS (M+1): 470.2.

[0437] Second-eluting isomer (Compound 97): White solid, 25 mg, RT=, ed=. 1H NMR (Bruker 400 MHz, DMSO-d6): 7.93 (s, 1H), 7.58 (dd, J=8.0, 1.5Hz, 1H), 7.41-7.29 (m, 2H), 7.20 (dd, J=7.6, 1.6Hz, 1H), 4.61 (dd, J=19.0, 14.6Hz, 2H), 3.17-2.95 (m, 3H), 2.47-2.29 (m, 2H), 2.12-1.92 (m, 5H), 1.86-1.51 (m, 4H), 1.44-1.28 (m, 2H). LC / MS (M+1): 470.2.

[0438] Compounds 98, 104, 99, 105: (5P)-2-[(3aR,6aS)-3a-(aminomethyl)-octahydrocyclopenta[c]pyrrol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide, (5P)-2-[(3aS,6aR)-3a-(aminomethyl)-octahydrocyclopenta[c]pyrrol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4 -carboxamide, (5M)-2-[(3aR,6aS)-3a-(aminomethyl)-octahydrocyclopenta[c]pyrrol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide, (5M)-2-[(3aS,6aR)-3a-(aminomethyl)-octahydrocyclopenta[c]pyrrol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Step 1: rac-2-[(3aS,6aR)-3a-(aminomethyl)-octahydrocyclopenta[c]pyrrol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide

[0439] [ka]

[0440] The title compound was obtained as a white amorphous solid (179 mg, 25%, 5 steps) according to the procedure described for compound 85, but starting from 6-amino-2-chloropyrimidine-4-carbonitrile (250 mg, 1.6 mmol) and rac-tert-butyl n-([(3ar,6ar)-octahydrocyclopenta[c]pyrrol-3a-yl]methyl)carbamate hydrochloride (enamine, 895 mg, 3.2 mmol). 1H NMR (400 MHz, DMSO-d6) d 7.69 (s, 1H), 7.51 (d, J=8.0Hz, 1H), 7.28 (t, J=7.8Hz, 1H), 7.21-7.04 (m, 2H), 6.02 (s, 2H), 3.80-3.36 LC / MS (M+1): 421.1.

[0441] Step 2: Separation of the four isomers

[0442] [ka]

[0443] The isomers of rac-2-[(3aS,6aR)-3a-(aminomethyl)-octahydrocyclopenta[c]pyrrol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide were separated by preparative SFC (column: IG, 250 × 21 mm, 5 micron, methanol + 20 mM NH4OH:CO2, 30:70%). Stereochemistry was arbitrarily assigned. Enantiomeric purity was assessed by SFC (methanol + 20 mM NH4OH) using a chiral column IC.

[0444] First eluting fraction (compound 98): White amorphous solid, 26 mg, RT=3.76 min, ed=95.9%. 1H NMR (400 MHz, DMSO-d6) δ 7.68 (s, 1H), 7.51 (dd, J=8.1, 1.6Hz, 1H), 7.28 (t, J=7.8Hz, 1H), 7.21-7.04 (m, 2H), 6.03 (s, 2H), 3.65 (ddd, J=35.0, 11.5, 6.8Hz, 2H), 3.26-3.19 (m, 1H), 2.42-2.26 (m, 1H), 1.93-1.40 (m, 8H), 1.24 (d, J=3.0Hz, 2H), 0.87 (dt, J=13.4, 7.2Hz, 1H). LC / MS (M+1): 421.1.

[0445] Second eluting fraction (compound 104): White amorphous solid, 35 mg, RT=3.82 min, ed=97.3%. 1H NMR (400 MHz, DMSO-d6) δ 7.69 (s, 1H), 7.51 (dd, J=8.1, 1.6Hz, 1H), 7.28 (t, J=7.8Hz, 1H), 7.16 (s, 1H), 7.09 (dd, J=7.6, 1.6Hz, 1H), 6.02 (s, 2H), 3.81-3.54 (m, 2H), 2.56 (s, 2H), 2.43-2.19 (m, 2H), 1.95-1.36 (m, 8H), 1.36-1.13 (m, 1H);LC / MS (M+1): 421.0.

[0446] Third eluting fraction (compound 99):White amorphous solid, 46 mg, RT=4.14 min, ed=95.1%. 1H NMR (400 MHz, DMSO-d6) δ 7.69 (s, 1H), 7.51 (dd, J=8.1, 1.6Hz, 1H), 7.28 (t, J=7.8Hz, 1H), 7.16 (s, 1H), 7.09 (dd, J=7.6, 1.6Hz, 1H), 6.02 (s, 2H), 3.81-3.54 (m, 2H), 2.56 (s, 2H), 2.43-2.19 (m, 2H), 1.95-1.36 (m, 8H), 1.36-1.13 (m, 1H);LC / MS (M+1): 421.0.

[0447] Fourth eluting fraction (compound 105): White amorphous solid, 29 mg, RT=4.2 min, ed=95.4%. 1H NMR (400 MHz, DMSO-d6) d 7.69 (s, 1H), 7.51 (dd, J=8.1, 1.5Hz, 1H), 7.28 (t, J=7.8Hz, 1H), 7.16 (s, 1H), 7.10 (dd, J=7.6, 1.6Hz, 1H), 6.02 (s, 2H), 3.77-3.54 (m, 2H), 2.56 (s, 2H), 2.43-2.22 (m, 2H), 1.94-1.41 (m, 8H), 1.24 (s, 1H);

[0448] Compounds 100, 101, 102, 103: (5P)-2-[(3aR,7aS)-3a-(aminomethyl)-octahydro-1H-isoindol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide, (5P)-2-[(3aS,7aR)-3a-(aminomethyl)-octahydro-1H-isoindol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine- 4-Carboxamide, (5M)-2-[(3aR,7aS)-3a-(aminomethyl)-octahydro-1H-isoindol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide, (5M)-2-[(3aS,7aR)-3a-(aminomethyl)-octahydro-1H-isoindol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Step 1: 2-[3a-(aminomethyl)-octahydro-1H-isoindol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide

[0449] [ka]

[0450] The title compound was obtained as a white amorphous solid (128 mg, 19% over 5 steps) according to the procedure described for compound 85, but starting from 6-amino-2-chloropyrimidine-4-carbonitrile (250 mg, 1.6 mmol) and tert-butyl n-(octahydro-1h-isoindol-3a-ylmethyl)carbamate (enamine, 823 mg, 3.2 mmol). 1H NMR (400 MHz, DMSO-d6) d 7.68 (s, 1H), 7.50 (d, 1H), 7.28 (t, J=7.8Hz, 1H), 7.23-7.04 (m, 2H), 6.00 (s, 2H), 3.70-3.34 (m, 4H), 2.63 (q, J=5.8Hz, 1H), 2.05 (dd, J=11.5, 5.8Hz, 2H), 1.72-1.20 (m, 8H);LC / MS (M+1): 435.1.

[0451] Step 2: Separation of the four isomers

[0452] [ka]

[0453] The isomers of 2-[3a-(aminomethyl)-octahydro-1H-isoindol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide were separated by preparative SFC (column: IG, 250 × 21 mm, 5 micron, methanol + 20 mM NH4OH:CO2, 30:70%). Stereochemistry was arbitrarily assigned. Enantiomeric purity was assessed by SFC (methanol + 20 mM NH4OH) using chiral column IG.

[0454] First eluting fraction (compound 100):White amorphous solid, 20 mg, RT = 3.67 min, ed = 95.0%. 1H NMR (400 MHz, DMSO-d6): 7.68 (s, 1H), 7.51 (dd, J = 8.0, 1.5 Hz, 1H), 7.28 (t, J = 7.8 Hz, 1H), 7.22-7.05 (m, 2H), 6.00 (s, 2H), 3.77-3.48 (m, 2H), 2.62 (d, J = 14.0 Hz, 2H), 2.04 (s, 2H), 1.69-1.17 (m, 10H), 0.95-0.74 (m, 1H); LC / MS (M+1): 435.0.

[0455] Second eluting fraction (compound 101): White amorphous solid, 19 mg, RT = 3.59 min, ed = 93.4%. 1H NMR (400 MHz, DMSO-d6): 7.76-7.59 (m, 1H), 7.51 (dd, J = 8.1, 1.6 Hz, 1H), 7.28 (t, J = 7.8 Hz, 1H), 7.22-7.04 (m, 2H), 6.00 (s, 2H), 3.73-3.43 (m, 2H), 2.64 (d, J = 14.3 Hz, 1H), 2.15-1.89 (m, 2H), 1.40 (t, J = 56.6 Hz, 9H), 0.96-0.72 (m, 1H); LC / MS (M+1): 435.0.

[0456] Third eluting fraction (compound 102): White amorphous solid, 20 mg, RT = 3.85 min, ed = 91.3%. 1H NMR (400 MHz, DMSO-d6): 7.68 (s, 1H), 7.51 (dd, J = 8.0, 1.6 Hz, 1H), 7.28 (t, J = 7.8 Hz, 1H), 7.22-7.01 (m, 2H), 6.00 (s, 2H), 3.73-3.43 (m, 2H), 2.64 (s, 2H), 2.03 (dt, J = 15.3, 7.2 Hz, 2H), 1.78-0.97 (m, 10H), 0.97-0.68 (m, 1H); LC / MS (M+1): 435.0.

[0457] Fourth eluting fraction (compound 103):White amorphous solid, 16 mg, RT=4.02 min, ed=94.2%. 1H NMR (400 MHz, DMSO-d6): 7.68 (s, 1H), 7.51 (d, J=7.8Hz, 1H), 7.28 (q, J=7.0, 6.3Hz, 1H), 7.22-7.00 (m, 2H), 6.00 (s, 2H), 3.51 (s, 2H), 2.04 (s, 2H), 1.34 (d, J=77.2Hz, 11H), 0.85 (s, 2H); LC / MS (M+1): 435.1.

[0458] Compounds 113 and 114: (5P)-2-[(1R)-1-amino-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide and (5M)-2-[(1R)-1-amino-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide

[0459] [ka]

[0460] The title compound was obtained as a white powder (43 mg, 31% for three steps, mixture of two atropisomers) following the procedure described for compound 85, but starting from tert-butyl N-[(1R)-8-(5-bromo-4-cyano-6-methylpyrimidin-2-yl)-8-azaspiro[4.5]decan-1-yl]carbamate (Intermediate 13, 100 mg; 0.22 mmol) and 2,3-dichlorophenylboronic acid (64 mg; 0.33 mmol). The two atropisomers were separated by preparative SFC (column Whelk-O, 250 × 21 mm, 5 microns, methanol + 20 mM NHOH:CO, 5-45).

[0461] First-eluting isomer(Compound 113): white solid, 9 mg, RT=3.51 min, ed=100%. 1H NMR (400 MHz, DMSO-d6): 7.91 (s, 1H), 7.58 (dd, J=8.0, 1.5Hz, 1H), 7.43-7.29 (m, 2H), 7.20 (dd, J=7.6, 1.6Hz, 1H), 4.55 (t, J=13.0Hz, 2H), 3.15-3.05 (m, 2H), 2.78 (t, J=7.4Hz, 1H), 2.00 (s, 3H), 1.96-1.72 (m, 3H), 1.73-1.29 (m, 7H), 1.29-1.14 (m, 2H). LC / MS (M+1): 434.0.

[0462] Second-eluting isomer (Compound 114): White solid, 9 mg, RT=4.03 min, ed=94.3%. 1H NMR (400 MHz, DMSO-d6): 7.90 (s, 1H), 7.58 (dd, J=8.1, 1.6Hz, 1H), 7.40-7.30 (m, 2H), 7.20 (dd, J=7.6, 1.6Hz, 1H), 4.54 (td, J=9.5, 5.1Hz, 2H), 3.20-3.05 (m, 2H), 2.73 (t, J=7.4Hz, 1H), 2.00 (s, 3H), 1.94-1.76 (m, 2H), 1.75-1.47 (m, 5H), 1.46-1.31 (m, 2H), 1.31-1.13 (m, 3H). LC / MS (M+1): 434.0.

[0463] Compounds 117 and 118: (5P)-6-amino-2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide and (5M)-6-amino-2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Step 1: 6-amino-2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carbonitrile

[0464] [ka]

[0465] A solution of 6-amino-5-(2,3-dichloro-phenyl)-2-methanesulfonyl-pyrimidine-4-carbonitrile (75 mg; 0.22 mmol; 1.00 equiv.), (3S)-1,3-dihydrospiro[indene-2,4'-piperidine]-3-amine dihydrochloride (Pharmablock, 90 mg; 0.33 mmol; 1.50 equiv.), and potassium carbonate (151 mg; 1.09 mmol; 5.00 equiv.) in MeCN (1.50 mL; 20.00 V) and N,N-dimethylformamide (0.75 mL; 10.00 V) was stirred at 100°C for 18 hours. The reaction mixture was diluted with EtOAc (40 mL) and washed with water (2 x 10 mL) and brine (10 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (EtOAc:MeOH, gradient 99:1 to 90:10) provided the title compound as a white solid (76 mg, 75%). 1H NMR (Bruker 400 MHz, DMSO-d6): 7.72 (dd, J=8.0, 1.7Hz, 1H), 7.45 (t, J=7.8Hz, 1H), 7.39 (dd, J=7.6, 1.6Hz, 1H), 7.30 (dd, J=6.6, 1.7Hz, 1H), 7.22-7.10 (m, 3H), 7.00-6.57 (m, 2H), 4.44 (t, J=14.2Hz, 2H), 3.83 (s, 1H), 3.21-3.02 (m, 3H), 2.62 (d, J=15.6Hz, 1H), 1.93-1.78 (m, 2H), 1.78-1.67 (m, 1H), 1.59 (td, J=12.6, 4.3Hz, 1H), 1.48 (d, J=13.2Hz, 1H), 1.07 (d, J=13.3Hz, 1H). LC / MS (M+1): 465.2.

[0466] Step 2: (5P)-6-amino-2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide and (5M)-6-amino-2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide

[0467] [ka]

[0468] A solution of 6-amino-2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carbonitrile (936 mg; 2.01 mmol), potassium carbonate (1.39 g; 10.1 mmol), and hydrogen peroxide, 30 wt% (4.1 mL; 36.2 mmol) in DMSO (23 mL) was stirred at 50°C for 4 h. The reaction mixture was diluted with EtOAc (800 mL) and washed with a solution of sodium thiosulfate pentahydrate (27 g; 109 mmol) in water (230 mL). The organic layer was washed with water (2 x 400 mL) and brine (400 mL), dried over sodium sulfate, filtered, and concentrated to give the title compound as a white solid (970 mg). The two atropisomers were separated by preparative SFC (column IC, 250 x 21 mm, 5 micron; methanol + 20 mM NH4OH:CO2, 45-55).

[0469] First-eluting isomer (Compound 117): White solid, 309 mg, RT=6.62 min, ed=100%. LC / MS (M+1) 483.1.

[0470] Second-eluting isomer(Compound 118): White solid, 328 mg, RT=7.98 min, ed=99.4%. 1H NMR (400 MHz, DMSO-d6): 7.74 (s, 1H), 7.53-7.50 (m, 1H), 7.37-7.25 (m, 2H), 7.25-7.15 (m, 4H), 7.12-7.10 (m, 1H), 6.12 (s, 2H), 4.54 (d, J=13.7Hz, 2H), 3.90 (s, 1H), 3.16-3.01 (m, 3H), 2.67 (d, J=15.6Hz, 1H), 1.79-1.68 (m, 1H), 1.64 ? 1.58 (m, 1H), 1.47 (d, J=13.0Hz, 1H), 1.12 (d, J=13.0Hz, 1H);LC / MS (M+1) 483.1.

[0471] Compounds 119 and 120: (M)-2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide and (P)-2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Step 1: 6-methyl-2-{1-oxo-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl}pyrimidine-4-carbonitrile

[0472] [ka]

[0473] A solution of 2-chloro-6-methylpyrimidine-4-carbonitrile (120 mg, 0.742 mmol), 1H-spiro[indene-2,4-piperidin]-3-one hydrochloride (Pharmablock, 279 mg, 1.114 mmol), and DIEA (303 mg, 2.23 mmol) in MeCN (5.0 mL) was stirred at 80° C. under a nitrogen atmosphere for 2 h. The resulting mixture was concentrated in vacuo and purified by flash chromatography on silica (PE:EtOAC, 1:1) to afford the title compound as a white solid (200 mg, 84%); LC / MS (M+1): 319.0.

[0474] Step 2: 5-Bromo-6-methyl-2-{1-oxo-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl}pyrimidine-4-carbonitrile

[0475] [ka]

[0476] A solution of 6-methyl-2-[3-oxo-1H-spiro[indene-2,4-piperidin]-1-yl]pyrimidine-4-carbonitrile (180 mg, 0.565 mmol) and NBS (158 mg, 0.847) in DMF (5.0 mL) was stirred at room temperature for 1 h. The reaction was quenched with water and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (1 × 30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (PE:EtOAc, 5:1) provided the title compound as a yellow solid (220 mg, 96.38%). LC / MS (M+1): 396.9.

[0477] Step 3: 5-(2,3-dichlorophenyl)-6-methyl-2-{3-oxo-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl}pyrimidine-4-carbonitrile

[0478] [ka]

[0479] A mixture of 5-bromo-6-methyl-2-[3-oxo-1H-spiro[indene-2,4-piperidin]-1-yl]pyrimidine-4-carbonitrile (590 mg, 1.46 mmol), 2,3-dichlorophenylboronic acid (880 mg, 4.38 mmol), KPO (978 mg, 4.38 mmol), XPhos Pd G3 (130 mg, 0.146 mmol), and XPhos (73 mg, 0.146 mmol) in 1,4-dioxane (5 mL) and water (3 mL) was stirred at 100 °C under a nitrogen atmosphere for 2 h. The resulting mixture was concentrated under reduced pressure and purified by preparative TLC on silica (PE:EtOAc, 1:1) to afford the title compound as a yellow solid (820 mg, 81%). LC / MS (M+1): 463.2.

[0480] Step 4: (R)—N-{1′-[4-cyano-5-(2,3-dichlorophenyl)-6-methylpyrimidin-2-yl]-1,3-dihydrospiro[indene-2,4′-piperidin]-3-ylidene}-2-methylpropane-2-sulfinamide

[0481] [ka]

[0482] A mixture of 5-(2,3-dichlorophenyl)-6-methyl-2-[3-oxo-1H-spiro[indene-2,4-piperidin]-1-yl]pyrimidine-4-carbonitrile (780 mg, 1.34 mmol) and (R)-2-methylpropane-2-sulfinamide (681 mg, 5.340 mmol) in Ti(OEt) (12.3 g, 53.5 mmol) was stirred at 90 °C under a nitrogen atmosphere for 2 h. The reaction mixture was then diluted with water and EtOAc and filtered. The filter cake was washed with EtOAc (100 mL), and the filtrate was concentrated under reduced pressure. The aqueous layer was extracted with EtOAc (3 × 120 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (PE:EtOAc, 1:1) provided the title compound as a yellow solid (800 mg, 64%). LC / MS (M+1): 566.2.

[0483] Step 5: (R)—N-[(3S)-1′-[4-cyano-5-(2,3-dichlorophenyl)-6-methylpyrimidin-2-yl]-1,3-dihydrospiro[indene-2,4′-piperidin]-3-yl]-2-methylpropane-2-sulfinamide

[0484] [ka]

[0485] A solution of NaBH4 (93 mg, 2.34 mmol) in water (1.3 mL) was slowly added to a solution of (R)-N-[1-[4-cyano-5-(2,3-dichlorophenyl)-6-methylpyrimidin-2-yl]-1H-spiro[indene-2,4-piperidin]-3-ylidene]-2-methylpropane-2-sulfinamide (440 mg, 0.468 mmol) in THF (8.8 mL) maintained at -50 °C. The resulting mixture was stirred at 25 °C under a N2 atmosphere for 1 h. The reaction was quenched by the addition of water / ice (30 mL), and the aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give the title compound as a yellow oil (320 mg, 63%). LC / MS (M+1): 568.2.

[0486] Step 6: 5-(2,3-dichlorophenyl)-6-methyl-2-[(3S)-3-{[(R)-2-methylpropane-2-sulfinyl]amino}-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl]pyrimidine-4-carboxamide

[0487] [ka]

[0488] To a 30 mL sealed tube was added a mixture of (R)—N-[(3S)-1-[4-cyano-5-(2,3-dichlorophenyl)-6-methylpyrimidin-2-yl]-1,3-dihydrospiro[indene-2,4-piperidin]-3-yl]-2-methylpropane-2-sulfinamide (300 mg, 0.275 mmol) and NaOH (200 mg, 4.750 mmol) in EtOH (5.00 mL) and water (5 mL), and the mixture was stirred in a sealed tube at 70° C. under a nitrogen atmosphere for 1 h. The reaction mixture was then extracted with EtOAc (3×30 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give the title compound as a yellow solid (400 mg, 88%). LC / MS (M+1): 586.2.

[0489] Step 7: 2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide

[0490] [ka]

[0491] A solution of 5-(2,3-dichlorophenyl)-6-methyl-2-[(1S)-1-[[(R)-2-methylpropane-2-sulfinyl]amino]-1,3-dihydrospiro[indene-2,4-piperidin]-1-yl]pyrimidine-4-carboxamide (100 mg, 0.17 mmol) and HCl (gas) in 1,4-dioxane (2.00 mL, 7.9 mmol, 12%) was stirred under a nitrogen atmosphere at 25° C. for 1 h. The solvent was removed under reduced pressure, and the residue was purified by reverse-phase flash chromatography on C18 silica gel (ACN:water+NH4OH, 0:100 to 50:50 gradient) to give the title compound as a white solid (50 mg, 60%). 1H NMR (400 MHz, DMSO-d6): 7.94 (s, 1H), 7.58 (d, J=7.9Hz, 1H), 7.41-7.29 (m, 3H), 7.24-7.14 (m, 4H), 4.62 (t, J=15.0Hz, 2H), 3.86 (s, 1H), 3.17 (s, 1H), 3.10 (d, J=15.7Hz, 1H), 2.66 (d, J=15.5Hz, 1H), 2.01 (s, 3H), 1.82-1.71 (m, 1H), 1.64 (dd, J=13.7, 9.4Hz, 1H), 1.52 (d, J=13.1Hz, 1H), 1.13 (d, J=13.4Hz, 1H). LC / MS (M+1): 482.2.

[0492] Step 8: Atropisomer Separation: (5M)-2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide and (5P)-2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide

[0493] [ka]

[0494] Atropisomers from 2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide were separated by preparative HPLC (column (R,R) whelk-O1, 4.6 x 50 mm, 3.5 um, hexane + 0.1% DEA:EtOH, 50:50).

[0495] First-eluting isomer (compound 119) :29mg, RT=1.1min, ed=97.9. 1H NMR (400 MHz, DMSO-d6): 7.94 (s, 1H), 7.58 (dd, J=8.1, 1.5Hz, 1H), 7.41-7.29 (m, 3H), 7.19 (ddd, J=15.5, 7.2, 2.8Hz, 4H), 4.62 (t, J=16.3Hz, 2H), 3.86 (s, 1H), 3.25-3.15 (m, 1H), 3.11 (d, J=15.7Hz, 1H), 2.66 (d, J=15.4Hz, 1H), 2.01 (s, 3H), 1.77 (t, J=11.3Hz, 1H), 1.62 (d, J=11.9Hz, 1H), 1.52 (d, J=12.9Hz, 1H), 1.13 (d, J=13.0Hz, 1H). LC / MS (M+1): 481.2. mp:114-115℃.

[0496] Second-eluting isomer (compound 120):19mg, RT=6.9min, ed=98.5. LC / MS (M+1): 481.2. mp:121-123℃.

[0497] Compound 121: 6-amino-2-[(4S)-4-amino-4,6-dihydrospiro[cyclopenta[d][1,3]thiazol-5,4'-piperidin]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Step 1: 6-amino-2-[(4S)-4-amino-4,6-dihydrospiro[cyclopenta[d][1,3]thiazol-5,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carbonitrile

[0498] [ka]

[0499] A mixture of (4S)-4,6-dihydrospiro[cyclopenta[d][1,3]thiazole-5,4-piperidine]-4-amine (Intermediate 16, 100 mg, 0.430 mmol), 6-amino-5-(2,3-dichlorophenyl)-2-methanesulfonylpyrimidine-4-carbonitrile (220 mg, 0.439 mmol), and KCO (10 mg, 0.069 mmol) in ACN (4.0 mL) was stirred at RT under a nitrogen atmosphere for 12 h. The solvent was removed under reduced pressure, and the residue was purified by chromatography on silica (PE:EtOAc, 1:9) to afford the title compound as a yellow solid (60 mg, 24%). LC / MS (M+1): 472.1.

[0500] Step 2: 6-amino-2-[(4S)-4-amino-4,6-dihydrospiro[cyclopenta[d][1,3]thiazol-5,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide

[0501] [ka]

[0502] A solution of 6-amino-2-[(4S)-4-amino-4,6-dihydrospiro[cyclopenta[d][1,3]thiazol-5,4-piperidin]-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carbonitrile (40 mg, 0.070 mmol), NaOH (73 mg, 1.73 mmol) in water (1 mL) and EtOH (1 mL) was stirred for 1 h at 50° C. The solvent was removed under reduced pressure and the residue was purified by preparative HPLC (column XBridge, Prep C18 OBD, 19 × 150 mm, 5 um, (water + 10 mmol NH4HCO3):ACN; gradient 70:30 to 50:50 in 8 min) to give the title compound as an off-white solid (5.6 mg, 16%). 1H NMR (400 MHz, DMSO-d6): 8.96 (s, 1H), 7.74 (s, 1H), 7.52 (dd, J=8.0, 1.5Hz, 1H), 7.29 (t, J=7.8Hz, 1H), 7.16 (s, 1H), 7.11 (d, 3.17 (m, 2H), 2.87 (d, J=15.3Hz, 1H), 2.75 (d, J=15.3Hz, 1H), 1.82-1.71 (m, 1H), 1.68-1.50 (m, 3H), 1.24 (s, 1H). LC / MS (M+1): 490.1.

[0503] Compound 122: 2-((S)-3-amino-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Step 1: 6-methyl-2-[3-oxospiro[1-benzofuran-2,4-piperidin]-1-yl]pyrimidine-4-carbonitrile

[0504] [ka]

[0505] A solution of 2-chloro-6-methylpyrimidine-4-carbonitrile (100 mg, 0.619 mmol), spiro[1-benzofuran-2,4-piperidin]-3-one (140 mg, 0.682 mmol), and DIEA (0.215 mL, 1.24 mmol, 2 equiv.) in CAN (4.0 mL) was stirred at 80° C. for 2 h. The resulting mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE / EtOAc, 1:1) to afford the title compound as a yellow solid (120 mg, 54%). LC / MS (M+1): 321.

[0506] Step 2: 5-Bromo-6-methyl-2-[3-oxospiro[1-benzofuran-2,4'-piperidine]-1'-yl]pyrimidine-4-carbonitrile

[0507] [ka]

[0508] NBS (105 mg, 0.563 mmol) was added to a solution of 6-methyl-2-[3-oxospiro[1-benzofuran-2,4-piperidin]-1-yl]pyrimidine-4-carbonitrile (100 mg, 0.281 mmol) in DMF (5.0 mL) at 25° C. The resulting mixture was stirred at 25° C. for 2 h. It was then diluted with water (40 mL) and extracted with EtOAc (3×45 mL). The combined organic layers were washed with brine (1×100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give the title compound as a yellow solid (110 mg, 85% yield). LC / MS (M+1): 399, 401.

[0509] Step 3: 5-(2,3-Dichlorophenyl)-6-methyl-2-{3-oxo-3H-spiro[1-benzofuran-2,4'-piperidine]-1'-yl}pyrimidine-4-carbonitrile

[0510] [ka]

[0511] A solution of 5-bromo-6-methyl-2-[3-oxospiro[1-benzofuran-2,4-piperidin]-1-yl]pyrimidine-4-carbonitrile (100 mg, 0.216 mmol), 2,3-dichlorophenylboronic acid (87 mg, 0.432 mmol), KPO (145 mg, 0.648 mmol), XPhos (22 mg, 0.043 mmol), and XPhos Pd G (39 mg, 0.043 mmol) in 1,4-dioxane (2 mL) and water (0.5 mL) was stirred at 100 °C for 2 h. The resulting mixture was cooled to room temperature and then concentrated under reduced pressure. The residue was diluted with DCM (5 mL), filtered, and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica (PE / EtOAc, 1:1) to give the title compound as a yellow solid (95 mg, 78%). LC / MS (M+1): 465.

[0512] Step 4: (S)—N-((E)-1′-(4-cyano-5-(2,3-dichlorophenyl)-6-methylpyrimidin-2-yl)-3H-spiro[benzofuran-2,4′-piperidin]-3-ylidene)-2-methylpropane-2-sulfinamide

[0513] [ka]

[0514] A mixture of 5-(2,3-dichlorophenyl)-6-methyl-2-[3-oxospiro[1-benzofuran-2,4-piperidin]-1-yl]pyrimidine-4-carbonitrile (90 mg, 0.18 mmol), (S)-2-methylpropane-2-sulfinamide (138 mg, 1.08 mmol), and Ti(OEt) (1 mL) was stirred at 90 °C for 4 h. The resulting mixture was cooled to room temperature, poured into a mixture of water (20 mL) and EtOAc (20 mL), and filtered. The two layers from the filtrate were separated, and the aqueous phase was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (PE / EtOAc, 1:1) provided the title compound as an off-white solid (180 mg, 100% yield). LC / MS (M+1): 568.2.

[0515] Step 5: 2-((S)-3-((tert-butylthio)amino)-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carbonitrile

[0516] [ka]

[0517] NaBH (31 mg, 0.782 mmol) was added to a solution of (S)—N-[1-[4-cyano-5-(2,3-dichlorophenyl)-6-methylpyrimidin-2-yl]spiro[1-benzofuran-2,4-piperidin]-3-ylidene]-2-methylpropane-2-sulfinamide (160 mg, 0.156 mmol) in THF (4.0 mL) and HO (1.0 mL) maintained at −50° C. under a nitrogen atmosphere. The resulting mixture was stirred at 25° C. for 1 h. It was then poured into water (10 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (1×30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give the title compound as a yellow solid (130 mg, 94% yield). LC / MS (M+1): 554, 556.

[0518] Step 6: 2-((S)-3-((tert-butylthio)amino)-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide

[0519] [ka]

[0520] A mixture of (S)—N-[(3S)-1-[4-cyano-5-(2,3-dichlorophenyl)-6-methylpyrimidin-2-yl]-3H-spiro[1-benzofuran-2,4-piperidin]-3-yl]-2-methylpropane-2-sulfinamide (130 mg, 0.142 mmol), aqueous NaOH (1.5 mL, 2 M), and EtOH (3.0 mL) was stirred at 70° C. for 1 h. The mixture was cooled to room temperature, and the solvent was removed under reduced pressure. The remaining aqueous layer was extracted with EtOAc (3×5 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (PE:EtOAc, 1:1) afforded the title compound as a yellow solid (120 mg, 94% yield). LC / MS (M+1): 572, 574.

[0521] Step 7: 2-((S)-3-amino-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide

[0522] [ka]

[0523] A mixture of 5-(2,3-dichlorophenyl)-6-methyl-2-[(3S)-3-[[(S)-2-methylpropane-2-sulfinyl]amino]-3H-spiro[1-benzofuran-2,4-piperidin]-1-yl]pyrimidine-4-carboxamide (70 mg, 0.113 mmol) and HCl / 1,4-dioxane (7 mL of a 4 M solution) was stirred for 2 h at 25° C. The resulting mixture was concentrated in vacuo and purified by reverse-phase chromatography (column: C18 silica gel; water + 10 mmol / L NHHCO:ACN, 0%-70% gradient in 40 min) to yield the title compound as an off-white solid (45.7 mg, 84%). 1 H-NMR (400 MHz, DMSO-d6): 8.00 (brs, 1H), 7.59 (dd, J=8.0, 1.2Hz, 1H), 7.41-7.33 (m, 3H), 7.22-7.14 (m, 2H), 6.88 (t, J=7.2Hz, 1H), 6.80 (d, J=7.6Hz, 1H), 4.68-4.57 (m, 2H), 4.13 (s, 1H), 3.49-3.33 (m, 2H), 2.03 (s, 3H), 1.94-1.70 (m, 4H). LC / MS (M+1): m / z = 484.1.

[0524] Compound 123: 6-amino-2-((R)-3-amino-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide dihydrochloride Step 1: 6-amino-2-[(3S)-3-amino-3H-spiro[1-benzofuran-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carbonitrile

[0525] [ka]

[0526] A solution of 6-amino-5-(2,3-dichlorophenyl)-2-methanesulfonylpyrimidine-4-carbonitrile (192 mg, 0.492 mmol), (3R)-3H-spiro[1-benzofuran-2,4'-piperidine]-3-amine (Intermediate 14, 204 mg, 0.985 mmol), and KCO (143 mg, 0.985 mmol) in DMF (10 mL) was stirred at 100 °C for 2 h. The reaction mixture was cooled to room temperature, poured into water (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. Purification by flash chromatography on silica (DCM:MeOH, 10:1) provided the title compound as a yellow solid (100 mg, 29% yield). LC / MS: 467.

[0527] Step 2: 6-amino-2-((R)-3-amino-3H-spiro[benzofuran-2,4'-piperidine]-1'-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide dihydrochloride

[0528] [ka]

[0529] A mixture of 6-amino-2-[(3R)-3-amino-3H-spiro[1-benzofuran-2,4-piperidin]-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carbonitrile (30 mg, 0.043 mmol), aqueous NaOH (0.5 mL, 2 M), and EtOH (0.50 mL) was stirred for 30 minutes at 70° C. The resulting mixture was cooled to room temperature, concentrated, and purified by reverse-phase chromatography (column: C18 silica gel; water + 0.05% HCl:CHCN, gradient 0%-70% in 40 minutes) to yield the title compound as an off-white solid (6.6 mg, 26%). 1H-NMR (400 MHz, DMSO-d6): 7.78 (s, 1H), 7.52 (dd, J=8.0, 1.6Hz, 1H), 7.33-7.27 (m, 2H), 7.18-7.10 (m, 3H), 6.86 (t, J=7.6Hz, 1H), 6.78 (d, J=8.0Hz, 1H), 6.16 (br s, 2H), 4.57-4.47 (m, 2H), 4.08 (s, 1H), 3.25-3.20 (m, 2H), 1.90-1.80 (m, 1H), 1.78-1.68 (m, 3H). LC / MS (M+1): 485.2.

[0530] Compounds 124, 125, 126, 127: (4M)-2-[(3R)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide, (4M)-2-[(3S)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine- 4-Carboxamide, (4P)-2-[(3R)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide, (4P)-2-[(3S)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Step 1: 2-[3-amino-3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carbonitrile

[0531] [ka]

[0532] A solution of 2-chloro-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carbonitrile (1.10 g, 3.65 mmol), 3H-spiro[furo[2,3-b]pyridine-2,4-piperidine]-3-amine (Intermediate 15, 1.15 g, 5.47 mmol), and DIEA (1.81 mL, 11.0 mmol) in ACN (12 mL) was stirred at 80 °C for 0.5 h. The resulting mixture was concentrated under reduced pressure, and purification by flash chromatography on silica (PE:EtOAc, 1:1) provided the title compound as a yellow solid (1.4 g, 81%). LC / MS (M+1): 467.1.

[0533] Step 2: 2-[3-amino-3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide

[0534] [ka]

[0535] A mixture of 2-[3-amino-3H-spiro[furo[2,3-b]pyridine-2,4-piperidin]-1-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carbonitrile (0.80 g, 1.70 mmol), NaOH (0.16 g, 3.80 mmol), EtOH (4 mL), and HO (4 mL) was stirred at 70° C. for 0.5 h. The mixture was cooled to room temperature and neutralized to pH 7 by the addition of 6 M HCl. The resulting mixture was concentrated under reduced pressure and purified by reverse-phase chromatography (column: C18 silica gel; water + 10 mmol / L NH4HCO3 containing: ACN; 10%-50% gradient in 30 minutes) to give 2-[3-amino-3H-spiro[furo[2,3-b]pyridine-2,4-piperidin]-1-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide (700 mg, 79%) as a white solid. LC / MS (M+1): 485.

[0536] Step 3: Isomer separation

[0537] [ka]

[0538] An initial separation by preparative HPLC (column: CHIRALPAK IC, 3 × 25 cm, 5 μm, hexane + 8 mmol / L NH3·MeOH:EtOH; 50%) gave two fractions: Fraction A (130 mg) (RT: 9.6 min) and Fraction B (300 mg) (RT: 14.64 min). The isomers from Fraction A were separated by preparative HPLC (column: CHIRALPAK IA, 3 × 25 cm, 5 μm, MTBE + 10 mM NH3-MEOH:EtOH, 20%).

[0539] First eluting isomer (124): 56 mg, RT: 11 minutes. 1H NMR (400 MHz, DMSO-d6) δ8.00 (s, 2H), 7.72 (d, J=7.2, 1H), 7.59 (dd, J=8.0, 1.6Hz, 1H), 7.43-7.33 (m, 2H), 7.21 (dd, J=8.0, 1.6Hz, 1H), 6.92 (dd, J=7.2, 5.2Hz, 1H), 4.71-4.61 (m, 2H), 4.14 (s, 1H), 3.51-3.39 (m, 2H), 2.20 (brs, 2H), 2.03 (s, 3H), 1.94-1.77 (m, 4H); LC / MS (M+1): 485.1 ;RT=1.82 minutes (Analytical method: Chiralpack IA, MtBE+0.1% DEA:EtOH, 80:20), purity: 100%.

[0540] Second eluting isomer (125): 60mg, RT:12.9 points. 1 H NMR (400 MHz, DMSO-d6): 8.01-8.00 (m, 2H), 7.72 (d, J=6.8Hz, 1H), 7.59 (dd, J=8.0, 1.2Hz, 1H), 7.40-7.34 (m, 2H), 7.22 (dd, J=7.6, 1.6Hz, 1H), 6.92 (dd, J=7.2, 5.2Hz, 1H), 4.72-4.61 (m, 2H), 4.14 (s, 1H), 3.51-3.39 (m, 2H), 2.20 (brs, 2H), 2.03 (s, 3H), 1.96-1.76 (m, 4H); LC / MS (M+1): 485.1; RT = 2.26 min (Analytical: Karam-CHIRALPACK IA, MtBE + 0.1% DEA:EtOH, 80:20); purity: 99.5%.

[0541] Draw the B heterogeneous body and separate it into HPLC Separation Kit (Karalu: CHIRALPACK ID, 3×25cm, 5um, MTBE+10mM NH3-MEOH: EtOH, 15%).

[0542] First eluting isomer (126): 92mg, RT: 12.0 points; 1H NMR (400 MHz, DMSO-d6): 8.01-8.00 (m, 2H), 7.72 (d, J=6.4, 1H), 7.59 (dd, J=8.0, 1.6Hz, 1H), 7.41-7.34 (m, 2H), 7.22 (dd, J=7.6, 1.6Hz, 1H), 6.91 (dd, J=7.2, 5.2Hz, 1H), 4.72-4.61 (m, 2H), 4.14 (s, 1H), 3.49-3.39 (m, 2H), 2.15 (brs, 2H), 2.03 (s, 3H), 1.93-1.77 (m, 4H). RT = 2.33 min (Analytical: Karam-CHIRALPACK AD, MtBE + 0.1% DEA:EtOH, 85:15); purity: 100%.

[0543] Second-eluting isomer (127) :111mg, RT:15.5 minutes, ed=99.1%, 1 H NMR (400 MHz, DMSO-d6): 8.01-8.00 (m, 2H), 7.71 (d, J=6.8Hz, 1H), 7.59 (dd, J=8.0, 1.2Hz, 1H), 7.40-7.34 (m, 2H), 7.22 (dd, J=7.6, 1.2Hz, 1H), 6.92 (dd, J=6.8, 4.8Hz, 1H), 4.71-4.61 (m, 2H), 4.14 (s, 1H), 3.49-3.39 (m, 2H), 2.19 (br s, 2H), 2.03 (s, 3H), 1.91-1.77 (m, 4H); LC / MS (M+1): 485.1. RT = 3.17 min (Analytical Caramel-CHIRALPACK ID, MtB + 0.1% DEA:EtOH, 85:15). Purity: 99.1.

[0544] Compounds 128, 129, 130, 131: (4P)-6-amino-2-[(3R)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4-piperidin]-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide, (4P)-6-amino-2-[(3S)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4-piperidin]-1-yl]-5-(2,3-dichlorophenyl)pyrimidine- 4-Carboxamide, (4M)-6-amino-2-[(3R)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4-piperidin]-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide, (4M)-6-amino-2-[(3S)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4-piperidin]-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Engineering 1:6-アミノ-2-[3-アミノ-3H-スピロ[フロ[2,3-b]ピリジン-2,4-ピペリジン]-1-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボニトリル

[0545]

change

[0546] A solution of DIEA (1.06 mL, 6.13 mmol, 2.00 equiv.), 6-amino-5-(2,3-dichlorophenyl)-2-methanesulfonylpyrimidine-4-carbonitrile (Intermediate 4, 1.04 g, 3.06 mmol), and 3H-spiro[furo[2,3-b]pyridine-2,4-piperidine]-3-amine (0.84 g, 3.89 mmol) in EtOH (12 mL) was stirred at 60° C. for 4 h. The resulting mixture was concentrated in vacuo and purified by flash chromatography on silica (PE:EtOAc, 1:9) to afford the title compound as a yellow solid (900 mg, 7% yield). LC / MS (M+1): 468.

[0547] Step 2: 6-amino-2-[3-amino-3H-spiro[furo[2,3-b]pyridine-2,4-piperidin]-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide

[0548] [ka]

[0549] The title compound was obtained as an off-white solid (600 mg, 83%) following a procedure similar to that described for compounds 124-127, step 2, but starting from 6-amino-2-[3-amino-3H-spiro[furo[2,3-b]pyridine-2,4-piperidin]-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carbonitrile (0.90 g, 1.47 mmol). LC / MS (M+1); 486.

[0550] Step 3: Isomer separation

[0551] [ka]

[0552] An initial separation by preparative HPLC (column: CHIRALPAK IA, 3 x 25 cm, 5 um; MTBE + 10 mM NH3-MEOH:EtOH, 15%) gave three fractions.

[0553] First eluting fraction: 150mg of a mixture of two isomers.

[0554] Second eluting fraction (128): White solid, 68 mg, RT=7.22 min, 1 H NMR (400 MHz, DMSO-d6): 8.00 (dd, J=4.8, 1.2Hz, 1H), 7.78 (s, 1H), 7.71 (d, J=6.8Hz, 1H), 7.52 (dd, J=8.0, 1.2Hz, 1H), 7.29 (t, J=7.6Hz, 1H), 7.18 (s, 1H), 7.12 (dd, J=7.6, 1.6Hz, 1H), 6.91 (dd, J=7.2, 5.2Hz, 1H), 6.17 (br s, 2H), 4.58-4.52 (m, 2H), 4.13 (s, 1H), 3.40-3.31 (m, 2H), 2.32 (br s, 2H), 1.95-1.85 (m, 1H), 1.79-1.72 (m, 3H). RT (Analytical Column-CHIRALPACK IA, MtBE+0.1%DEA:EtOH=85:15)=1.98 min; Purity: 95.1%.

[0555] Third eluting fraction (129): White solid, 62 mg, RT=9.57 min, 1H NMR (400 MHz, DMSO-d6) δ8.00 (dd, J=4.8, 1.2Hz, 1H), 7.78 (s, 1H), 7.70 (d, J=6.8Hz, 1H), 7.52 (dd, J=8.0, 1.2Hz, 1H), 7.29 (t, J=8.0Hz, 1H), 7.18 (s, 1H), 7.12 (dd, J=7.6, 1.6Hz, 1H), 6.91 (dd, J=7.2, 5.2Hz, 1H), 6.17 (brs, 2H), 4.58-4.51 (m, 2H), 4.12 (s, 1H), 3.40-3.31 (m, 2H), 2.32 (brs, 1H), 1.95-1.85 (m, 1H), 1.79-1.72 (m, 3H), RT (Analytical Column - CHIRALPACK IA, MtBE+0.1%DEA:EtOH=85:15)=2.45 min; Purity: 92.7%.

[0556] The isomers from the first eluting fraction were separated by preparative HPLC (CHIRALPACK IA, 3 x 25 cm, 5 um:Hex:DCM = 3:1 + 10 mM NH3-MEOH:EtOH, 15%).

[0557] First eluting isomer (130): White solid, 46 mg, RT=7.22 min, 1H NMR (400 MHz, DMSO-d6) δ7.99 (d, J=5.6Hz, 1H), 7.78 (s, 1H), 7.70 (d, J=6.8Hz, 1H), 7.52 (dd, J=8.0, 1.6Hz, 1H), 7.29 (t, J=8.0Hz, 1H), 7.18 (s, 1H), 7.11 (dd, J=7.0, 1.6Hz, 1H), 6.90 (dd, J=7.2, 5.2Hz, 1H), 6.17 (br s, 1H), 4.62-4.51 (m, 2H), 4.12 (s, 1H), 3.39-3.31 (m, 2H), 1.95-1.86 (m, 1H), 1.79-1.74 (m, 3H). RT=2.81 min (Analytical column-CHIRALPACK IA, Hex:DCM=3:1+0.1%DEA:EtOH=85:15); Purity: 92.3%.

[0558] Second eluting isomer (131): White solid, 39 mg, Rt=13.8 min, 1 H NMR (400 MHz, DMSO-d6): 7.99 (d, J=3.6Hz, 1H), 7.78 (s, 1H), 7.70 (d, J=7.6Hz, 1H), 7.52 (dd, J=8.0, 1.2Hz, 1H), 7.29 (t, J=8.0Hz, 1H), 7.18 (s, 1H), 7.11 (d, J=7.6, 1H), 6.90 (dd, J=7.2, 5.2Hz, 1H), 6.17 (brs, 1H), 4.62-4.51 (m, 2H), 4.11 (s, 1H), 3.35-3.31 (m, 2H), 2.10 (brs, 1H), 1.95-1.86 (m, 1H), 1.78-1.71 (m, 3H). RT=2.42 min (Analytical column-CHIRALPACK IA, Hex:DCM=3:1+0.1%DEA:EtOH=85:15); Purity: 99.9%.

[0559] The compounds in Table 3 were prepared following synthetic routes similar to those described above:

[0560] [Table 4-1]

Table 4-2

Table 4-3

Table 4-4

Table 4-5

Table 4-6

Table 4-7

Table 4-8

Table 4-9

[0561] Example 3: Testing of compounds of the present invention for inhibitory activity against SHP2 and ERK1 / 2 SHP2 biochemical assay : Inhibition of SHP2 by compounds of the present invention was monitored using the surrogate substrate DiFMUP after protein activation with a peptide containing two appropriately spaced phosphotyrosines. Full-length SHP2 protein (recombinant human SHP-2, Ser2Arg593 from E. coli, N-terminal 6His tag from R&D systems; 0.0.24 nM) was incubated with the activation peptide, IRSI_2pY (New England Peptide, 140 nM), and DiFMUP (Molecular Probes, 80 μM) in buffer (HEPES, pH 7.2, 60 mM, DDT 5 mM, KCl 75 mM, NaCl 75 mM, EDTA 1 mM, Tween 20 0.05%) in the presence of compound (10 concentration range, highest concentration 50 μM) for 60 min at RT. Generation of DiFMU product by activated SHP2 was monitored by fluorescence measurement using a PerkinElmer Envision reader. Inhibition-dose response curves were analyzed by Genedata Screener. IC for compounds of the present invention 50 The ranges are shown in Table 4 below.

[0562] p-Erk cell assay in MDA-MB-468 and KYSE528 : The effects of SHP2 inhibitors on pERK levels were assessed using a mesoscale quantification platform with a phospho-specific antibody. For measuring changes in pERK levels using mesoscale analysis, 30,000 MDA MB468 and KYSE520 cells were seeded in 175 μl of medium into 96-well tissue culture-treated plates. After overnight incubation at 37°C, various SHP2 inhibitors were added at different concentrations to each well, maintaining duplicate wells across the plate. The compounds were incubated with the inhibitors for 2 h at 37°C and then washed with ice-cold PBS buffer. Cells were then lysed with lysis buffer and processed and analyzed for p-ERK / ERK according to the manufacturer's instructions (Mesoscale discovery, catalog number K15107D-3). IC for compounds of the present invention. 50 The ranges are shown in Table 4 below.

[0563] [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4]

[0564] Example 4: In vitro safety profile - testing the selectivity of hErg Inhibition of the hErg (or Kv11.1) ion channel current causes QT interval prolongation, which leads to a potentially fatal ventricular arrhythmia called torsades de pointes ventricular tachycardia, which is one of the major causes of cardiotoxicity, and hErg channel activity is usually assessed early in the drug discovery process to mitigate the risk of cardiotoxicity.

[0565] hERG ion channel activity was assessed using the patch clamp technique in stably Kv11.1 (hERG)-transfected human embryonic kidney cell line (HEK293). Whole-cell recordings were performed using an automated patch clamp device, Patchliner™, from Nanion Technologies (Munich), according to the manufacturer's recommendations. Varying concentrations of test compound or the reference substance quinidine were applied to whole-cell suspensions, and currents were measured using a pulse pattern with fixed amplitude. Effects on Kv11.1 (hERG) ion channel activity were determined from the tail current amplitude and the change in Kv11.1 (hERG) ion channel activity between the control value (defined as 100%) and the test compound, and reported as a percentage change in COI from the control value.

[0566] [Table 6]

[0567] result The compounds of the present invention exhibit a much better split between hErg activity (Ki in patch clamp assay) and cellular activity (IC50 in KYSE) compared to the known SHP2 inhibitors SHP-099 and RMC-4550, which should translate into less likelihood of cardiotoxicity when administered to subjects.

[0568] Example 5: Testing the pharmacokinetic properties of compounds of the invention in mice Female CD1 mice (N=3) received a single oral (gavage) or intravenous (bolus) injection of compound. The dosing vehicle was typically administered by oral gavage as 0.5% Methocel K4M / 0.25% Tween 20 in sodium citrate buffer, 0.1 M, pH 3.0, or, for IV administration, as 10% Kolliphor HS15 solution in sodium acetate buffer, 0.01 M, pH 4.5. Serial blood samples were collected sublingually from the animals under isoflurane inhalation at 0.083 (IV), 0.25, 0.5, 1, 2, 4, 6, and 24 hours and further processed to obtain plasma. Samples were protein precipitated and analyzed by LC / MS / MS.

[0569] [Table 7]

[0570] result In mouse PK, the compounds of the present invention (Nos. 27 and 95) show lower clearance and higher exposure compared to the reference compound SHP-099.

[0571] Example 6: Testing of compounds of the present invention for inhibitory activity against SHP2 active mutant E76K with or without activation peptide A selection of compounds were tested in a biochemical assay with the autoactivated mutant protein SHP2 E76K using the same conditions as described in Example 3, but with and without the addition of the activating peptide IRSI_2pY (New England Peptide, 140 nM).

[0572] [Table 8]

[0573] Under conditions of strong SHP2 activation, our compounds maintained potency in the nM range, whereas the inhibitor SHP099 lost potency by several log orders under similar conditions, which may be advantageous in treating cancers with strongly activating SHP2 mutations.

[0574] Example 6: Activity in U937 cells Selected compounds were tested in a cytokine release assay in monocytic cells (U937) to assess their anti-inflammatory properties. Cells were seeded in 96-well cell culture plates using serum-free medium. Cells were treated with the indicated concentrations of SHP-2 inhibitors for 30 minutes, followed by overnight stimulation with recombinant IL-6 (50 ng / ml). MCP-1 production in the culture supernatant was measured using an MCP-1 AlphaLISA kit (Perkin Elmer).

[0575] The compound mixture (117+118) inhibited MCP-1 production in IL-6-stimulated U937 cells, and IC 50 =67 nM (see Figure 1). This result indicates that the compounds of the present invention, as described herein, should be useful in treating immune system-related hyperproliferative diseases.

[0576] Example 7: Injection vial A solution of 100 g of the compound of the present invention and 5 g of disodium hydrogen phosphate in 3 L of double distilled water is adjusted to pH 6.5 with 2 N hydrochloric acid, filtered under sterile conditions, transferred into injection vials, lyophilized under sterile conditions, and sealed under sterile conditions, each injection vial containing 5 mg of the compound of the present invention.

[0577] Example 8: Liquid Formulation A solution is prepared from 1 g of a compound of the invention, 9.38 g of NaH2PO4·2H2O, 28.48 g of Na2HPO4·12H2O, and 0.1 g of benzalkonium chloride in 940 ml of double-distilled water. The pH is adjusted to 6.8, the solution made up to 1 L, and sterilized by irradiation.

[0578] Example 9: Ampoule A solution of 1 kg of a compound of the invention in 60 L of double-distilled water is filtered under sterile conditions, transferred into ampoules, lyophilized under sterile conditions, and sealed under sterile conditions, each ampoule containing 10 mg of a compound of the invention.

Claims

1. Formula (I): 【Chemical 1】 (In the formula, When R1 is cyclohexyl, cyclopentyl, or piperidinyl, X is —NH— or —N(Me)—, and each of the cyclohexyl, cyclopentyl, or piperidinyl is —F, —NH ２ , and -CH ２ NH ２ may be substituted by one or two substituents selected from When R1 represents the following formula, X represents a bond. 【Chemistry 2】 A is the point of attachment to the pyrimidine ring of formula (I); n is 0, 1, 2, or 3; Each of R9, R10, R11, R12, R13, R14, R15 and R16, if present, is selected from the group consisting of —H, C １ -C ３ Alkyl, —NH ２ , -OH, -Cl, -F, -Br, C １ -C ３ Aminoalkyl, C １ -C ３ Hydroxyalkyl, C １ -C ３ independently selected from alkoxy, and phenyl; or Two of R9, R11, R13 and R16 together optionally represent C １ -C ３ Alkyl, —NH ２ , -OH, -Cl, -F, -Br, C １ -C ３ Aminoalkyl, C １ -C ３ Hydroxyalkyl, C １ -C ３ forming a bridged bicyclic heterocyclic ring system optionally substituted with 1 to 3 substituents selected from alkoxy, and phenyl; or Two of R9, R10, R11, R12, R13, R14, R15, and R16 bonded to the same carbon atom together form C １ -C ３ Alkyl, —NH ２ , -OH, -Cl, -F, -Br, C １ -C ３ Aminoalkyl, C １ -C ３ Hydroxyalkyl, C １ -C ３ form a mono- or bicyclic spirocyclyl optionally substituted by 1 to 3 substituents selected from alkoxy, and phenyl; or Two of R9, R10, R11, R12, R13, R14, R15, and R16 bonded to adjacent carbon atoms together form C １ -C ３ Alkyl, —NH ２ , -OH, -Cl, -F, -Br, C １ -C ３ Aminoalkyl, C １ -C ３ Hydroxyalkyl, C １ -C ３ forming a fused carbocyclyl or heterocyclyl optionally substituted with 1 to 3 substituents selected from alkoxy, and phenyl; and R2 is —F, —Cl, —CF ３ , C １ -C ３ Alkoxy and C １ -C ３ aryl or heteroaryl, optionally substituted with 1 to 3 groups selected from alkyl; R3 is —H, —NH ２ , —OH, —Cl, —F, —Br, or —CH ３ and Y is —N; and R4 and R5 are independently —H, —NH ２ , -OH, C １ -C ３ Alkyl, or C １ -C ３ hydroxyalkyl) or a pharmaceutically acceptable salt thereof.

2. Each of the R2 is —F, —Cl, or —CF ３ , -OCH ３ and -CH ３ 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from phenyl, pyridine, indole, 2,1,3-benzoxadiazole, and 1,3-benzodiazole, optionally and independently substituted with 1 to 3 groups selected from:

3. Each of the R2 is —Cl, —F, or —CF ３ and -OCH ３ 3. The compound of claim 1 or 2, wherein the compound is selected from phenyl and pyridine, optionally and independently substituted with 1 to 3 groups selected from:

4. The compound according to any one of claims 1 to 3, wherein one of R4 and R5 is -H, and the other is -OH, or a pharmaceutically acceptable salt thereof.

5. The following formula (Ia): 【Chemistry 3】 (wherein R6, R7, and R8 each represent —H, —F, —Cl, —CF ３ , C １ -C ３ Alkoxy and C １ -C ３ alkyl) 2. The compound of claim 1, wherein the compound is represented by: or a pharmaceutically acceptable salt thereof.

6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein X is a bond.

7. wherein X-R1 is: 【Chemistry 4】 2. The compound of claim 1, wherein A is the point of attachment to the pyrimidine ring, or a pharmaceutically acceptable salt thereof.

8. X is -NH- or -N(Me)-, and R1 is one -CH ２ NH ２ cyclopentyl substituted by one —NH ２ 2. The compound of claim 1, wherein the compound is cyclohexyl substituted by one -F, or piperidine substituted by one -F, or a pharmaceutically acceptable salt thereof.

9. The following formula (Ib): 【Chemistry 5】 (In the formula: R1 is: 【Chemistry 6】 where: A is the point of attachment to the pyrimidine ring of formula (Ib); Each of R6, R7, and R8 is —H, —F, —Cl, —CF ３ , C １ -C ３ Alkoxy and C １ -C ３ independently selected from alkyl; n is 0, 1, 2, or 3; and each of R9, R10, R11, R12, R13, R14, R15, and R16, if present, is —H, C １ -C ３ Alkyl, —NH ２ , -OH, -Cl, -F, -Br, C １ -C ３ Aminoalkyl, C １ -C ３ Hydroxyalkyl, C １ -C ３ independently selected from alkoxy, and phenyl; or Two of R9, R11, R13 and R16 together optionally represent C １ -C ３ Alkyl, —NH ２ , -OH, -Cl, -F, -Br, C １ -C ３ Aminoalkyl, C １ -C ３ Hydroxyalkyl, C １ -C ３ forming a bridged bicyclic heterocyclic ring system optionally substituted with 1 to 3 substituents selected from alkoxy, and phenyl; or Two of R9, R10, R11, R12, R13, R14, R15, and R16 bonded to the same carbon atom together form C １ -C ３ Alkyl, —NH ２ , -OH, -Cl, -F, -Br, C １ -C ３ Aminoalkyl, C １ -C ３ Hydroxyalkyl, C １ -C ３ form a mono- or bicyclic spirocyclyl optionally substituted by 1 to 3 substituents selected from alkoxy, and phenyl; or Two of R9, R10, R11, R12, R13, R14, R15, and R16 bonded to adjacent carbon atoms together form C １ -C ３ Alkyl, —NH ２ , -OH, -Cl, -F, -Br, C １ -C ３ Aminoalkyl, C １ -C ３ Hydroxyalkyl, C １ -C ３ forming a fused carbocyclyl or heterocyclyl optionally substituted with 1 to 3 substituents selected from alkoxy, and phenyl; The compound according to any one of claims 1 to 5, wherein the compound is represented by the formula: or a pharmaceutically acceptable salt thereof.

10. wherein R1 is: 【Chemistry 7】 【Chemistry 8】 10. The compound of claim 9, wherein A is selected from the group consisting of: and wherein A represents the point of attachment to the pyrimidine ring, or a pharmaceutically acceptable salt thereof.

11. 10. The compound according to claim 9, represented by the following formula (Ic), or a pharmaceutically acceptable salt thereof: 【Chemistry 9】

12. 10. The compound according to claim 9, represented by the following formula (Id), or a pharmaceutically acceptable salt thereof: 【Chemistry 10】

13. substituent 【Chemistry 11】 but, 【Chemistry 12】 13. The compound of claim 12, wherein A represents the point of attachment to the pyrimidine ring, or a pharmaceutically acceptable salt thereof.

14. 14. The compound according to claim 13, or a pharmaceutically acceptable salt thereof, of the following formula (Ie): 【Chemistry 13】

15. substituent 【Chemistry 14】 but, 【Chemistry 15】 15. The compound of claim 14, wherein A represents the point of attachment to the pyrimidine ring, or a pharmaceutically acceptable salt thereof.

16. 10. The compound according to claim 9, represented by the following formula (If), or a pharmaceutically acceptable salt thereof: 【Chemistry 16】

17. substituent 【Chemistry 17】 but, 【Chemistry 18】 17. The compound of claim 16, wherein A represents the point of attachment to the pyrimidine ring, or a pharmaceutically acceptable salt thereof.

18. The R3 is —CH ３ 2. The compound of claim 1, wherein:

19. The R3 is —NH ２ 2. The compound of claim 1, wherein:

20. The compound of claim 1, wherein R3 is —H.

21. The compound of claim 1, wherein R3 is -Cl.

22. 9. The compound of claim 8, wherein R8 is —H and both R6 and R7 are —Cl.

23. 10. The compound of claim 1, selected from the group consisting of: 2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxamide; 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(3-chloro-phenyl)-pyrimidine-4-carboxylic acid amide; 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid amide; 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(3-fluoro-phenyl)-pyrimidine-4-carboxylic acid amide; 6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro-[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 6-amino-2-{9-amino-3-azabicyclo[3.3.1]nonan-3-yl}-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 6-amino-2-[(1R)-1-amino-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 6-amino-2-[(1R)-1-amino-3,3-difluoro-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid methylamide; 6-amino-2-[6-amino-7-hydroxy-1-(propan-2-yl)-2-azaspiro[3.4]octan-2-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 6-amino-2-[8-(aminomethyl)-6-azaspiro[3.4]octan-6-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 6-amino-2-[3-(aminomethyl)-8-azabicyclo[3.2.1]octan-8-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 6-amino-5-(2,3-dichlorophenyl)-2-[(1R,7S,11s)-11-amino-1,7-dimethyl-9-azabicyclo[5.3.1]undecan-9-yl]pyrimidine-4-carboxamide; 6-amino-5-(2,3-dichlorophenyl)-2-[(1R,7S,11r)-11-amino-1,7-dimethyl-9-azabicyclo[5.3.1]undecan-9-yl]pyrimidine-4-carboxamide; 2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-6-hydroxy-pyrimidine-4-carboxylic acid amide; 2-(4-amino-4-methyl-piperidin-1-yl)-6-chloro-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid amide; 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid (2-hydroxy-ethyl)-amide; 2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichlorophenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-(4-amino-4-methyl-piperidin-1-yl)-6-chloro-5-(3-fluoro-phenyl)-pyrimidine-4-carboxylic acid amide; 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid hydroxyamide; 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid hydrazide; 2-(4-amino-4-methyl-piperidin-1-yl)-6-fluoro-5-(3-fluoro-phenyl)-pyrimidine-4-carboxylic acid amide; 6-amino-2-[4-(aminomethyl)-8-oxa-2-azaspiro[4.5]decan-2-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 2-[3a-(aminomethyl)-octahydro-1H-isoindol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 2-(4-amino-4-methyl-piperidin-1-yl)-5-(3-fluoro-phenyl)-6-hydroxy-pyrimidine-4-carboxylic acid amide; (4P)-6-amino-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; (4M)-6-amino-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 2-(3-amino-cyclohexylamino)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 6-amino-2-[4-amino-4-(hydroxymethyl)piperidin-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; (4M)-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; (4P)-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; 2-[(4-amino-cyclohexyl)-methyl-amino]-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-(7-amino-3-oxa-9-aza-bicyclo[3.3.1]non-9-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 6-amino-2-[8-(aminomethyl)-2-oxa-6-azaspiro[3.4]octan-6-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 2-((R)-6-amino-2-aza-spiro[4.4]non-2-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-(3-aminomethyl-cyclopentylamino)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-((S)-6-amino-2-aza-spiro[4.4]non-2-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 6-amino-2-{4-amino-1-oxa-9-azaspiro[5.5]undecan-9-yl}-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 6-amino-2-[4-(3-aminooxan-2-yl)piperidin-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 6-amino-2-[3-(aminomethyl)-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 6-amino-2-[4-(aminomethyl)-4-methylpiperidin-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 2-(4-amino-hexahydro-cyclopenta[c]pyrrol-2-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide hydrochloride; 2-(2-aminomethyl-cyclopentylamino)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-(3-aminomethyl-3-fluoro-azetidin-1-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-(4-amino-4-methyl-azepan-1-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-(2-aminomethyl-azetidin-1-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; (4P)-2-[(3R)-3-(aminomethyl)morpholin-4-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide hydrochloride; (4P)-2-[(3S)-3-(aminomethyl)morpholin-4-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide hydrochloride; 6-amino-2-(4-aminoazepan-1-yl)-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; 6-amino-2-(4-amino-octahydro-1H-isoindol-2-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 6-amino-2-[(3R,4R)-3-(aminomethyl)-4-phenylpyrrolidin-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 6-amino-2-(4-amino-4-propylpiperidin-1-yl)-5-(2,3-dichloro-phenyl)pyrimidine-4-carboxamide; 6-amino-2-[3-(aminomethyl)-3-hydroxyazetidin-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 6-amino-2-[3-(aminomethyl)-3-methylazetidin-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 5-(2,3-dichloro-phenyl)-6-methyl-2-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-pyrimidine-4-carboxylic acid amide; 2-(3-amino-3-hydroxymethyl-azetidin-1-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-(1-amino-5-aza-spiro[2.4]hept-5-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-(4-amino-4-methyl-piperidin-1-yl)-5-(1H-benzimidazol-4-yl)-pyrimidine-4-carboxylic acid amide; 2-(4-amino-4-methyl-piperidin-1-yl)-5-benzo[1,2,5]-oxadiazol-4-yl-pyrimidine-4-carboxylic acid amide; 6-amino-2-(4-amino-4-methyl-piperidin-1-yl)-5-(7-chloro-1H-indazol-6-yl)-pyrimidine-4-carboxylic acid amide; 5-(2,3-dichloro-phenyl)-6-methyl-2-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-pyrimidine-4-carboxylic acid amide; (5M)-6-amino-5-(2,3-dichlorophenyl)-2-{[(3S,4R)-3-fluoropiperidin-4-yl]amino}-pyrimidine-4-carboxamide; 6-amino-2-{[(1R,2S)-2-aminocyclohexyl]amino}-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; (5P)-6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; (5M)-6-amino-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; 2-(3,9-diaza-bicyclo[4.2.1]-non-3-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 6-amino-2-(3-aminoazetidin-1-yl)-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; 6-amino-2-[(1R,5S,6R)-6-(aminomethyl)-3-azabicyclo-[3.1.0]hexan-3-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 6-amino-2-[2-(aminomethyl)-azetidin-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 2-((3aR,4R,6aS)-4-amino-hexahydro-cyclopenta-[c]pyrrol-2-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-((3aS,6aS)-4-amino-hexahydro-cyclopenta-[c]pyrrol-2-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-((3aS,4S,6aR)-4-amino-hexahydro-cyclopenta-[c]pyrrol-2-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-((3aS,4R,6aR)-4-amino-hexahydro-cyclopenta[c]pyrrol-2-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-((3aR,6aR)-4-amino-hexahydro-cyclopenta-[c]pyrrol-2-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-((3aR,4S,6aS)-4-amino-hexahydro-cyclopenta-[c]pyrrol-2-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; (4M)-2-(4-amino-4-methylpiperidin-1-yl)-6-chloro-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; (4P)-2-(4-amino-4-methylpiperidin-1-yl)-6-chloro-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; 2-((3R,4S)-3-amino-4-hydroxy-pyrrolidin-1-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-(4-amino-4-methyl-piperidin-1-yl)-5-(2,3-dichloro-pyridin-4-yl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-(4-amino-4-methyl-piperidin-1-yl)-5-(2-chloro-4-fluoro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-(4-amino-4-methyl-piperidin-1-yl)-5-(4-chloro-pyridin-3-yl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-((3S,4S)-3-amino-4-hydroxy-pyrrolidin-1-yl)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; 2-(4-amino-4-methyl-piperidin-1-yl)-6-methyl-5-pyridin-4-yl-pyrimidine-4-carboxylic acid amide; (4M)-2-{[(1S,3R)-3-aminocyclohexyl]amino}-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; (4M)-2-{[(1R,3S)-3-aminocyclohexyl]amino}-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; (4P)-2-{[(1R,3S)-3-aminocyclohexyl]amino}-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; (4P)-2-{[(1S,3R)-3-aminocyclohexyl]amino}-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; 6-amino-2-(4-amino-4-methyl-azepan-1-yl)-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid amide; 2-(4-amino-4-methyl-piperidin-1-yl)-5-(1H-indol-3-yl)-6-methyl-pyrimidine-4-carboxylic acid amide; 2-(4-amino-cyclohexyl-amino)-5-(2,3-dichloro-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; (5M)-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]-decan-8-yl]-5-(2,3-dichloro-phenyl)-6-methylpyrimidine-4-carboxamide; (5P)-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]-decan-8-yl]-5-(2,3-dichloro-phenyl)-6-methylpyrimidine-4-carboxamide; (5M)-2-[(1R)-1-amino-3,3-difluoro-8-azaspiro[4.5]-decan-8-yl]-5-(2,3-dichloro-phenyl)-6-methylpyrimidine-4-carboxamide; (5P)-2-[(1R)-1-amino-3,3-difluoro-8-azaspiro[4.5]-decan-8-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; (5P)-2-[(3aR,6aS)-3a-(aminomethyl)-octahydro-cyclopenta[c]pyrrol-2-yl]-6-amino-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; (5M)-2-[(3aR,6aS)-3a-(aminomethyl)-octahydro-cyclopenta[c]pyrrol-2-yl]-6-amino-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; (5P)-2-[(3aR,7aS)-3a-(aminomethyl)-octahydro-1H-isoindol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; (5P)-2-[(3aS,7aR)-3a-(aminomethyl)-octahydro-1H-isoindol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; (5M)-2-[(3aR,7aS)-3a-(aminomethyl)-octahydro-1H-isoindol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; (5M)-2-[(3aS,7aR)-3a-(aminomethyl)-octahydro-1H-isoindol-2-yl]-6-amino-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; (5P)-2-[(3aS,6aR)-3a-(aminomethyl)-octahydro-cyclopenta[c]pyrrol-2-yl]-6-amino-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; (5M)-2-[(3aS,6aR)-3a-(aminomethyl)-octahydro-cyclopenta[c]pyrrol-2-yl]-6-amino-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; (5P)-6-amino-2-[4-amino-4-(difluoromethyl)piperidin-1-yl]-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; (5M)-6-amino-2-[4-amino-4-(difluoromethyl)piperidin-1-yl]-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; (5P)-6-amino-2-[(4S)-4-amino-4-methylazepan-1-yl]-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; (5P)-6-amino-2-[(4R)-4-amino-4-methylazepan-1-yl]-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; (5M)-6-amino-2-[(4S)-4-amino-4-methylazepan-1-yl]-5-(2,3-dichlorophenyl)-pyrimidine-4-carboxamide; 2-(4-amino-4-methyl-piperidin-1-yl)-5-(2-chloro-3-trifluoromethyl-phenyl)-6-methyl-pyrimidine-4-carboxylic acid amide; 6-amino-2-[(4-amino-cyclohexyl)-methyl-amino]-5-(2,3-dichloro-phenyl)-pyrimidine-4-carboxylic acid amide; (5M)-2-[(1R)-1-amino-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; (5P)-2-[(1R)-1-amino-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; (4M)-2-(4-amino-4-methylpiperidin-1-yl)-5-(2-chloro-4-fluoro-3-methoxyphenyl)-6-methylpyrimidine-4-carboxamide; (4P)-2-(4-amino-4-methylpiperidin-1-yl)-5-(2-chloro-4-fluoro-3-methoxyphenyl)-6-methylpyrimidine-4-carboxamide; (5P)-6-amino-2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; (5M)-6-amino-2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; (5M)-2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; (5P)-2-[(1S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; 6-amino-2-[(4S)-4-amino-4,6-dihydrospiro[cyclopenta[d][1,3]thiazol-5,4'-piperidin]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; 2-[(3R)-3-amino-3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; 6-amino-2-[(3R)-3-amino-3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; (4M)-2-[(3R)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; (4M)-2-[(3S)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4′-piperidine]-1′-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; (4P)-2-[(3R)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; (4P)-2-[(3S)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide; (4P)-6-amino-2-[(3R)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; (4P)-6-amino-2-[(3S)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; (4M)-6-amino-2-[(3R)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4′-piperidine]-1′-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide; and (4M)-6-amino-2-[(3S)-3-amino-3H-spiro[furo[2,3-b]pyridine-2,4′-piperidine]-1′-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide.

24. 10. A pharmaceutical composition comprising a compound according to claim 1 together with a pharmaceutically acceptable carrier, adjuvant and / or excipient.

Images